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SUMMARY 
 
Unhealthy nutrition and overweight may increase the risk for chronic health problems after 
childhood cancer treatment. It is therefore important to get a better understanding of the dietary 
intake of survivors and the personal and clinical characteristics related to adherence to dietary 
recommendations. Additionally, it is key to determine risk factors related to weight gain during 
and after treatment, e.g. type of cancer, treatment, age, gender etc. 
 
Our research is based on several sources of information. As part of the “Swiss Childhood 
Cancer Survivor Study” project, we sent two questionnaires. Childhood cancer survivors who 
survived at least 5 years filled in the first questionnaire. This questionnaire assessed 
adherence to dietary recommendations, and height and weight to calculate body mass index. 
The second questionnaire was a newly developed follow-up questionnaire completed by 1578 
survivors, which assessed dietary intake in detail. Next, we measured several times height and 
weight of childhood cancer patients during treatment. Finally, we collected urine spot samples 
from 125 survivors and patients to compare them with detailed dietary intake information. For 
this last step, the analyses are ongoing. 
 
Analyses on all these sources of information allowed us to make the following observations:  
 
Only 43% of the survivors met the national recommended dietary intakes for meat, 34% for 
fruit, 30% for fish, 18% for dairy products, 11% for vegetables, and 7% for combined fruit and 
vegetables. Results were similar for siblings and the general population. Adherence was not 
better for those survivors with high cardiovascular risks. In all groups, characteristics related 
to dietary adherence were similar.  
 
After treatment, the prevalence of and risk factors for being overweight were the same for 
survivors and their peers. But, survivors treated with head radiation therapy of 20 gray or more 
were more often overweight after treatment. Glucocorticoid chemotherapy seemed to have no 
impact on overweight in the long term. 
 
During treatment, being a boy and having been diagnosed with a specific type of leukemia 
(acute lymphoblastic leukemia, ALL) or lymphoma were risk factors for weight gain. Children 
affected by other types of cancer tended to lose initially weight before gaining weight during 
the second half of treatment. 
 
Based on these results, we suggest that prevention methods for unhealthy diet and overweight 
can be similar for survivors as for the general population. An important exception are survivors 
treated with cranial radiotherapy of 20 gray or more who may need extra attention during 
follow-up care. Besides, patients diagnosed with ALL or lymphoma might benefit from early 
lifestyle interventions.  
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RÉSUMÉ  
 
Une mauvaise alimentation et un surpoids augmentent le risque de problèmes de santé 
chroniques après un traitement contre le cancer chez les enfants. Il est donc important de 
mieux comprendre l’apport alimentaire des survivants et les caractéristiques personnelles et 
cliniques liées à l'observance des recommandations alimentaires. Il est également important 
de déterminer quels sont les facteurs qui peuvent provoquer une prise de poids durant et 
après le traitement, p.ex. type de cancer, de traitements, âge, sexe de l’enfant, etc. 
 
Notre recherche se base sur plusieurs sources d’information. Dans le cadre du projet ‘Swiss 
Childhood Cancer Survivor Study’, nous avons envoyé deux questionnaires aux survivants 
d’un cancer durant l’enfance. Les anciens patients qui ont survécu au moins 5 ans ont rempli 
le premier questionnaire. Ce questionnaire a évalué l'observance des recommandations 
alimentaires, la taille et le poids pour calculer l'indice de masse corporelle (IMC). Le 
deuxième questionnaire était un nouveau questionnaire de suivi rempli par 1578 survivants, 
qui a évalué l'apport alimentaire en détail. Nous avons également relevé la taille et le poids 
des enfants à plusieurs reprises durant le traitement. Finalement, nous avons collecté des 
échantillons d'urine de 125 survivants et patients afin de les comparer aux informations 
détaillées sur l'apport alimentaire. Les analyses sont encore en cours pour cette dernière 
étape.  
 
L’analyse de toutes ces informations nous ont permis de faire les observations suivantes:  
 
Comparé aux lignes directrices nationales, seulement 43% des survivants respectaient les 
apports nutritionnels recommandés pour la viande, 34% pour les fruits, 30% pour le poisson, 
18% pour les produits laitiers, 11% pour les légumes et 7% pour les fruits et légumes 
combinés. Les résultats étaient similaires pour les frères et sœurs et dans la population 
générale. Cela est également le cas pour les survivants ayant un risque cardiovasculaire 
élevé. Les caractéristiques liées à l'observance des recommandations alimentaires étaient 
semblables dans tous les groupes.  
 
Après le traitement, la prévalence et les facteurs de risque d'être en surpoids étaient les 
mêmes chez les survivants et leurs pairs. Mais les survivants traités avec une radiothérapie 
de la tête de 20 grays ou plus étaient plus souvent en surpoids après le traitement. La 
chimiothérapie aux glucocorticoïde semble n’avoir aucun impact sur le surpoids à long 
terme. 
 
Durant le traitement, le fait d'être un garçon et d'avoir été diagnostiqué avec un type 
spécifique de leucémie (la leucémie lymphoblastique aiguë, LLA) ou avec un lymphome, 
était un facteur de risque de prise de poids. Les enfants touchés par d'autres types de 
cancer avaient tendance à perdre du poids avant de prendre du poids pendant la seconde 
moitié du traitement. 
 
Sur la base de ces résultats, nous suggérons que les mesures de prévention contre une 
mauvaise alimentation et le surpoids peuvent être similaires pour les survivants comme pour 
la population générale. Une attention particulière doit être donnée durant les soins de suivi 
aux survivants traités par une radiothérapie de plus de 20 grays à la tête. De plus, les 
patients diagnostiqués avec une LLA ou un lymphome pourraient bénéficier d'interventions 
précoces de modification du style de vie.  
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CHILDHOOD CANCER 
Childhood cancer is rare and accounts for less than 1% of all cancer cases in Switzerland [1]. 
Every year between 250 and 300 children under the age of 21 are diagnosed in Switzerland, 
an annual number which is stable over the last twenty years [2]. The overall age-standardised 
incidence rate of childhood cancer in Switzerland is comparable to other European countries 
with 16.3 per 100,000 person-years in children aged 0-14 years of any cancer (excluding 
Langerhans cell histiocytosis) [2, 3]. 
 
The types and causes for cancer in children are different from adults. Some types of cancer 
are only found in children, whereas common adult cancers, such as carcinomas of the lung 
and breast, are rare in children [4]. The most common forms of childhood cancer are leukaemia 
(33%), central nervous system (CNS) tumours (20%), and lymphomas (12%), but this 
distribution differs by age category [2] (Figure 1). Most cancers are the results of gene 
mutations leading to uncontrolled cell growth. In adults, these mutations may be the result of 
long-term exposure of cancer-causing factors like smoking, asbestos, sun exposure, or simply 
the consequences of aging [4]. In children, the cause of these mutations is unknown for most 
cases of cancer. Inherited genetic mutations and genetic conditions like the Down syndrome 
can increase the risk of developing childhood cancer, but also environmental factors like pre-
and postnatal irradiation [5].  
 
Figure 1. Main diagnostic groups of childhood cancer according to the International 
Classification of Childhood Cancer, third edition (ICCC-3), by age at diagnosis from the Annual 
Report of the Swiss Childhood Cancer Registry [2] 
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 1976-2016; all diagnoses (ICCC-3 or Langerhans cell 
histiocytosis); N=7043; with of bar represents size of population in the corresponding age group. 
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Although most children are successfully treated [6], cancer remains the second leading cause 
of death after accidents [7]. 
 
In this thesis, the term “childhood cancer” refers to cancer diagnosed before the age of 21 
years including leukaemia, CNS tumours, lymphomas, and malignant solid tumours according 
to the ICCC-3 as well as Langerhans cell histiocytosis (LCH) [8]. The term “childhood cancer 
survivor (CCS)” is used for a person who survived childhood cancer at least 5 years after 
diagnosis. The term “childhood cancer patient (CCP)” is used for a person who receives 
childhood cancer treatment.  
LATE EFFECTS OF CHILDHOOD CANCER 
Childhood cancer treatment is a success story. Only fifty years ago, children had little hope on 
cure. Due to new and improved treatments survival rates among childhood cancer patients 
(CCP) have markedly increased over the last decades and currently exceed 80% [6]. With 
patients living longer, effective strategies to promote long-term overall health of childhood 
cancer survivors (CCS) become increasingly important. Complications and disabilities from 
treatment such as chemo- and radiotherapy, the cancer progress, or both can affect morbidity 
and mortality many years after cancer diagnosis [6, 9]. Medical assessments of 1713 adult 
CCS in the St. Jude Lifetime (SJLIFE) cohort study showed that, by the age of 45 years a big 
proportion of CCS experienced late effects. The estimated cumulative prevalence was 95% 
for having at least one chronic health condition and 80% for a severe, life-threatening or 
disabling condition [10]. Within the same cohort, Bhakta et al found that at age 45 years the 
burden of late effects was twice compared to the general population. CCS had on average 
seven or more additional chronic health conditions than the general population of whom two 
were severe, disabling or life-threatening. Frequently reported late effects secondary to 
childhood cancer or its treatment were cardiovascular disease (CVD), endocrine disorders, 
musculoskeletal problems, and secondary malignancies [9]. Development and severity of late 
effects depends on many unmodifiable or modifiable factors, e.g. age at diagnosis, type and 
harshness of given treatment, lifestyle (Figure 2). Current findings underline that post-
treatment care of CCS should not only focus on preventing cancer recurrences or second 
malignancies but also on preventing and managing late effects, which may influence 
progression of other disease associated with aging or lifestyle. To anticipate on this late effects 
burden, both treatment related and patient specific risk factors should be taken into account. 
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Figure 2. Risk factors for morbidity and mortality in childhood cancer survivors  
Risk factors are seperated in unmodifiable risk factors (red), future plausible modifiable risk factors (green striped), and modifiable 
risk factors (blue)  
Adapted from data source: reference [11].  
 
Treatment related risk factors  
Childhood cancer treatment and its related toxicities varies and depends on the type of cancer, 
tumour stage, histology, and response to treatment. In general, most children are treated with 
chemotherapy, radiation, surgery, or a combination of them. Although children tend to respond 
well to these treatments, they can have negative consequences over time (Table I). The 
emerging information of the occurrence of late effects has driven research to continously make 
efforts to discover and integrate novel treatments and have modified cancer treatment and 
follow-up care where possible. During the last years this has led to a reduction in treatment 
intensity for children with good prognosis while maintaining the levels of cure [12]. Due to the 
latency of the occurrence of many side effects, long-term follow-up remains important to 
determine late effects later in life as CCS are living longer.  
 
Table I. Metabolic late effects in childhood cancer survivors and their risk factors [11, 13-15]  
Late effects Treatment-related risk factors Patient specific risk factors 
Overweight, obesity -Glucocorticoids 
-Cranial radiation therapy  
-Total body radiation 
-Abdominal radiation 
-Hypothalamic injury; surgery or tumour growth 
-Younger age at treatment 
-Female gender 
-Unhealthy diet 
-Physical inactivity 
-Older age 
-Mental health 
-Medical conditions, e.g. familial 
dyslipidaemia, growth hormone deficiency etc. 
Metabolic syndrome, 
diabetes mellitus  
-Cranial radiation therapy 
-Total body radiation 
-Abdominal radiation 
-Glucocorticoids 
-Alkylating agents 
-Haematopoietic stem cell transplantation 
-Younger age at treatment 
- Unhealthy diet 
-Physical inactivity 
-Abdominal obesity 
-Family history of diabetes melllitus 
Hypothalamic/pituitary 
dysfunction 
-Cranial radiation therapy  
-Total body radiation 
-Hypothalamic injury; surgery or tumour growth 
-Tyrosine kinase inhibitors 
-Younger age at treatment 
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Radiation  
Radiation is frequently given to CCP and depending on the tumour can be given in different 
doses and locations. Although the introduction of radiation has improved survival rates, it can 
lead to several late effects for example subsequent neoplasms depending on the affected area 
and dosage [16]. With this in mind the proportion and the overall total dose of radiation per 
patient has been reduced over the years [16, 17]. In the North American Childhood Cancer 
Survivor Study (CCSS) they found that the proportion of CCS who were treated with any type 
of radiation decreased from 77% in the 1970s, to 54% in the 1980s, and even further to 33% 
in the 1990s. Median overall radiation treatment dose decreased from 30 Gy in the 1970s to 
26 Gy in the 1990s [16].  
 
Cranial radiation therapy (CRT), abdominal, and total body irradiation (TBI) have been 
associated with a variety of late effects, e.g. metabolic syndrome, diabetes mellitus, 
overweight, obesity, and hypothalamic/pituitary dysfunction like growth hormone deficiency 
(Table I). Dose-response relationships have been observed between radiation and these 
endocrine late effects, leading to efforts to either reduce or eliminate radiation completely 
during treatment. An example of this is the reduced use of CRT. Since the 1980s, CRT is not 
longer a standard element in acute lymphoblastic leukaemia (ALL) treatment protocols and 
cumulative doses have decreased [17-19]. In the US, the percentage of children with ALL who 
received CRT during treatment droped from 85% in the 1970s to only 19% in the 1990s [17]. 
Restricting CRT usage and decreased doses have also been observed in CNS tumour 
treatment protocols [17, 20].  
 
Chemotherapy 
Before 1970 cancer treatment was often based only on radiation and surgery, but survival 
markedly improved after the introduction of chemotherapy regimens [12]. Over the years 
different combinations of aggressive chemotherapies were introduced [5] and patients 
received more often chemotherapy including alkylating agents and anthracyclines [17]. Studies 
showed strong dose-response associations between the exposure of these chemotherapeutic 
agents and late effects. Alkylating agents increase the risk to develop gonadal dysfunction 
leading to infertility and anthracyclines exposure can lead to congestive heart failure which can 
be even further increased when CCS are also exposed to chest radiation [14, 21]. The 
proportion of ALL patients who received anthracyclines increased from 30% in the 1970s to 
84% in the 1990s. Although the mean cumulative dose of anthracycline chemotherapy dropped 
from 289 mg/m2 to almost half (158 mg/m2), in an attempt to reduce late effects. A similar 
anthracycline dose reduction has been seen in children with Hodking lymphoma and Wilms 
tumours over the years [17].  
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To compensate for the reduced cranial radiation treatment in the 1980s, intrathecal and 
systemic chemotherapy regimens are developed to sustain CNS remissions in ALL, acute 
myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL) patients [11, 22]. Although ALL 
treatment has changed little after the 1980s recent treatment advances have come from 
refined use of chemotherapy agents [22]. For example, overall glucocorticoids have an 
antileukaemic effect and are an important component in ALL treatment. But prednisone is 
sometimes replaced by dexamethasone due to the lower risk of relapse and improved event-
free survival [22, 23]. There is still debate about the most optimal use of glucocorticoids in the 
treatment of ALL due to their short- and longterm side effects, e.g. weight gain, osteopenia, 
behavioural problems, infections. Glucocorticoids regulate maturation and metabolism of 
adipose tissue, which can lead to redistribution of fat deposits from arms and legs to the 
abdominal area with accumulating visceral fat in the long-term [24]. Furthermore, prolonged 
glucocorticoid use leads to increased appetite and psychological changes, which may 
influence dietary intake, and together with less energy expenditure due to physical inactivity 
could lead to weight gain [23, 25]. The choice of type, dose, and duration of glucorticoids 
remains a topic of dicussion within the goal of minimizing toxicity during the different phases 
of treatment.  
 
Patient specific risk factors 
CCP with equal treatment do not always develop the same morbidities, which suggests that 
the development of late effects is not only related to cancer and its treatment. Patient specific 
risk factors, like genetic, sociodemographic, and lifestyle factors may play a role in the 
development and severity of late effects. Increasing awareness of patient specific risk factors 
could detect chronic health conditions earlier and potentially prolong life and reduce 
morbidities. 
 
Sociodemographic factors 
Sociodemographic factors, like gender and age at diagnosis, are unmodifiable but investigating 
these factors can benefit surveillance and prevent late effects. It is suggested that cancer and 
its treatment negatively effects female survivors more compared to male survivors. Higher 
standardised all-cause mortality ratios were found in women compared to men in the CCSS 
performed in North America (women: 21.2: men: 10.0) [17], the Britsh Childhood Cancer 
Survivor Study (women: 11.7: men: 7.9) [12], as well as in the Swiss Childhood Cancer 
Survivor Study (SCCSS) (women: 18.4: men: 8.5) [26]. Women seem to also have a higher 
risk to develop chronic health conditions compared to men [27] after childhood cancer. 
Compared to men, women are more susceptible for cardiotoxic effects of anthracyclines and 
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to develop obesity after CRT [14]. The underlying mechanisms for these gender difference in 
late effects are not well understood and need further investigation [11].  
 
The age at diagnosis and subsequently the age at treatment may impact the development of 
late effects since children experience a critical period of growth and body development. 
Children who receive CRT at a young age seem to be more susptible to develop endocrine 
late effects like obesity, diabetes mellitus, and hypothalamic/pituitary dysfunction (Table I). 
Young age at time of treatment is also associated with cardiac toxicity after anthracyline 
treatment, cardiac and pulmonary toxicity after chest radiation, and musculoskeletal growth 
problems after TBI [14].  
 
Lifestyle factors 
Post-treatment care may benefit from identifying modifiable risk factors that are not directly 
linked to late effects after cancer such as lifestyle. Risky health related behaviours including 
smoking, binge drinking, and an unhealthy diet may increase, whereas health promoting 
behaviours may reduce the risk to develop chronic diseases and second cancers [28, 29]. 
Despite the fact that CCS have already an elevated risk to develop late effects due to their 
earlier cancer and its treatment, the rates of smoking [30], frequent alcohol consumption or 
binge drinking [31], unsufficient sun protection [32], low physical activity [33], and having an 
unhealthy diet [34-38] are equally or more frequently seen in CCS compared to their siblings 
or the general population. 
 
Health promoting lifestyles, including increased physical activity and improved diet, and 
comorbidity management could modifiy the morbidity and mortality trajectory that CCS 
experience due to unmodifiable cancer treatment-related and patient specific risk factors 
(Figure 3). 
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Figure 3. Conceptual schematic of late effect risk and potential modifiers in childhood cancer 
survivors  
Adapted from data source: reference [39] 
OVERWEIGHT, OBESITY, AND ITS PREDICTORS IN PATIENTS AND 
SURVIVORS  
Childhood cancer patients and survivors face several risk factors that predispose them to 
overweight and obesity due to their cancer treatment received often at a very young age, e.g. 
reduced physical activity, unhealthy dietary intake, pituitary hormonal deficiencies, and 
impaired satiety signals (Figure 4). Overweight and obesity can occur both during and beyond 
cancer treatment and is seen as a modifiable patient specific risk factor to develop chronic 
health conditions like diabetes, dyslipidaemia, hypertension, and CVD [40]. Since CCS are 
more susceptible to develop these chronic health conditions due to their cancer treatment, it 
is important to prevent an early onset of excessive weight gain and keep a healthy weight 
throughout life.  
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Figure 4. A schematic model of weight gain and overweight/ obesity during and beyond 
childhood cancer treatment  
BMI, body mass index; dx, diagnosis 
 
Overweight and obesity in acute lymphoblastic leukaemia patients and survivors  
During treatment, increased weight is reported in ALL patients with obesity proportions 
between 9% and 48% at end of treatment versus 2% to 19% at diagnosis [41-45]. During the 
induction phase and early maintenance cycles, ALL patients tend to experience especially 
weight gain. Induction and early maintenance cycles normally contain excessive doses of 
glucocorticoids [43, 45-47]. These results were supported by a meta-analysis of Zhang et al. 
that reported results of 1791 childhood ALL patients and short-term survivors [46]. They found 
an overall mean increase of 0.8 (95% CI 0.3-1.4) body mass index (BMI) z-score from 
diagnosis until the end of treatment, with a tendency for a rapid weight gain during induction 
and during maintenance. A tendency for weight increase was also observed beyond treatment 
completion, with a diminishing increase in BMI Z-score over the years. These findings may 
suggest that weight gain during treatment is unlikely to be reversed after childhood cancer 
treatment, but heterogeneous results have been found. A meta-analysis of Zhang et al. 
showed that recent survivors tended to be more obese than those who survived longer [48]. A 
mean BMI z-score of 0.89 (95% CI 0.6-1.2) was found in 1391 childhood ALL survivors who 
were less than 5 years off treatment, and of 0.64 (95% CI 0.4-0.9) in 755 survivors 5 to 9 years 
off treatment. The survivors who were still mostly children and adolescents at time of 
evaluation had a higher BMI than the general reference population regardless of CRT receipt, 
gender, and age at diagnosis. Fewer studies looked at the prevalence of obesity at the long 
term, ≥10 years off treatment. In one of the largest long term studies, an overall similar BMI 
was found in 1451 adult survivors of childhood ALL 25 years after diagnosis compared to 2167 
siblings. Subgroup differences were identified. ALL survivors exposed to CRT, who were 
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treated at a young age, and were women were more likely to have an increased BMI compared 
to their siblings [49]. This makes it doubtable that obesity persist long after treatment in ALL 
survivors. 
 
Overweight and obesity in other types of childhood cancer patients and survivors  
Studies about overweight or obesity during treatment have been mainly conducted in ALL and 
CNS tumour patients. In a meta-analysis of Wang et al. no difference was seen in the 
overweight and obesity prevalence between overall childhood brain tumour survivors and the 
general population, with the exception to craniopharyngiomas survivors [50]. Children with 
craniopharyngiomas can develop hypothalamic obesity during and after treatment [51]. 
Hypothalamic damage, a disruption of hormone satiety signalling, a decreased metabolic rate, 
and pituitary hormone deficiencies are seen due to tumour pressure or the damage caused by 
treatment within these CNS tumours patients [51, 52]. Besides childhood craniopharyngioma 
patients, also astrocytoma and ependymoma patients have been reported to be at increased 
risk of overweight after treatment [42, 53]. In a report of the CCSS including 14290 CCS of all 
types of cancer (median age 32 years, range 5-58) 24 years after diagnosis, it was found that 
survivors had an overall similar risk of becoming obese compared to their siblings [54]. But, a 
higher risk for obesity was found when survivors were treated with CRT with doses over 18 Gy 
which often include ALL and CNS tumour survivors. 
DIETARY INTAKE OF CHILDHOOD CANCER SURVIVORS 
Observational studies have shown that CCS poorly adhere to dietary guidelines [35, 36, 38, 
55-57]. A low percentage of CCS meet the recommended five or more portions of fruit and 
vegetables per day, have inadequate amounts of vitamin D, vitamin E, calcium, magnesium, 
potassium, and fibre, and excessive intakes of sodium and saturated fat compared to the age-
specific dietary reference intakes (Table II). Dietary quality based on the Healthy Eating Index 
(HEI) was low. A poor diet quality with a low intake of whole grain and a high intakes of sodium 
and empty calories was found in the St. Jude Lifetime (SJLIFE) cohort in 2570 adult CCS 24 
years after diagnosis [37] and similar results are also reported by smaller studies [36, 55-58].  
 
Dietary intake of CCS is often assessed by food frequency questionnaires (FFQ) [37, 55, 58, 
59], food diaries [36], repeated 24-hour dietary recalls [56], or via food/nutrient screening 
questionnaires [60]. Since these self-reported assessment tools can lead to inaccuracy or 
under- or over-reporting, results needs to be handled with caution (Table III). Assessing dietary 
intake with a FFQ, could lead to recall bias, misreportig, or underreporting as the reported 
intake is limited to the food items on the list. The food item list is created to assess the habitual 
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intake and is therefore population and country specific. The 24-hour dietary recall is an in-
depth interview to assess in detail everything the participant has eaten over the past 24-hours. 
This in-depth interview could lead to a good dietary intake report, but recall bias remains, and 
only a single recall can give a poor individual measurement. Each dietary assessment tool has 
its strengths and limitations to assess absolute intake (Table III). However, if we look at the 
relative intake instead of the absolute intake by comparing CCS to the general population we 
see that both groups adhere equally poor to recommended dietary intakes [36, 38]. This may 
be of concern, given the susceptibility of certain somatic late effects in CCS (Figure 3). Within 
the Chicago Healthy Living Study there was also no difference in the overall adherence to the 
American Cancer Society Guidelines on Nutrition and Physical Activity between 431 CCS and 
361 controls [35]. Of the CCS, 10% were adherent to fibre intake, 18% to fruit and vegetables 
intake, 46% to red/processed meat intake, and less than 5% were adherent to all three dietary 
components. 
 
With the current very limited level of evidence, the effectiveness of targeted nutritional 
interventions to improve nutritional intake and reduce chronic diseases later in life is lacking. 
Even though it seems crucial that CCS need to practice healthy behaviours equally well or 
better than the general population more research is needed.  
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Table II. Nutritional findings within the worldwide childhood cancer survivor studies1  
 BCCSS  
UK 
CCSS 
US 
SCCSS  
CH 
SJLIFE 
US 
% of CCS who meet 
nutritional 
recommendations  
Department of Health UK:  
 
 
-Alcohol (≤21 units/week [M]/ 
≤14 units/week [F]): 76% [61] 
WCRF/AICR recommendations: 
-Fruit and vegetables (≥5 servings/d):  
 25% [62]; +/-50% [55] 
-Alcohol (<14 g/day [F]/ <28 g/d [M]): 92% [63] 
 only 10% consumed any alcohol [55] 
-Sodium (<2400 mg/d): 35% [55] 
-Red meat (<3-4 times/week): 32% [63] 
General findings: 
-Fruit and vegetables (≥1 
servings/d): 72% [64] 
-Alcohol (<1 drink/d): 94% [64] 
WCRF/AICR recommendations: 
-Fruit and vegetables (≥5 servings/d): 26% [59] 
 
-Alcohol (<14 g/d [F]/ <28 g/d [M]): 94% [59] 
 
-Sodium (<2400 mg/d): 30% [59] 
-Red meat (<80 g/d): 10% [59] 
-Complex carbohydrates (≥400 g/d): 48% [59] 
% of DRI  -  - -Vitamin D: 27% [37] 
-Vitamin E: 54% [37] 
-Potassium: 58% [37] 
-Fibre: 59% [37] 
-Magnesium: 84% [37] 
-Calcium: 90% [37]  
-Sodium: 155% [37] 
-Saturated fat: 115% [37] 
-71% of CCS has a DRI level of  
≥0.8 g protein/kg body weight [65] 
Dietary intake, 
mean/ median 
(range) 
- -Sodium (mean): 3113 mg/d [55] 
-Daily meat (mean): 4.6 oz (=130 g) [55]  
-Whole grain (mean): 1.5 servings [55] 
- -Energy (medium [range]): 1995 (1536-2543) 
kcal/d [65] 
-Fat (medium [range]): 686 (511-910) kcal/d [65] 
-Protein (medium [range]): 314 (241-408) kcal/d 
[65] 
-Carbohydrates (medium [range]): 965 (720-1252) 
kcal/d [65] 
-Sodium (medium [range]): 3428 (2656-4238) 
mg/d [65] 
-Fibre (medium [range]): 13 (9-17) g/d [65] 
Diet quality - HEI-2005: 55.5 ± SE1.0 [36] 
Child Health and Illness Profile-Adolescent 
Edition:  
-low healthy foods in diet2: 32% [66] 
-high unhealthy foods in diet3: 35% [66] 
- HEI-2010: 57.9 ± 12.4 [37] 
BCCSS, British Childhood Cancer Survivor Study; CCSS, Childhood Cancer Survivor Study; CH, Switzerland; CHO, carbohydrates; d, day; DRI, Dietary Reference Intakes; HEI, Healthy Eating Index; SCCSS, Swiss 
Childhood Cancer Survivor Study; SE, standard error; SJLIFE, St. Jude Lifetime cohort; UK, United Kingdom; US, United States of America; WCRF/AICR, World Cancer Research Fund/American Institute for Cancer 
Research 
1: No nutritional findings were available for the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) and “De Stichting Kinderoncologie Nederland LAnge TERmijn effecten na behandeling van kinderkanker”, 
The Netherlands (SKION LATER)  
2: Healthy diet behaviours was based on fruit/vegetable, lean meat, low-fat dairy, and whole grain intake within the past 4 weeks 
3: Unhealthy diet behaviours was based on fast food, salty food, and sweets intake within the past 4 weeks 
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Table III. Dietary intake assessment tools and their strengths and limitations [67, 68] 
Tool Method Strengths Limitations 
Food Frequency 
Questionnaire  
Self-administered 
retrospective 
questionnaire based on 
a food item list to assess 
habitual diet 
(frequency/semi-
quantitative: portion 
sizes) over a reference 
period (month/year) 
-Low participant burden 
-Suitable for large surveys 
-Can be self-complete  
-Captures habitual intake and foods not 
consumed on a regular basis 
-Relative low costs, computerized 
processing 
-Useful to repeat dietary assessment over 
a number of years 
-Food items may be missing and 
reported intake is limited to the food 
items on the list 
-Requires literacy and numeracy of 
participant 
-Population specific 
-Estimated portion sizes 
-Misreporting 
-Recall bias 
Diet history Retrospective structured 
interview method to 
capture detailed 
information on habitual 
food intake or food 
intake at a specific life 
stage/time period 
-Usual diet in one assessment 
-Detailed individual foods 
-Captures foods not consumed on a 
regular basis 
 
-Requires trained interviewers and 
results depend on interviewer skills 
-Observer bias 
-Recall bias 
-Misreporting 
-Not self-administered 
-Expensive 
Technology assisted 
dietary assessment  
Prospective electronic 
recording of foods and 
beverages consumed, 
photographs of 
consumed food with a 
smartphone application 
-Standardisation of assessment, less 
prone to errors of participant/ interviewer 
-Less burdensome data collection and 
data entry 
-Suitable for large studies 
-Internet access is needed 
-Computer literacy is needed 
-Nonresponse bias 
-High development costs 
24-hour dietary recall In-depth interview by a 
trained interviewer to 
assess in detail 
everything the participant 
has eaten over the past 
24-hours 
-Low participant burden 
-Suitable for large surveys 
-Participant does not know moment of 
recall, less prone for altering eating 
behaviour 
-Sensitive to ethnicity-specific eating 
behaviours 
-Requires trained interviewers and 
results depend on protocol and 
interviewer skills 
-Estimated portion sizes 
-Recall bias 
-Single recall gives poor individual 
measurement  
-Expensive (time consuming, labour 
intense) 
Food records 
 
 
 
 
 
 
 
-Prospective food diary 
in which participant 
records details on food 
and beverages 
consumed at the time of 
consumption 
-Portion sizes can either 
be weighted or estimated 
-Does not require recall 
-Detailed food descriptions and records of 
eating moments 
-Capture food eaten on a regular basis 
-High participant burden 
-Misreporting/ can alter eating 
behaviour 
-Expensive  
-Irregular eaten food will not be 
captured 
-Several days of recording are 
needed, “study fatigue” 
Weighted 
 
 -Precision of portion sizes 
 
-Requires literacy, numeracy, and 
motivation of participant 
-Erratic lifestyle habits can be difficult 
with weighing and recording away 
from home.  
 
Estimated  -Lower participant burden than weighted 
food records 
-Suits erratic lifestyle habits (eating 
outside home) 
-Estimated portion sizes 
Biochemical 
indicators of dietary 
intake 
Collection of biological 
specimen from the 
participant 
-Objective (no recall, social desirability) 
-Can be used to validate a dietary 
assessment tool 
-Useful assessment of the intake of 
certain nutrients 
-Sensitive to intake, within-person 
variation 
-Focus on single agents instead of 
whole diet 
-Time integration (reflection of short-
term/ long-term intake, day to day 
fluctuations) 
-Contamination 
-Stability during storage 
-No feasible biochemical indicator of 
intake can be available  
-Expensive 
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Dietary intake and late effects  
Unhealthy dietary intake is an important element in the development of type II diabetes, 
metabolic syndrome, and CVD in the general population (Table IV). It is therefore widely 
recommended in populations suffering from these comorbidities to consume a diet rich in fruit, 
vegetables, fibre and complex carbohydrates, low in saturated and trans-fatty acids, and 
moderate in alcohol consumption (Table IV). Accumulating research among CCS shows that 
such late effects can be reduced, with diet adaptations, weight management, and physical 
activity [25, 58, 59, 69]. The extensively investigated Mediterranean diet, with high intakes of 
fish, fruit, vegetables, legumes, nuts, whole grains, and monounsaturated fats from olive oil, 
has shown a reduction, or even a prevention, of CVD, diabetes, obesity, metabolic syndrome, 
and cancer in the general population [70-74]. This makes nutrition one of the main 
determinants of health in the general population, and particularly relevant for people with 
additional risk factors, including cancer survivors. In the SJLIFE cohort study adherence to the 
lifestyle habits based on dietary intake, BMI, and physical activity according to the World 
Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) 
recommendations was associated with a lower risk of the metabolic syndrome in 1598 CCS 
[59]. In 117 adult survivors of childhood ALL, adherence to the Mediterranean diet was also 
associated with a reduced risk for the metabolic syndrome, lower visceral and subcutaneous 
fat, and a lower BMI [58]. In this study, each point increase on the Mediterranean diet score, 
representing for example an extra half serving of vegetables per day led to a 31% decrease of 
the metabolic syndrome risk [58].   
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Table IV. Long-term endocrine abnormalities and cardiovascular diseases seen in childhood 
cancer survivors, nutritional recommendation for prevention in the general population, and its 
level of evidence 
Late effects seen in CCS Nutritional recommendations for prevention or 
management in the general population 
Level of evidence 
(A-C)1 
Endocrine abnormalities   
   Hypothalamic-pituitary axis- 
related endocrinopathies, e.g 
growth hormone, gonadotropin, 
TSH, or ACTH deficiency 
- - 
   Overweight, obesity, metabolic 
syndrome 
Energy restricted/ healthy diet to achieve weight loss  
Mediterranean-type diet 
Olive oil instead of other fats 
Dietary Approached to Stop Hypertension diet, new 
Nordic diet, plant-based/vegetarian diets 
Cereals (whole grains) 
Fish 
Dairy 
Reduce/replace sugar-sweetened beverages 
Moderate alcohol 
A [75, 76] 
B [75] 
A [75] 
B [75] 
 
B [75] 
C [75] 
B [75] 
B-C [75] 
B [75] 
   Type II diabetes, insulin 
resistance or insufficiency, 
dyslipidaemia 
  
Low-carbohydrate or low-fat calorie restricted diets 
(weight loss) 
Fibre, whole grains 
Moderate alcohol 
Legumes 
Limit saturated fat 
Fish 
-associations found with obesity- 
A [77] 
 
B [77] 
B [77] 
A [75] 
A [77] 
B [77] 
 
  Hypothyroidism, hyperthyroidism, 
thyroid nodules, thyroid cancer 
Iodine (deficiency prevention) [78] 
-associations found with obesity- 
 
   Osteoporosis, osteopenia Calcium  A [79] 
 Vitamin D, dairy  B [79] 
   Azoospermia, Leydig cell failure, 
premature ovarian insuffiency 
-associations found with obesity-  
Cardiovascular diseases   
(lowering blood pressure, low-density 
lipoprotein cholesterol) 
Limit sodium intake [80, 81] 
Limit saturated fat, trans-fat [80, 81] 
Limit dietary cholesterol [80] 
Variety of fruit and vegetables, whole grains, high-fibre 
foods, low-fat or fat-free diary, lean protein foods (fish, 
poultry, meat, alternatives), nuts, seeds, vegetables oils 
[80, 81] 
Legumes  
Whole grains  
Nuts 
-associations found with obesity- 
A - B [81] 
A [81] 
C/Insufficient [81] 
A [81] 
 
 
 
A [75] 
A [75] 
A [75] 
ACTH, adrenocorticotropin hormone; CCS, childhood cancer survivors; TSH, thyroid-stimulating hormone;  
1 Evidence grading system, A: strong evidence [randomised controlled trials, meta-analyses], B: moderate/intermediate evidence 
[cohort studies, case-control studies]; C: weak evidence [poorly controlled or uncontrolled studies, case series, case reports, 
expert consensus or clinical experience] 
Current gaps in knowledge 
So far, little is known about the dietary intake of CCS [38, 82] and its potential relationship with 
late effect development. Research performed to date suffers from methodological 
shortcomings, e.g. small sample sizes, short follow-up times, poorly detailed dietary 
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descriptions, are only based on self-reported questionnaire-based data instead of objective 
biochemical indicators of dietary intake, or lack of control groups. Well-performed studies are 
needed to describe dietary habits of CCS. This could help determining whether adverse 
somatic late effects may also be due to unhealthy lifestyle habits and malnutrition. Further, we 
should investigate if unhealthy habits are linked to childhood cancer, or are merely a 
consequence of cancer treatments, e.g. cranial surgery or CRT. It seems clear that overall 
malnutrition adds to the risks of comorbidity and mortality in children with cancer on short or 
long-terms. However, the potential harmful effects of long-standing malnutrition, the specific 
nutritional needs, and the exact link with adverse somatic late effects are unknown.  
 
Studies conducted on overweight or obesity to date have been of somewhat limited relevance 
to CCS. Research on overweight and obesity prevalence has involved mostly ALL survivors 
[41, 43, 45, 49], whereas study of risk factors has led to inconsistent conclusions [48], e.g. 
sociodemographic, treatment, lifestyle, and pre-treatment factors like birthweight and 
bodyweight status at diagnosis (Figure 4). Most studies on this topic have been conducted in 
the US reflecting the lifestyles and eating habits of CCS in that country [43, 45, 47, 49, 54], 
whereas the duration of follow-up in other studies has been only short to medium term [46, 
48], and many have had small sample sizes [41, 43, 45, 48]. Lastly, there is insufficient 
knowledge if the risk for obesity in CCS differs between cancer types with similar treatments.  
 
Among adult cancer survivors healthy diets and weight-control management have been 
suggested to improve metabolic outcomes and reduce cancer recurrence and all-cause 
mortality [83]. This has resulted in dietary and physical activity guidelines for cancer survivors 
from various associations: the WCRF/AICR [84], the American Cancer Society [85], and the 
American College of Sports Medicine [86]. In adults, adherence to these dietary guidelines has 
shown encouraging results in terms of clinical outcomes, e.g. mortality and chronic disease 
development. However, evidence-based nutritional guidelines for children with cancer or CCS 
are not available to support nutritional practice. The Children’s Oncology Group (COG) 
developed CCS guidelines, but gives general advice on nutrition and physical activity 
comparable to the general population [28]. Standardised international guidelines for weight 
management are currently lacking. Nonetheless, efforts are made by the International Late 
Effects of Childhood Cancer Guideline Harmonization Group (IGHG) to develop guidelines for 
metabolic syndrome surveillance, including obesity (see Appendices- Future projects).  
 
Continuous efforts are needed to overcome the current nutrition related knowledge gaps, and 
promote late effects surveillance and healthy lifestyle behaviours “so that the increasing 
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numbers of successfully treated children of today do not become the chronically ill adults of 
tomorrow” as only “cure is not enough” [87].  
 
AIM AND THESIS OUTLINE 
The overall aim of this thesis is to improve our knowledge about the dietary intake in Swiss 
CCS and to gain insights in the potential risk factors for being overweight during and long after 
treatment (Figure 5). For this purpose, we compare the level of adherence to the national 
dietary recommendations in CCS, their siblings, and the general population (Chapter 2). In 
chapter 3 we investigate the dietary intake of CCS by using a FFQ and compare it with several 
comparison groups representing the general Swiss population. In chapter 4 we validated the 
FFQ with biomarkers assessed in urine spot samples in CCS and patients from the French-
speaking region of Switzerland. In chapter 5, 6, and 7 we show results of studies that 
investigated the socio-demographic, lifestyle, and clinical risk factors to develop overweight. 
In chapter 5 we focus on overweight prevalence and its risk factors in childhood cancer 
patients from diagnosis till end of treatment. We look at weight change during treatment by 
type of cancer. We used data from three paediatric oncology clinics in the German speaking 
part of Switzerland. In chapter 6 we assess the prevalence of overweight in CCS, with a focus 
on leukaemia survivors, compare it with their peers, and determine potential risk factors long 
after treatment. In chapter 7 we further focus on the long-term effects of cancer treatment on 
overweight in CCS by looking at the cumulative dosage of glucocorticoids given during 
treatment. In the appendices we show future projects. We will compare the risk factors for 
overweight in ALL survivors between the US and Switzerland in a collaboration between the 
Childhood Cancer Survivor Study (CCSS, US, Memphis) and the SCCSS to investigate if risk 
factors are country specific or if they are applicable to all ALL survivors. Lastly, we will support 
the Obesity taskforce within the Metabolic Syndrome Working Group, IGHG in abstract 
reviewing and writing. 
In the final chapter (Chapter 8), the presented results are summarized and discussed, and 
implications and directions for further research are presented.    
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Figure 5. Overview of PhD thesis 
Ch, chapter; FFQ, food frequency questionnaire; ICCC-3, International classification of childhood cancer, 3rd edition 
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SUMMARY 
 
Background & aims: Poor diet may increase the risk that childhood cancer survivors (CCS) 
will suffer from chronic disease. We compared adherence to national dietary recommendations 
between CCS, their siblings and the Swiss population, identified determinants of adherence, 
and assessed the association of adherence with cardiovascular disease (CVD) risk profiles.  
 
Methods: As part of the Swiss Childhood Cancer Survivor Study (SCCSS), a questionnaire 
was sent to all Swiss resident CCS aged <21 years at diagnosis, who survived ≥5 years and 
were 16-45 years old at the time of the survey. We compared dietary adherence between CCS, 
their siblings and participants in the Swiss Health Survey (SHS), a representative survey of 
the general population. A multivariable logistic regression was used to assess characteristics 
associated with dietary adherence. We sorted CCS into four kinds of CVD risk groups based 
on type of treatment (anthracyclines, chest irradiation, a combination, or neither).  
 
Results: We included 1’864 CCS, 698 siblings and 8’258 participants of the general 
population. Only 43% of the CCS met the recommended dietary intakes for meat, 34% for fruit, 
30% for fish, 18% for dairy products, 11% for vegetables, and 7% for combined fruit and 
vegetables. Results were similar for both control groups. In all groups, dietary adherence was 
associated with gender, parental education, migration background, language region in 
Switzerland, smoking, alcohol consumption and sport participation. CCS with a higher CVD 
risk profile because of cardiotoxic treatment had no better adherence.  
 
Conclusions: CCS have similar food patterns as their siblings and the general population, 
and poorly adhere to current recommendations. Awareness of the importance of a healthy diet 
should be raised among CCS, to prevent chronic diseases like CVD.  
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INTRODUCTION 
Cancer or the late effects of its treatment cause more than two-thirds of childhood cancer 
survivors (CCS) to develop chronic diseases later in life. Chronic diseases reduce quality of 
life, and increase morbidity and premature mortality [1, 2]. CCS are up to 15 times more likely 
to develop heart failure than their siblings, and almost 13 times more likely to die from 
circulatory diseases than their peers in the general population [1, 3]. This increased risk could 
be the result of cardiotoxic therapy effects due to anthracycline-containing chemotherapy and 
radiation therapy involving the heart. Unhealthy lifestyles, including unbalanced diets, physical 
inactivity and being overweight or obese, could also each significantly increase the risk of 
cardiovascular disease (CVD) [4].  
Excess calorie intake, and consuming too little fish, fruit and vegetables are associated 
with higher risk of CVD in the general population. Better dietary habits may improve 
cardiovascular health [4, 5]. Unbalanced diet is a major modifiable risk factor for CVD, Type II 
diabetes, metabolic syndrome, and osteoporosis [4-7]. But a recent review that included 14 
observational studies showed that childhood cancer patients and survivors in the US, Australia, 
Germany, Canada, and the UK rarely adhere to dietary recommendations [8]. CCS do not eat 
enough fruit and vegetables [9-11], dairy products [10, 11], whole grains [11, 12], or the 
micronutrients calcium and vitamin D [12]. They also eat too much sodium and meat [9].  
Most studies that investigated dietary adherence had low sample sizes (N<500) [9-13], no 
control group [9, 10, 12, 14], and did not investigate the association between dietary adherence 
and CVD risk profiles based on received type of therapy [9, 10, 12-14]. Therefore, we analysed 
data from the Swiss Childhood Cancer Survivor Study (SCCSS) to (1) compare adherence to 
national dietary recommendations among CCS, their siblings and the general population, (2) 
identify socio-demographic and clinical factors associated with adherence to national dietary 
recommendations, and (3) determine if adherence to dietary recommendations in CCS differed 
by cardiovascular risk profiles.  
 
METHODS  
Sampling 
The Swiss Childhood Cancer Survivor Study (SCCSS) 
The SCCSS is a nationwide long-term follow-up study of all ≥5-year CCS registered in the 
Swiss Childhood Cancer Registry (SCCR), diagnosed between 1976 and 2005, and alive at 
the time of the study [15]. The SCCR registers children and adolescents under age 21, who 
are diagnosed in Switzerland with leukaemia, lymphoma, central nervous system (CNS) 
tumours, malignant solid tumours or Langerhans cell histiocytosis [16, 17].  
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 From 2007 to 2012, we traced all addresses of eligible survivors for the SCCSS and 
sent them a long questionnaire. Non-responders were sent a second copy of the questionnaire 
four to six weeks later. Non-responders to the second copy were contacted by phone. We used 
questionnaires similar to those used in US and UK CCS studies [18, 19], but added questions 
about health behaviours and socio-demographic measures from the Swiss Health Survey 2007 
(SHS) [20] and the Swiss Census 2000 [21]. The main domains covered by the questionnaire 
were quality of life, somatic health, fertility, use of current medication and health services, 
psychological distress, health behaviours, and socio-economic status. Detailed information on 
our study design was published previously [15]. 
 The Ethics Committee of the Canton of Bern gave ethical approval to the SCCR and 
the SCCSS.  
 
Sibling controls 
From 2007 to 2012, when we sent out the questionnaire to CCS, we asked them to give us 
consent to contact their siblings and to provide sibling contact information. Beginning in 2010, 
we sent siblings the same questionnaire as CCS, but omitted questions about cancer history. 
Siblings who did not respond were sent another copy of the questionnaire four to six weeks 
later, but were not contacted by phone.  
 
General population controls (Swiss Health Survey) 
The second control group consisted of participants in the 2007 SHS survey. The SHS is a 
national representative telephone survey repeated every five years. The SHS compiled a 
randomly selected representative sample of 28’332 Swiss households with telephone land 
lines and attempted to contact one person per household. Of households called, 6’185 did not 
answer, and 3’414 refused to participate. The final sample included 18’760 participants (66% 
response rate) [20]. Sampling was stratified by region and conducted stepwise. Households 
were selected first, and then the survey was administered to anyone 15 or older who answered 
the phone.  
 
Measurements  
Dietary intake and adherence to dietary recommendations 
In CCS and control groups, dietary intake was assessed with standardised open and closed 
questions. The same standard units and serving sizes for each food item were used in the 
CCS and sibling surveys. They were also the same in the SHS survey for the general 
population. The questionnaire to survivors and siblings offers a choice of six responses to 
describe frequency of intake, ranging from “never” to “several times per day”. It also offers 
open questions where participants can indicate the portions they consume per day 
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(Supplemental Figure S1). The SHS survey offers similar options, though questions about 
frequency of fruit and vegetable intake were phrased slightly differently. We thus transformed 
the SHS questions on fruit and vegetable intake into the following daily consumption 
frequencies: “never”=0; “less than 1/day”=0.5; “1-2/day”=1.5; “3-4/day”=3.5 and “5+/day”=5.5. 
From the SHS survey, we obtained fruit and vegetable consumption by summing up fresh and 
conserved fruit or vegetable products and fruit or vegetable juices. The questionnaire to CCS 
and siblings assessed only fruit and vegetable products. Questions about fish intake also 
differed slightly. In the SHS survey, the general population could indicate the exact number of 
days per week they consumed fish, but CCS and siblings could only select from categories 
that specified a range. 
We used current recommendations from the Swiss Society of Nutrition (SSN) to 
determine adequate intake of fruit, vegetable, meat, fish, and dairy products [22]. SSN 
recommendations are in line with those of other European countries [23-25]. We determined 
failure to comply with these dietary recommendations by calculating the proportion of 
participants who did not eat the minimum recommended daily number of servings of each food 
group. The lowest values of the following recommended ranges were our cut-off values: two 
portions of fruit (120g) per day; three portions of vegetable (120g) per day; one portion of fish 
(100-120g) per week, and three portions of dairy (2dl milk, 150-200g yoghurt or 30-60g 
cheese) per day. We used the maximum cut-off value for meat: three portions of meat (100-
120g) per week.  
 
Explanatory variables from the Swiss Childhood Cancer Survivor Study (SCCSS) 
We assessed the following explanatory variables from the questionnaires submitted by CCS, 
siblings, and the general population: socio-demographic data (gender; age at survey; 
education level; parents’ education level; migration background; and, language region in 
Switzerland) and lifestyle factors (body mass index [BMI]); smoking; sport participation; and, 
alcohol consumption). Participants who were not Swiss citizens at birth, not born in 
Switzerland, or had at least one parent who was not a Swiss citizen were designated to have 
a migration background. We classed education into four categories, according to the Swiss 
Census: compulsory schooling only (≤9 years); vocational training (10-13 years); upper 
secondary education (higher vocational training or college); and, university degree. We divided 
highest education level of parents into three categories: primary schooling (compulsory 
schooling only [≤9 years]); secondary education (vocational training [10-13 years]; higher 
vocational training or college); and, tertiary education (university degree). We calculated BMI 
from self-measured height and weight, dividing weight by height in meters squared (kg/m2). 
For adolescents (16–19 years at survey), we standardized BMI into z-scores for age and 
gender using the Swiss references [26]. BMI was classified as underweight (>19yrs: 
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<18.5kg/m2; ≤19yrs: <-2 Z-scores), normal weight (>19yrs: ≥18.5 - <25kg/m2; ≤19yrs: ≥-2 - ≤1 
Z-scores), overweight (>19yrs: ≥25 - <30kg/m2; ≤19yrs: >1 - ≤2 Z-scores), and obese (>19yrs: 
≥30kg/m2; ≤19yrs: >2 Z-scores). Sport participation was classified as ‘‘sports’’ if respondents 
reported engaging at least somewhat intensely in a targeted gym or sport for at least one hour 
per week, or ‘‘no sports’’ if participation was lower. 
 
Explanatory variables from the Swiss Childhood Cancer Registry (SCCR) 
Clinical information was extracted from the SCCR. We recorded diagnosis and the age at 
which cancer was diagnosed. Diagnosis was classified according to the International 
Classification of Childhood Cancer – 3rd Edition [27]. Chemotherapy was divided into 
“anthracyclines”; “other chemotherapeutic agents” or “no chemotherapy”. Radiotherapy was 
classified as “chest radiotherapy” if direct radiation was applied to the chest, “other 
radiotherapy” or “no radiotherapy”. Chest radiotherapy included total body irradiation, 
mantlefield irradiation or irradiation to the thorax, mediastinum, or thoracic spine. There was a 
record if a CCS had relapsed during follow-up time.  
 
Statistical Analyses  
Our analysis included all participants in the SCCSS (CCS and siblings) and the SHS (general 
population), aged 16-45 years at time of survey. Both control groups included more women 
and older persons than the CCS. Migrants and non-German speakers were less frequent 
among siblings, but more frequent in the general population. To increase the validity of the 
comparison between CCS and the control groups, we standardised both control groups for 
gender, age, migration background, and language region, according to the distribution in CCS 
(Table I). Standardisation was applied in all analyses, and was used as in previous 
publications [28, 29].  
The first step in our analysis was to compare socio-demographic and clinical 
characteristics and adherence to national dietary recommendations in CCS and control groups 
using chi2 tests.  
Second, we used logistic regressions to determine factors associated with dietary 
adherence by estimating crude and adjusted odds ratios (OR) and 95% confidence intervals 
(95%CI). In univariable analyses, we tested each individual socio-demographic and lifestyle 
variable. If variables were significant on a p-value of <0.05, we included them in the 
multivariable analyses. We performed Wald tests to calculate global p-values. We used 
interaction terms to formally test differences in effects of risk factors between CCS and 
controls. We selected potential confounders and effect modifiers based on the literature.  
Third, and in CCS only, we investigated associations between adherence to dietary 
recommendations and different CVD risk profiles (the profiles were based on type of 
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treatment). CVD risk profiles were categorized as “no chemo- and radiotherapy”, “other chemo- 
and/or radiotherapy” (no anthracyclines and no chest radiotherapy), “either anthracyclines or 
chest radiotherapy”, and “both anthracyclines and chest radiotherapy”. We conducted tests for 
linear trend for the ordered categorical CVD risk profiles. 
We performed sensitivity analyses to compare standardised data for gender, age, 
migration background and language region in both control groups according to the distribution 
in CCS to non-standardised data. We used Stata software (version 14, Stata Corporation, 
Austin, Texas) for all statistical analysis. All statistical significance tests were two-sided with a 
significance level of 5%. 
 
RESULTS 
Characteristics of study population 
We traced and contacted 3’593 of 4’116 eligible CCS. Of those we contacted, 2’527 (70%) 
returned the full questionnaire. We excluded 520 participants who were younger than 16 or 
older than 45 years, and 143 participants who did not provide data on diet. We thus included 
1’864 CCS in the analysis (Supplemental Figure S2). We had consent to contact 1’295 
siblings, of whom 733 returned the questionnaire; 32 were outside the age range, and three 
did not provide data on diet. Of 28’332 households surveyed, one person per each of 18’760 
households (66%) replied to the survey. Of these, 8’258 were between 16-45 years old. 
More CCS than controls had completed compulsory schooling only (12% vs. 7% 
siblings and 5% general population) and fewer CCS had earned a university degree (7% vs. 
11% siblings and 10% general population; all p<0.001) (Table I). Mean BMI did not differ 
between groups, but BMI categorisation was significantly different: CCS were more likely to be 
underweight (4% vs. 1% siblings and 2% general population) or obese (7% vs. 4% siblings; 
and 4% general population; psiblings=0.001 and pSHS<0.001). CCS were less likely to smoke than 
the general population (24% vs. 34%, pSHS<0.001). We found no significant difference between 
CCS and siblings for smoking. More CCS than controls consumed never or rarely alcohol (51% 
vs. 36% siblings and 44% general population; all p<0.001). CCS were less likely to engage in 
sports than both control groups (55% vs. 65% siblings and 64% general population; all 
p<0.001).  
Among CCS, the largest diagnostic group was leukaemia (32%), followed by lymphoma 
(20%) and CNS tumours (14%) (Table II). When we divided CCS into CVD risk profiles, 17% 
did not receive chemo- and radiotherapy (lowest risk category), 37% had received other 
chemotherapeutic agents than anthracyclines and/or other radiotherapy than chest 
radiotherapy, 39% either anthracyclines or chest radiotherapy, and 7% had both 
anthracyclines and chest radiotherapy (highest risk category). Mean age at diagnosis was 8.8 
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± 5.5 years and mean time since diagnosis was 17.2 ± 6.9 years. Twelve percent had 
experienced a relapse.  
Table I. General characteristics of childhood cancer survivors (CCS), their siblings and the 
general population (Swiss Health Survey)  
 CCS 
(n=1864) 
Siblingsa  
(n=698) 
General populationa 
(n=8258) 
Characteristics n  (%) n  (%std)      p-valueb n  (%std)        p-valuec 
Gender 
  Male 
  Female 
 
978    (52) 
886    (48) 
 
288   (53)         n.a. 
410   (47) 
 
3886  (53)         n.a. 
4372  (47) 
Age at survey (years) 
  <20 
  20-29 
  30-39 
  ≥40 
 
449    (24) 
886    (48) 
438    (24) 
91      (5) 
 
110   (24)         n.a. 
331   (48) 
201   (23) 
56     (5) 
 
747    (25)         n.a. 
1959  (47) 
3246  (23) 
2306  (5) 
Education (highest degree) 
  Compulsory schooling 
  Vocational training 
  Upper secondary education 
  University education 
 
230    (12) 
872    (47) 
632    (34) 
130    (7) 
 
45     (7)      <0.001 
292   (42) 
286   (40) 
75     (11) 
 
596    (5)      <0.001 
4668  (63) 
1924  (22) 
1070  (10) 
Parents’ education (highest degree) 
  Primary schooling 
  Secondary education 
  Tertiary education 
 
169    (9) 
1351  (73) 
344    (19) 
 
59     (7)        0.214 
513   (73) 
126   (20) 
 
n.a.d                            n.a. 
Migration  
  No migration background 
  Migration background 
 
1423  (76) 
441    (24) 
 
561   (77)         n.a. 
137   (23) 
 
4901  (77)         n.a. 
3357  (23) 
Language region of Switzerland 
  German speaking 
  French speaking 
  Italian speaking 
 
1310  (70) 
495    (27) 
59      (3) 
 
565   (71)         n.a. 
112   (26) 
21     (3) 
 
5068  (70)         n.a. 
2580  (27) 
610    (3) 
BMIe 
  Underweight  
  Normal  
  Overweight  
  Obese  
 
72      (4) 
1324  (71) 
347    (19) 
121    (7) 
 
11     (1)        0.001 
508   (75) 
146   (20) 
33     (4) 
 
178    (2)      <0.001 
5702  (76) 
1907  (18) 
471    (4)  
Smoking 
  Current smoker 
  Stopped smoking 
  Never smoked 
 
443    (24) 
210    (11) 
1211  (65) 
 
155   (23)      0.491 
101   (13) 
442   (64) 
 
2688  (34)    <0.001 
1209  (10) 
4361  (56) 
Alcohol 
  Never/rarely 
  Weekly, ≥1 std drink/week 
  Daily, 1 std drink/day 
  Frequently, >1 std drink/day 
 
956    (51) 
747    (40) 
65      (3) 
96      (5) 
 
275   (36)    <0.001 
358   (52) 
22     (3) 
43     (9) 
 
3728  (44)    <0.001 
4012  (53) 
435    (3) 
83      (6) 
Sports 
  Yes  
  No 
 
1016  (55) 
848    (46) 
 
447   (65)    <0.001 
251   (35) 
 
4722  (64)    <0.001 
3536  (36) 
BMI: body mass index; n.a.: not applicable; std: standard alcoholic drink;  
a: Standardized on gender, age at survey, migration background and language region according to the CCS population;  
b: p-value calculated from Chi-Square statistics comparing CCS to siblings (2-sided test);  
c: p-value calculated from Chi-Square statistics comparing CCS to general Swiss population (2-sided test);  
d: No data on parental education within the Swiss Health Survey available;  
e: BMI Z-scores were calculated for subjects ≤19 years, BMI scores (kg/m2) were calculated for adults (>19 years). 
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Table II. Clinical characteristics of childhood cancer survivors (CCS)  
 CCS 
(n=1864) 
Characteristics n       (%) 
Clinical treatment 
  Paediatric cancer centrea 
  Other clinic 
 
1590  (85) 
274    (15) 
ICCC3 diagnosis 
  I: Leukaemia 
  II: Lymphoma 
  III: CNS tumour 
  IV: Neuroblastoma 
  V: Retinoblastoma 
  VI: Renal tumour 
  VII: Hepatic tumour 
  VIII: Bone tumour 
  IX: Soft tissue sarcoma 
  X: Germ cell tumour 
  XI & XII: Other tumour 
  Langerhans Cell Histiocytosis 
 
600    (32) 
371    (20) 
261    (14) 
76      (4) 
40      (2) 
108    (6) 
11      (1) 
81      (4) 
112    (6) 
89      (5) 
47      (3) 
68      (4) 
CVD risk profile 
  No chemo- and RT  
  Other chemo- and/or RT (no anthracyclines and no chest RT)b 
  Either anthracyclines or chest RTc  
  Both antracyclines and chest RT 
 
314    (17) 
694    (37) 
718    (39) 
138    (7) 
Age at diagnosis (years) 
  <5 
  5-9 
  10-14 
  15-20 
 
604    (32) 
455    (24) 
521    (28) 
284    (15) 
Time since diagnosis (years) 
  <15 
  ≥15 
 
746    (40) 
1118  (60) 
History of relapse 
  No 
  Yes 
 
1636  (88) 
228    (12) 
CNS: central nervous system; CVD: cardiovascular disease; ICCC3: International Classification of Childhood Cancer, 3rd edition; 
RT: radiotherapy;  
a: Including the following clinics with paediatric oncology units Kantonsspital Aarau AG, Universitäts-Kinderspital Basel, Ospedale 
S. Giovanni Bellinzona, Universitäts-Kinderklinik Bern, Hôpital des Enfants Genève, CHUV Lausanne, Kantonsspital Luzern, 
Ostschweizer Kinderspital St. Gallen, Universitäts-Kinderspital Zurich;  
b: Other chemotherapeutic agents and radiotherapy than anthracyclines and chest radiotherapy;  
c: Chest radiotherapy includes direct radiation applied to the chest, including total body irradiation, mantlefield irradiation or 
irradiation to the thorax, mediastinum, or thoracic spine. 
 
Dietary adherence in CCS and control groups 
Overall dietary adherence was low (Figure I, Supplemental Table S1). The highest scores 
on adherence were for meat (37-43%), fish (26-55%) and fruit (24-39%). The lowest scores 
for adherence were for the combination of two servings of fruit/day and three servings of 
vegetables/day (6-7%). We saw no large differences between CCS, their siblings, and the 
general population. CCS were slightly less adherent than their siblings to fruit intake 
recommendations (psiblings=0.011), more adherent to recommendations for eating meat 
(psiblings=0.011), and tended to adhere better to recommendations for eating fish (psiblings=0.075). 
CCS were more adherent than the general population to recommendations for fruit 
(pSHS<0.001), meat (pSHS=0.003) or dairy products (pSHS<0.001), but less adherent to 
recommendations for vegetables (pSHS=0.009) or fish (pSHS<0.001). Although these differences 
42 
 
were statistically significant, the absolute differences between the groups were small and 
clinically irrelevant.  
 
 
Figure 1. Adherence to dietary recommendations among childhood cancer survivors (CCS), 
their siblings and the general population (Swiss Health Survey) 
Data are proportions with 95% confidence intervals. Siblings and the general population (SHS) are standardised on gender, age, 
migration background and language region according to the CCS population. P-values were calculated from Chi-Square statistics 
comparing CCS to siblings or CCS to the general population (SHS) (2-sided test), *: p-value<0.05, **: p-value<0.001  
 
Determinants of dietary adherence in CCS and control groups 
In univariable logistic regressions, factors associated with better adherence to dietary 
recommendations were female gender, age (depending on the food group), higher education, 
higher parental education, migration background, residence in the French or Italian speaking 
part of Switzerland, being underweight or having a healthy BMI, not a smoker, no-to-rarely 
alcohol consumption (those who ate enough fish tended to consume more alcohol), and sport 
participation (Results available upon request). Since all socio-demographic and lifestyle 
variables were significant for at least one outcome, we included all of them in the multivariable 
models when we investigated CCS (Table III, Supplemental Table S2), their siblings (Results 
available upon request), and the general population (Supplemental Table S3), and when we 
looked at cancer-related determinants in CCS only (Supplemental Table S5). 
Socio-demographic and lifestyle determinants. In CCS, several socio-demographic 
and lifestyle factors were related to adherence to dietary recommendations in multivariable 
logistic regressions (Table III, Supplemental Table S2). CCS who ate enough fruit and 
vegetables were more often female, had more educated parents, a migration background, 
residence in the French-speaking part of Switzerland, participated in sports, and tended to 
have higher BMI. Meat adherence was associated with female gender, older age, a migration 
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background, residence in the French- or Italian-speaking part of Switzerland, current smoking, 
never-to-rare alcohol consumption, and sports participation. As with adherence to 
recommendations for meat intake, CCS who ate enough fish were older; had a migration 
background, were from the French- or Italian-speaking part of Switzerland, and participated in 
sports. More highly educated participants and non-smokers were more likely to eat enough 
fish. The opposite was true for the intake of dairy products. Maleness, younger age, and no 
migration background were associated with adherence to recommendations for dairy intake. 
After we performed interaction tests (Supplemental Table S4), we found no evidence 
that the effect of risk factors differed between CCS and their siblings (all interaction p-values 
>0.05). This means that the same socio-demographic and lifestyle factors were associated 
with dietary adherence in both CCS and siblings. However, the strength of the associations 
between some risk factors and dietary adherence differed between CCS and the general 
population (interaction p-values <0.05) (Supplemental Table S4). When comparing effect sizes 
between CCS (Table III, Supplemental Table S2) and the general population (Supplemental 
Table S3), differences were small and hardly clinically relevant.  
Cancer-related determinants. After controlling for socio-demographic and lifestyle 
factors, we found that cancer-related factors among CCS were not significantly associated with 
adherence to dietary recommendations (Supplemental Table S5). CCS diagnosed at age 5-9 
were less likely to adhere to combined fruit and vegetables and vegetable recommendations 
than CCS diagnosed younger than five years.  
We found no important differences in the sensitivity analyses that compared 
standardised data to non-standardised data. Both types of analyses led to the same 
conclusions. 
 
Dietary adherence among different CVD risk profiles 
There was no relevant difference in adherence to dietary recommendations between CVD risk 
profiles based on type of chemo- and radiotherapy and p-values for trend were insignificant 
(p>0.10) (Figure 2). We did see a trend for adherence to meat recommendations, which was 
slightly higher in all risk groups than in the group of CCS who had not received chemo- and 
radiotherapy.  
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Table III. Adherence to dietary recommendations among childhood cancer survivors, and socio-demographic predictors for adherence (retrieved 
from multivariable logistic regressions)  
 Fruit/vegetable ≥5 portions/day 
(n=123) 
Fruit ≥2 portions/day 
(n=624) 
Vegetable ≥3 portions/day 
(n=196) 
 %a    OR (95%CI)b p-valuec %a OR (95%CI)b p-value c %a OR (95%CI)b p-value c 
Gender  
  Male 
  Female 
 
5 
8 
 
1.00 (ref)  
1.48 (1.00; 2.18) 
 
0.051 
 
26 
42 
 
1.00 (ref)  
2.18 (1.77; 2.69) 
 
<0.001 
 
8 
13 
 
1.00 (ref)  
1.67 (1.21; 2.29) 
 
0.002 
Age at survey (years) 
  <20  
  20-29 
  30-39 
  ≥40 
 
7 
7 
7 
3 
 
1.00 (ref)  
1.23 (0.75; 2.02) 
1.26 (0.70; 2.25) 
0.56 (0.16; 1.96) 
 
0.512 
 
35 
34 
32 
31 
 
1.00 (ref)  
1.02 (0.78; 1.34) 
0.97 (0.70; 1.33) 
0.89 (0.53; 1.50) 
 
0.938 
 
11 
11 
9 
9 
 
1.00 (ref)  
1.18 (0.79; 1.76) 
0.91 (0.56; 1.48) 
0.83 (0.36; 1.89) 
 
0.542 
Education (highest degree) 
  Compulsory schooling 
  Vocational training 
  Upper secondary education 
  University education 
 
9 
6 
8 
3 
 
1.44 (0.83; 2.52) 
1.00 (ref)  
1.16 (0.75; 1.79) 
0.39 (0.13; 1.18) 
 
0.138 
 
36 
32 
35 
31 
 
1.20 (0.87; 1.65) 
1.00 (ref)  
1.02 (0.81; 1.29) 
0.78 (0.50; 1.21) 
 
0.416 
 
13 
10 
12 
8 
 
1.33 (0.84; 2.10) 
1.00 (ref)  
1.19 (0.83; 1.69) 
0.75 (0.36; 1.58) 
 
0.379 
Parents’ education (highest degree) 
  Primary schooling 
  Secondary education 
  Tertiary education 
 
6 
6 
9 
 
1.00 (ref)  
1.53 (0.75; 3.12) 
2.64 (1.19; 5.88) 
 
0.022 
 
31 
32 
39 
 
1.00 (ref)  
1.15 (0.79; 1.67) 
1.55 (1.00; 2.39) 
 
0.055 
 
13 
10 
13 
 
1.00 (ref)  
0.91 (0.54; 1.53) 
1.35 (0.74; 2.46) 
 
0.141 
Migration 
  No migration background 
  Migration background 
 
6 
10 
 
1.00 (ref)  
2.07 (1.37; 3.14) 
 
<0.001 
 
32 
37 
 
1.00 (ref)  
1.31 (1.02; 1.68) 
 
0.034 
 
9 
16 
 
1.00 (ref)  
1.92 (1.36; 2.70) 
 
<0.001 
Language region  
  German speaking  
  French speaking 
  Italian speaking 
 
6 
8 
5 
 
1.00 (ref)  
1.29 (0.85; 1.95) 
0.79 (0.24; 2.63) 
 
0.423 
 
32 
38 
27 
 
1.00 (ref)  
1.31 (1.04; 1.65) 
0.75 (0.41; 1.37) 
 
0.032 
 
10 
12 
9 
 
1.00 (ref)  
1.13 (0.80; 1.59) 
0.75 (0.29; 1.95) 
 
0.629 
 Meat ≤1-3 days/week 
(n=807) 
Fish ≥1 day/week 
(n=554) 
Dairy ≥3 portions/day 
(n=330) 
Gender  
  Male 
  Female 
 
29 
59 
 
1.00 (ref)  
3.09 (2.52; 3.79) 
 
<0.001 
 
31 
28 
 
1.00 (ref) 
0.95 (0.76; 1.18) 
 
0.616 
 
20 
15 
 
1.00 (ref) 
0.63 (0.49; 0.82) 
 
<0.001 
Age at survey (years) 
  <20  
  20-29 
  30-39 
  ≥40 
 
38 
45 
45 
45 
 
1.00 (ref)  
1.41 (1.08; 1.85) 
1.62 (1.18; 2.22) 
1.58 (0.95; 2.63) 
 
0.021 
 
26 
27 
38 
37 
 
1.00 (ref)  
1.14 (0.85; 1.53) 
1.76 (1.26; 2.45) 
1.76 (1.05; 2.95) 
 
0.001 
 
25 
17 
14 
10 
 
1.00 (ref) 
0.66 (0.48; 0.90) 
0.56 (0.38; 0.83) 
0.34 (0.16; 0.72) 
 
0.004 
Education (highest degree) 
  Compulsory schooling 
  Vocational training 
 
51 
40 
 
1.50 (1.09; 2.06) 
1.00 (ref) 
 
0.096 
 
30 
25 
 
1.37 (0.97; 1.93) 
1.00 (ref)  
 
0.022 
 
21 
19 
 
1.01 (0.69; 1.48) 
1.00 (ref)  
 
0.517 
45 
 
  Upper secondary education 
  University education 
45 
45 
1.10 (0.88; 1.39) 
1.05 (0.68; 1.60) 
32 
48 
1.25 (0.98; 1.60) 
1.77 (1.17; 2.68) 
16 
11 
0.87 (0.66; 1.16) 
0.66 (0.36; 1.22) 
Parents’ education (highest degree) 
  Primary schooling 
  Secondary education 
  Tertiary education 
 
48 
42 
46 
 
1.00 (ref)  
0.98 (0.68; 1.41) 
1.20 (0.78; 1.83) 
 
0.356 
 
37 
28 
35 
 
1.00 (ref)  
0.83 (0.58; 1.20) 
1.03 (0.67; 1.59) 
 
0.231 
 
11 
16 
24 
 
1.00 (ref)  
1.10 (0.68; 1.78) 
1.29 (0.74; 2.24) 
 
0.548 
Migration 
  No migration background 
  Migration background 
 
41 
50 
 
1.00 (ref)  
1.49 (1.16; 1.90) 
 
0.002 
 
27 
40 
 
1.00 (ref)  
1.72 (1.34; 2.21) 
 
<0.001 
 
19 
15 
 
1.00 (ref)  
0.70 (0.51; 0.97) 
 
0.032 
Language region  
  German speaking  
  French speaking 
  Italian speaking 
 
42 
46 
59 
 
1.00 (ref)  
1.18 (0.94; 1.49) 
2.08 (1.17; 3.69) 
 
0.023 
 
24 
42 
44 
 
1.00 (ref)  
1.98 (1.57; 2.49) 
2.25 (1.30; 3.90) 
 
<0.001 
 
19 
14 
15 
 
1.00 (ref)  
0.76 (0.57; 1.03) 
0.80 (0.38; 1.68) 
 
0.196 
CI: confidence interval; OR: odds ratio;  
a: Column percentages are given;  
b: Adjusted for: 1) socio-demographic variables: gender, age category, education level, migration background, and language region in Switzerland and 2) lifestyle factors: BMI category, smoking status, 
alcohol intake, and sport participation;  
c: global p-value for an association between adherence to national dietary recommendations and the variable as a whole (Wald test comparing models with and without the variable)
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Figure 2. Adherence to dietary recommendations among childhood cancer survivors over 4 
cardiovascular disease risk profiles  
Dots are OR’s and whiskers 95% CI. CI: confidence interval; CVD: cardiovascular disease; OR: odds ratio; RT: radiotherapy not 
including chest. Multivariable analysis for adherence to nutritional recommendations per CVD risk profile were adjusted for: 1) 
socio-demographic variables: gender, age category, education level, parental education level, migration background, and 
language region in Switzerland and 2) lifestyle factors: BMI category, smoking status, alcohol intake, and sport participation; All 
p-values for trend were insignificant (p-value>0.10) between the different CVD risk profiles for adherence to dietary 
recommendations;  
Other chemo- and/or RT indicates other chemotherapeutic agents and radiotherapy than anthracyclines and chest radiotherapy. 
 
DISCUSSION  
Principal findings 
We found that CCS poorly adhered to dietary recommendations, but that adherence of siblings 
and the general Swiss population was equally poor. Predictors of adherence in CCS were 
similar in siblings, but differed somewhat from the general population. Adherence to dietary 
recommendations was not better among CCS with a higher CVD risk because of cardiotoxic 
treatment.  
 
Dietary adherence in Switzerland and the rest of the world 
Ours is the largest study to compare the adherence of adolescents and young adult CCS and 
control groups to national dietary recommendations. Our findings on low adherence are in line 
with data from the 6th Swiss Nutrition Report [30] and the population-based cross-sectional 
study of de Abreu et al. 2013 in the French-speaking part of Switzerland, which reported only 
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39% of the participants adhered to Swiss recommendations for fruit intake, 7% for vegetables, 
61% for meat, 66% for fish and 8% for dairy products [31]. We found adherence for meat was 
lower, probably because national recommendation guidelines for consumption of meat 
dropped from ≤5 days per week to ≤1-3 days per week [22] between de Abreu’s and our study. 
Our findings also concord with the few studies that reported dietary adherence among CCS. 
Demark-Wahnefried et al. found that only 20% of the 209 US CCS consumed the 
recommended five servings of fruit and vegetables per day [32]. Similar poor adherence levels 
for fruit and vegetables were observed in more recent and larger US studies [13, 14]. Although 
meat recommendations were different in previous studies, overall meat adherence was low in 
CCS. Only 10% adhered to the World Cancer Research Fund/American Institute for Cancer 
Research guidelines to consume less than 80 grams of red meat per day [14]. A study from 
the US CCSS also found that less than half of CCS met the American Cancer Society (ACS) 
recommendations to eat less than 18 oz (+/-500g) of red and processed meat per week [13]. 
 
Dietary adherence among CCS compared to control groups 
CCS and siblings had similar levels of dietary adherence, as also found by a US study based 
on Healthy Eating Index-2005 (HEI) scores [11]. However, our comparison of CCS to the 
general population revealed more significant differences in adherence. When we looked at the 
proportion of CCS and the general population that adhered to dietary recommendations (e.g., 
18% adherence for dairy products among CCS vs. 12% among the general population) we 
found the observed differences were, although statistically significant, clinically irrelevant. A 
cross-sectional study between CCS and the general US population came to similar 
conclusions, finding no relevant differences after basing their analyses on adherence criteria 
from the ACS Guidelines on nutrition [13].  
 
Gender and migration background differences 
Females adhered better to fruit, vegetable, and meat recommendations. Males were more 
adherent to dairy products recommendations. These match previous Swiss [31, 33] and 
European [34] findings. The reasons for these gender differences are unclear. Males and 
females may be socialized differently, and exposed to different amounts of information about 
diet and health. It is also possible that males and females have different tastes, different levels 
of interest in healthy diets, and different eating goals. Although women were almost twice as 
likely to adhere to dietary recommendations for fruit, vegetable and meat intake than men were, 
adherence levels were still far from ideal for either gender and both need improvement.  
 Migration background was associated with higher adherence to recommendations for all 
food groups except dairy products. Much of the Swiss population with a migration background 
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is from Southern Europe, where people commonly eat a Mediterranean diet already rich in 
fruit, vegetables and fish, and poor in meat and dairy products [35].  
 
Dietary adherence and CVD risk profiles 
Low intake of fruit, vegetable, fish and dairy products are already a concern in the general 
population, but may have a more deleterious effect on CCS. Better adherence to dietary 
recommendations lowers the risk of all-cause mortality, CVD mortality, cancer incidence and 
mortality, and Type II diabetes mellitus among adults by 15 to 22% [6]. Since CCS are up to 
15 times more likely to have heart failure than their siblings [27], risk factors like poor diet may 
exacerbate this [4-6]. CCS with baseline risk elevated by cancer treatment may strongly benefit 
from a good diet, but we found no differences in adherence levels among CCS for different 
CVD risk profiles. As in our study, Landy et al. found little to no difference between dietary 
intake and cancer diagnosis and therapy, except for exposure to cranial irradiation, which was 
related to even poorer adherence [11].  
 
Implications for clinical practice  
The national organisation Swiss Cancer League (www.liguecancer.ch) emphasizes in cancer 
prevention campaigns to increase fruit and vegetable consumption and reduce alcohol, red 
and processed meat intake. This could partly explain the higher levels of fruit and meat 
adherence in CCS. However, it is unclear to which extent CCS are aware of these dietary 
recommendations and if diet is perceived as a risk factor for late effects. Current CCS 
guidelines do not specifically focus on diet [8]. 
We performed a short survey among the nine Swiss paediatric oncology clinics to 
assess whether they discussed diet issues during follow-up visits. Six replied that they discuss 
diet in case CCS suffer from nutritional related late effects, and three indicated to discuss it 
routinely during each follow-up visit (personal communication). Given the strong evidence 
about diet and health in general and the increasing data for CCS, focus should be placed on 
the importance of good eating habits during annual long-term follow up visits. Follow-up visits 
are especially recommended for CCS with moderate to severe late health effects or high risk 
cancer treatment, a group which could benefit of dietary counselling [36]. 
General dietary recommendation campaigns are equally widespread between 
language regions within Switzerland. As regional differences in adherence are seen, 
campaigns should be adapted to federal state and regional level, which will not only benefit 
CCS but also the general population. 
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Strengths and limitations 
Our study is limited by the fact that all available data were self-reported; so social desirability 
bias and subjective interpretation could have favourably biased the results. The different 
survey designs (questionnaire in CCS and siblings, telephone interviews in the general 
population) might have influenced the results. For example, respondents might list alcohol 
consumption more moderately in a telephone interview than a written survey. Differences in 
level of adherence to recommendations for fruit and fish intake between CCS and the general 
population may have been a product of differently worded survey answers. Our study was 
strengthened by its national coverage of the SCCSS, our large sample size, and the high 
response rate among CCS, which made our results representative. We had access to high 
quality clinical information extracted from the SCCR. The questionnaires gave us access to a 
wide variety of socio-demographic, and lifestyle factors. We compared adherence of CCS with 
both siblings (who share environmental factors with CCS) and a representative population-
based study performed simultaneously in Switzerland (so we could account for different 
environmental factors). 
 
CONCLUSION  
Large-scale studies with systematic and standardised dietary assessments, such as 24h 
recalls and validated food frequency questionnaires would help more precisely assess 
nutritional intake among CCS, and determine if food intake patterns are associated with cancer 
diagnoses, treatments, patient characteristics, adverse somatic late effects, and survival 
outcomes. Finding these connections would provide incentive for CCS to eat a balanced diet 
because it could lessen their chance of suffering adverse late effects. Poor eating habits may 
predispose CCS to chronic comorbidities or increase the likelihood they will develop a 
secondary neoplasm [4-6, 8, 14]. More focus should be placed on improving dietary adherence 
during clinical follow up, especially for CCS with high CVD risk profiles. 
Though no worse than their siblings or the general population, CCS adhere poorly to 
nutritional recommendations, and may be more susceptible to health problems caused by poor 
nutrition.  
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SUPPLEMENTARY MATERIAL 
 
Table S1. Adherence to dietary recommendations among childhood cancer survivors (CCS), their 
siblings and the general population (Swiss Health Survey)  
 CCS 
(n=1864) 
Siblingsa 
(n=698) 
General populationa 
(n=8258) 
 n  (%) n  (%std)    p-valueb n  (%std)    p-valuec 
Dietary intake 
Fruit/vegetable, portion: +/-120g 
  Non-adherence: <5 portions/day 
  Adherence: ≥ 5 portions/day  
 
1741  (93) 
123    (7) 
 
654   (94) 
44     (6)      0.702 
 
7684  (93) 
574    (7)       0.839 
Fruit, portion: +/-120g 
  Non-adherence: <2 portions/day  
  Adherence: ≥2 portions/day  
 
1240  (67) 
624    (34) 
 
411   (61) 
287   (39)    0.011 
 
6350  (76) 
1908  (24)   <0.001 
Vegetable, portion: +/-120g 
  Non-adherence: <3 portions/day 
  Adherence: ≥3 portions/day  
 
1668  (90) 
196    (11) 
 
632   (91) 
66     (9)      0.421 
 
7142  (87) 
1116  (13)     0.009 
Meat  
  Non-adherence: ≥4-5 days/week  
  Adherence: ≤1-3 days/week 
 
1057  (57) 
807    (43) 
 
429   (63)    
269   (37)    0.011  
 
4479  (61)   
3779  (39)     0.003 
Fish  
  Non-adherence: <1 day/week 
  Adherence: ≥1 day/week 
 
1310  (70)d 
554    (30) 
 
531   (74)d 
167   (26)    0.075 
 
3112  (45)d 
5146  (55)   <0.001 
Dairy, portion: +/-2dl, 125ml or 30-60g 
  Non-adherence: <3 portions/day 
  Adherence: ≥3 portions/day  
 
1534  (82) 
330    (18) 
 
592   (84) 
106   (16)    0.345 
 
7433  (88) 
825    (12)   <0.001 
CCS: childhood cancer survivors;  
a: Standardized on gender, age, migration background and language region according to the CCS population;  
b: p-value calculated from Chi-Square statistics comparing CCS to siblings (2-sided test);  
c: p-value calculated from Chi-Square statistics comparing CCS to general Swiss population (2-sided test);  
d: Missing observation for fish intake: 6% (n=106), 4% (n=31), and <1% (n=10) for CCS, siblings and the general Swiss population, 
respectively. Missing values were assigned to medium intake  
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Table S2. Adherence to dietary recommendations among childhood cancer survivors, and lifestyle predictors for 
adherence (retrieved from multivariable logistic regressions)  
BMI: body mass index; CI: confidence interval; OR: odds ratio; std: standard alcoholic drink;  
a: Column percentages are given; 
b: Adjusted for: 1) socio-demographic variables: gender, age category, education level, migration background, and language region in Switzerland and 2) 
lifestyle factors: BMI category, smoking status, alcohol intake, and sport participation;  
c: global p-value for an association between adherence to national dietary recommendations and the variable as a whole (Wald test comparing models with 
and without the variable).  
 Fruit/vegetable ≥5 portions/day 
(n=123) 
Fruit ≥2 portions/day 
(n=624) 
Vegetable ≥3 portions/day 
(n=196) 
 %a    OR (95%CI)b p-valuec %a OR (95%CI)b p-value c %a OR (95%CI)b p-value c 
BMI 
  Underweight  
  Normal  
  Overweight  
  Obese  
 
7 
6 
7 
10 
 
0.99 (0.38; 2.58) 
1.00 (ref)  
1.29 (0.80; 2.10) 
1.82 (0.93; 3.56) 
 
0.303 
 
22 
34 
30 
40 
 
0.48 (0.27; 0.86) 
1.00 (ref)  
0.97 (0.74; 1.27) 
1.44 (0.96; 2.16) 
 
0.019 
 
11 
10 
11 
16 
 
1.01 (0.47; 2.19) 
1.00 (ref)  
1.24 (0.83; 1.85) 
1.83 (1.05; 3.17) 
 
0.167 
Smoking 
  Never smoked  
  Stopped smoking 
  Current smoker 
 
7 
8 
6 
 
1.00 (ref)  
1.26 (0.70; 2.26) 
0.97 (0.60; 1.56) 
 
0.699 
 
35 
33 
30 
 
1.00 (ref)  
0.95 (0.68; 1.32) 
0.91 (0.70; 1.16) 
 
0.732 
 
10 
12 
11 
 
1.00 (ref)  
1.32 (0.82; 2.13) 
1.16 (0.80; 1.68) 
 
0.468 
Alcohol 
  Never/rarely 
  Weekly, ≥1 std drink/week 
  Daily, 1 std drink/day 
  Frequently, >1 std drink/day 
 
7 
6 
2 
5 
 
1.00 (ref)  
0.97 (0.64; 1.49) 
0.26 (0.03; 1.93) 
0.87 (0.32; 2.36) 
 
0.616 
 
36 
33 
25 
21 
 
1.00 (ref)  
1.02 (0.82; 1.29) 
0.84 (0.45; 1.54) 
0.63 (0.37; 1.08) 
 
0.333 
 
12 
10 
3 
10 
 
1.00 (ref)  
0.94 (0.67; 1.33) 
0.29 (0.07; 1.24) 
1.16 (0.55; 2.42) 
 
0.384 
Sports 
  No  
  Yes  
 
7 
6 
 
1.00 (ref)  
0.99 (0.68; 1.46) 
 
0.978 
 
29 
37 
 
1.00 (ref)  
1.60 (1.30; 1.97) 
 
<0.001 
 
10 
11 
 
1.00 (ref)  
1.18 (0.86; 1.61) 
 
0.311 
 Meat ≤1-3 days/week 
(n=807) 
Fish ≥1 day/week 
(n=554) 
Dairy ≥3 portions/day 
(n=330) 
BMI 
  Underweight  
  Normal 
  Overweight  
  Obese  
 
58 
44 
36 
46 
 
1.50 (0.90; 2.51) 
1.00 (ref)  
0.81 (0.62; 1.06) 
0.93 (0.62; 1.40) 
 
0.155 
 
24 
30 
32 
29 
 
0.77 (0.43; 1.37) 
1.00 (ref)  
1.07 (0.81; 1.41) 
1.05 (0.68; 1.62) 
 
0.766 
 
22 
17 
16 
24 
 
1.48 (0.82; 2.67) 
1.00 (ref) 
0.96 (0.69; 1.35) 
1.68 (1.05; 2.67) 
 
0.094 
Smoking 
  Never smoked  
  Stopped smoking 
  Current smoker 
 
42 
46 
45 
 
1.00 (ref)  
1.25 (0.90; 1.72) 
1.50 (1.17; 1.91) 
 
0.005 
 
30 
37 
27 
 
1.00 (ref)  
1.31 (0.94; 1.81) 
0.83 (0.64; 1.08) 
 
0.051 
 
19 
13 
16 
 
1.00 (ref)  
0.75 (0.48; 1.17) 
0.93 (0.69; 1.27) 
 
0.450 
Alcohol 
  Never/rarely 
  Weekly, ≥1 std drink/week 
  Daily, 1 std drink/day 
  Frequently, >1 std drink/day 
 
50 
40 
23 
16 
 
1.00 (ref)  
0.73 (0.58; 0.91) 
0.32 (0.17; 0.61) 
0.26 (0.14; 0.48) 
 
<0.001 
 
27 
33 
35 
30 
 
1.00 (ref)  
1.27 (1.00; 1.61) 
1.19 (0.67; 2.13) 
1.26 (0.76; 2.08) 
 
0.254 
 
19 
16 
9 
19 
 
1.00 (ref) 
0.85 (0.64; 1.12) 
0.47 (0.19; 1.13) 
0.73 (0.41; 1.30) 
 
0.243 
Sports 
  No  
  Yes  
 
43 
44 
 
1.00 (ref)  
1.26 (1.03; 1.55) 
 
0.026 
 
27 
32 
 
1.00 (ref)  
1.33 (1.07; 1.65) 
 
0.009 
 
17 
18 
 
1.00 (ref)  
1.11 (0.86; 1.43) 
 
0.409 
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Table S3. Adherence to dietary recommendations among the general population (Swiss Health Survey), and 
predictors for adherence (retrieved from multivariable logistic regressions)  
 Fruit/vegetable ≥5 
portions/day  
 (n=574) 
Fruit ≥2 portions/day 
 (n=1908) 
Vegetable ≥3 portions/day 
 (n=1116) 
 %a OR (95%CI)b p-valuec %a OR (95%CI)b p-valuec %a OR (95%CI)b  p-valuec 
Gender  
  Male 
  Female 
 
5 
9 
 
1.00 (ref)  
1.90 (1.45; 2.49) 
 
<0.001 
 
 
15 
33 
 
1.00 (ref)  
2.75 (2.33; 3.25) 
 
<0.001 
 
 
10 
16 
 
1.00 (ref)  
1.79 (1.46; 2.19) 
 
<0.001 
 
Age at survey (years) 
  <20  
  20-29 
  30-39 
  ≥40 
 
9 
6 
6 
7 
 
1.00 (ref)  
0.58 (0.41; 0.82) 
0.57 (0.41; 0.80) 
0.70 (0.49; 0.99) 
 
  0.004 
 
 
29 
22 
22 
23 
 
1.00 (ref)  
0.60 (0.48; 0.75) 
0.60 (0.48; 0.74) 
0.64 (0.51; 0.80) 
 
<0.001 
 
 
16 
12 
12 
14 
 
1.00 (ref)  
0.57 (0.44; 0.74) 
0.58 (0.45; 0.75) 
0.74 (0.57; 0.97) 
 
<0.001 
 
Education (highest degree) 
  Compulsory schooling 
  Vocational training 
  Upper secondary education 
  University education 
 
6 
6 
7 
8 
 
0.83 (0.44; 1.57) 
1.00 (ref)  
1.28 (0.94; 1.73) 
1.49 (1.01; 2.18) 
 
0.109 
 
 
20 
23 
25 
29 
 
0.90 (0.64; 1.28) 
1.00 (ref)  
1.24 (1.03: 1.49) 
1.63 (1.29; 2.06) 
 
<0.001 
 
 
10 
12 
14 
17 
 
0.85 (0.53; 1.37) 
1.00 (ref)  
1.31 (1.05; 1.65) 
1.68 (1.27; 2.23) 
 
<0.001 
 
Migration 
  No migration background 
  Migration background 
 
7 
7 
 
1.00 (ref)  
0.98 (0.76; 1.26) 
 
0.850 
 
 
25 
21 
 
1.00 (ref)  
0.80 (0.68; 0.93) 
 
0.004 
 
 
13 
13 
 
1.00 (ref)  
0.93 (0.77; 1.13) 
 
0.458 
 
Language region  
  German speaking  
  French speaking 
  Italian speaking 
 
5 
11 
9 
 
1.00 (ref)  
2.25 (1.74: 2.91) 
1.78 (1.09; 2.91) 
 
<0.001 
 
 
23 
26 
21 
 
1.00 (ref)  
1.27 (1.08; 1.50) 
0.86 (0.62; 1.19) 
 
0.005 
 
 
11 
19 
14 
 
1.00 (ref)  
2.09 (1.72; 2.55) 
1.42 (0.97; 2.08) 
 
<0.001 
 
BMI 
  Underweight  
  Normal 
  Overweight  
  Obese  
 
10 
7 
5 
5 
 
1.38 (0.71; 2.66) 
1.00 (ref) 
0.83 (0.60; 1.15) 
0.86 (0.48; 1.52) 
 
0.459 
 
 
32 
25 
20 
17 
 
1.20 (0.79; 1.82) 
1.00 (ref)  
1.04 (0.85; 1.27) 
0.76 (0.53; 1.10) 
 
0.349 
 
 
14 
14 
9 
13 
 
0.97 (0.55; 1.73) 
1.00 (ref) 
0.77 (0.60; 0.98) 
1.14 (0.73; 1.78) 
 
0.173 
 
Smoking 
  Never smoked  
  Stopped smoking 
  Current smoker 
 
5 
9 
7 
 
1.00 (ref)  
1.47 (1.06; 2.06) 
0.87 (0.64; 1.17) 
 
0.018 
 
 
18 
28 
26 
 
1.00 (ref)  
1.24 (0.99; 1.55) 
0.79 (0.66; 0.94) 
 
<0.001 
 
 
13 
15 
12 
 
1.00 (ref)  
1.27 (0.97; 1.66) 
1.03 (0.83; 1.28) 
 
0.226 
 
Alcohol 
  Never/rarely 
  Weekly, ≥1 std drink/week 
  Daily, 1 std drink/day 
  Frequently, >1 std drink/day 
 
8 
6 
7 
2 
 
1.00 (ref)  
0.77 (0.59; 1.00) 
1.15 (0.57; 2.34) 
0.28 (0.10; 0.80) 
 
0.026 
 
28 
20 
22 
17 
 
1.00 (ref)  
0.77 (0.66; 0.91) 
1.22 (0.78; 1.90) 
1.15 (0.45; 2.99) 
 
0.007 
 
14 
12 
13 
12 
 
1.00 (ref)  
0.95 (0.77; 1.16) 
1.21 (0.75; 1.97) 
1.17 (0.44; 3.10) 
 
0.731 
Sports 
  No  
  Yes  
 
5 
8 
 
1.00 (ref)  
1.59 (1.21; 2.10) 
 
<0.001 
 
19 
26 
 
1.00 (ref)  
1.51 (1.28; 1.78) 
 
<0.001 
 
11 
14 
 
1.00 (ref)  
1.43 (1.17; 1.76) 
 
<0.001 
 Meat ≤1-3 days/week 
(n=3779) 
Fish ≥1 day/week 
(n=5146) 
Dairy ≥3 portions/day 
(n=825) 
Gender  
  Male 
  Female 
 
26 
54 
 
1.00 (ref)  
3.03 (2.64; 3.47) 
 
<0.001 
 
55 
56 
 
1.00 (ref) 
1.08 (0.94; 1.24) 
 
0.299 
 
15 
10 
 
1.00 (ref) 
0.64 (0.52; 0.79) 
 
<0.001 
Age at survey (years) 
  <20  
  20-29 
  30-39 
  ≥40 
 
31 
42 
43 
46 
 
1.00 (ref)  
1.52 (1.24; 1.86) 
1.64 (1.35; 2.00) 
1.98 (1.61; 2.44) 
 
<0.001 
 
50 
54 
61 
62 
 
1.00 (ref)  
1.15 (0.95; 1.41) 
1.60 (1.31; 1.94) 
1.69 (1.38; 2.07) 
 
<0.001 
 
16 
12 
10 
9 
 
1.00 (ref) 
0.78 (0.59; 1.02) 
0.69 (0.53; 0.90) 
0.60 (0.45; 0.80) 
 
0.004 
Education (highest degree) 
  Compulsory schooling 
  Vocational training 
  Upper secondary education 
  University education 
 
38 
37 
43 
50 
 
0.93 (0.70; 1.23) 
1.00 (ref) 
1.14 (0.98; 1.34) 
1.57 (1.27; 1.93) 
 
<0.001 
 
 
56 
54 
56 
61 
 
0.96 (0.72; 1.28) 
1.00 (ref) 
0.98 (0.84; 1.15) 
1.03 (0.83; 1.28) 
 
0.971 
 
 
12 
13 
12 
9 
 
0.96 (0.59; 1.57) 
1.00 (ref) 
1.02 (0.80; 1.29) 
0.75 (0.53; 1.06) 
 
0.392 
 
Migration 
  No migration background 
  Migration background 
 
37 
48 
 
1.00 (ref)  
1.64 (1.44; 1.88) 
 
<0.001 
 
52 
65 
 
1.00 (ref)  
1.62 (1.42; 1.85) 
 
<0.001 
 
13 
10 
 
1.00 (ref)  
0.75 (0.60; 0.93) 
 
0.008 
Language region  
  German speaking  
  French speaking 
  Italian speaking 
 
39 
37 
63 
 
1.00 (ref)  
0.89 (0.77; 1.03) 
2.77 (2.04; 3.74) 
 
<0.001 
 
48 
71 
74 
 
1.00 (ref)  
2.62 (2.26; 3.03) 
3.08 (2.31; 4.10) 
 
<0.001 
 
13 
11 
6 
 
1.00 (ref)  
0.90 (0.72; 1.12) 
0.41 (0.24; 0.70) 
 
0.004 
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BMI: body mass index; CI: confidence interval; OR: odds ratio; std: standard alcoholic drink;  
a: Column percentages are given. Percentages for the general population are standardized for gender, age, migration background and language region 
according to the CCS population;  
b: Adjusted for: 1) socio-demographic variables: gender, age category, education level, migration background, and language region in Switzerland and 2) 
lifestyle factors: BMI category, smoking status, alcohol intake, and sport participation;  
c: global p-value for an association between adherence to national dietary recommendations and the variable as a whole (Wald test comparing models 
with and without the variable).  
BMI 
  Underweight  
  Normal 
  Overweight  
  Obese  
 
62 
41 
31 
32 
 
1.47 (0.95; 2.27) 
1.00 (ref) 
0.74 (0.63; 0.88) 
0.66 (0.49; 0.89) 
 
<0.001 
 
59 
55 
55 
57 
 
1.15 (0.74; 1.79) 
1.00 (ref)  
0.95 (0.80; 1.12) 
1.05 (0.78; 1.41) 
 
0.805 
 
4 
12 
13 
13 
 
0.41 (0.19; 0.86) 
1.00 (ref) 
1.10 (0.85; 1.41) 
1.20 (0.78; 1.86) 
 
0.074 
Smoking 
  Never smoked  
  Stopped smoking 
  Current smoker 
 
40 
45 
37 
 
1.00 (ref)  
1.15 (0.94; 1.40) 
1.04 (0.90; 1.21) 
 
0.411 
 
55 
60 
53 
 
1.00 (ref)  
1.00 (0.82; 1.22) 
0.83 (0.72; 0.97) 
 
0.042 
 
14 
8 
11 
 
1.00 (ref)  
0.63 (0.45; 0.87) 
0.77 (0.61; 0.97) 
 
0.007 
Alcohol 
  Never/rarely 
  Weekly, ≥1 std drink/week 
  Daily, 1 std drink/day 
  Frequently, >1 std drink/day 
 
45 
35 
31 
22 
 
1.00 (ref)  
0.80 (0.69; 0.92) 
0.66 (0.46; 0.93) 
0.51 (0.27; 0.96) 
 
0.002 
 
53 
57 
64 
45 
 
1.00 (ref)  
1.30 (1.12; 1.50) 
1.52 (1.05; 2.20) 
0.54 (0.29; 1.00) 
 
<0.001 
 
12 
12 
15 
5 
 
1.00 (ref) 
0.96 (0.77; 1.19) 
1.40 (0.85; 2.31) 
0.39 (0.13; 1.22) 
 
0.172 
Sports 
  No  
  Yes  
 
38 
40 
 
1.00 (ref)  
1.28 (1.12; 1.47) 
 
<0.001 
 
54 
56 
 
1.00 (ref)  
1.24 (1.08; 1.43) 
 
0.002 
 
 
12 
12 
 
1.00 (ref)  
0.91 (0.74; 1.13) 
 
0.402 
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Table S4. Interaction of study group with socio-demographic and lifestyle determinants (retrieved from 
multivariable logistic regressionsa) 
BMI: body mass index; CCS: childhood cancer survivors; n.a.: not applicable.  
a: Adjusted for: 1) socio-demographic variables: gender, age category, education level, migration background, and language region in 
Switzerland and 2) lifestyle factors: BMI category, smoking status, alcohol intake, and sport participation;  
b: p-value for interaction (study group: Siblings versus CCS x determinant) was calculated with the likelihood ratio test;  
c: p-value for interaction (study group: General population versus CCS x determinant) was calculated with the likelihood ratio test.
 Fruit/vegetable  
≥5 portions/day  
p-values for interactions  
Fruit ≥2 portions/day 
p-values for interactions 
Vegetable ≥3 
portions/day 
p-values for interactions 
 
 
CCS vs. 
siblingsb 
CCS vs. 
general 
populationc 
CCS vs. 
siblingsb 
CCS vs. 
general 
populationc 
CCS vs. 
siblingsb 
CCS vs. 
general 
populationc 
Socio-demographic  
Gender  
 
0.722 
 
0.098 
 
0.785 
 
0.214 
 
0.611 
 
0.318 
Age at survey (years) 0.379 0.194 0.273 0.235 0.733 0.125 
Education (highest degree) 0.855 0.003 0.511 0.021 0.392 <0.001 
Parents’ education (highest degree) 0.494 n.a. 0.459 n.a. 0.972 n.a. 
Migration 0.204 0.002 0.615 0.006 0.524 <0.001 
Language region  0.183 0.200 0.430 0.866 0.201 0.014 
Lifestyle 
BMI 
 
0.011 
 
0.027 
 
0.182 
 
<0.001 
 
0.153 
 
0.026 
Smoking 0.969 0.452 0.272 0.173 0.498 0.411 
Alcohol 0.852 0.399 0.333 0.136 0.725 0.108 
Sports 0.639 0.004 0.679 0.494 0.149 0.016 
 Meat ≤1-3 days/week Fish ≥1 day/week Dairy ≥3 portions/day 
Socio-demographic  
Gender  
 
0.118 
 
0.004 
 
0.062 
 
0.037 
 
0.980 
 
0.451 
Age at survey (years) 0.447 0.849 0.606 0.771 0.547 0.278 
Education (highest degree) 0.386 0.009 0.693 0.099 0.852 0.129 
Parents’ education (highest degree) 0.755 n.a. 0.065 n.a. 0.050 n.a. 
Migration 0.536 0.662 0.774 0.944 0.814 0.974 
Language region  0.589 0.076 0.704 0.487 0.478 0.248 
Lifestyle 
BMI 
 
0.324 
 
0.457 
 
0.128 
 
0.574 
 
0.068 
 
0.449 
Smoking 0.295 0.199 0.330 0.266 0.279 0.785 
Alcohol 0.328 0.005 0.850 0.568 0.476 0.199 
Sports 0.428 0.288 0.806 0.768 0.738 0.496 
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Table S5. Cancer-related factors associated with adherence to dietary recommendations among childhood cancer survivors (CCS) (retrieved from multivariable 
logistic regressions) 
 Fruit/vegetable ≥5 
portions/day 
Fruit ≥2 
portions/day  
Vegetable ≥3 
portions/day 
Meat ≤1-3 days/week Fish ≥1 day/week 
 
Dairy ≥3 portions/day 
 OR (95%CI)a       p-valueb OR (95%CI)a       p-valueb OR (95%CI)a       p-valueb OR (95%CI)a       p-valueb OR (95%CI)a       p-valueb OR (95%CI)a       p-valueb 
Clinical treatment 
  Paediatric cancer centrec 
  Other clinic 
 
1.00 (ref)             0.959 
1.02 (0.57; 1.80) 
 
1.00 (ref)             0.918 
1.02 (0.74; 1.39) 
 
1.00 (ref)             0.703 
1.10 (0.69; 1.75) 
 
1.00 (ref)             0.230 
0.83 (0.60; 1.13) 
 
1.00 (ref)             0.796 
0.96 (0.70; 1.31) 
 
1.00 (ref)             0.732 
0.93 (0.61; 1.42) 
ICCC3 diagnosis 
  I: Leukaemia 
  II: Lymphoma 
  III: CNS tumour 
  IV: Neuroblastoma 
  V: Retinoblastoma 
  VI: Renal tumour 
  VII: Hepatic tumour 
  VIII: Bone tumour 
  IX: Soft tissue sarcoma 
  X: Germ cell tumour 
  XI & XII: Other tumour 
  Langerhans Cell Histiocytosis 
 
1.00 (ref)              0.230 
0.76 (0.44; 1.32) 
0.66 (0.35; 1.24) 
1.09 (0.44; 2.69) 
-  
0.45 (0.16; 1.30) 
1.97 (0.39; 9.97) 
0.98 (0.39; 2.43) 
0.75 (0.31; 1.82) 
0.58 (0.20; 1.69) 
2.46 (1.08; 5.64) 
0.77 (0.26; 2.26) 
 
1.00 (ref)             0.349 
1.16 (0.87; 1.55) 
1.12 (0.81; 1.55) 
1.33 (0.79; 2.23) 
0.62 (0.29; 1.34) 
1.03 (0.66; 1.62) 
3.84 (1.07; 13.76) 
0.90 (0.53; 1.53) 
1.32 (0.85; 2.05) 
1.19 (0.73; 1.95) 
1.05 (0.56; 1.99) 
1.68 (0.98; 2.87) 
 
1.00 (ref)             0.320 
0.79 (0.51; 1.23) 
0.64 (0.38; 1.08) 
1.04 (0.49; 2.20) 
0.14 (0.02; 1.05) 
0.79 (0.40; 1.57) 
2.19 (0.54; 8.91) 
0.96 (0.45; 2.05) 
0.97 (0.50; 1.88) 
0.64 (0.28; 1.46) 
1.70 (0.79; 3.68) 
0.76 (0.31; 1.84) 
  
1.00 (ref)             0.667 
0.98 (0.73; 1.30) 
1.01 (0.74; 1.39) 
0.89 (0.53; 1.50) 
0.67 (0.33; 1.37) 
1.20 (0.77; 1.88) 
0.79 (0.21; 2.90) 
0.58 (0.34; 0.99) 
0.89 (0.57; 1.39) 
0.86 (0.53; 1.41) 
1.40 (0.73; 2.67) 
1.07 (0.62; 1.86) 
 
1.00 (ref)             0.897 
0.96 (0.72; 1.30) 
0.98 (0.70; 1.38) 
1.19 (0.69; 2.04) 
1.65 (0.83; 3.27) 
0.94 (0.58; 1.54) 
0.58 (0.14; 2.35) 
1.27 (0.76; 2.13) 
0.79 (0.48; 1.28) 
1.03 (0.62; 1.71) 
0.88 (0.46; 1.70) 
0.97 (0.54; 1.74) 
 
1.00 (ref)             0.277 
0.79 (0.55; 1.14) 
0.87 (0.59; 1.27) 
0.91 (0.50; 1.69) 
0.46 (0.16; 1.35) 
0.96 (0.57; 1.64) 
0.90 (0.18; 4.56) 
0.71 (0.36; 1.40) 
0.65 (0.36; 1.18) 
0.69 (0.36; 1.34) 
1.97 (0.97; 4.03) 
1.37 (0.76; 2.47) 
CVD risk profile 
  No chemo- and RT 
  Other chemo- and/or RTd 
  Either anthracyclines or chest RTe  
  Both antracyclines and chest RT 
 
1.00 (ref)             0.705 
1.16 (0.66; 2.04) 
1.32 (0.76; 2.32) 
0.93 (0.38; 2.31) 
 
1.00 (ref)             0.676 
1.03 (0.77; 1.38) 
0.94 (0.70; 1.26) 
1.19 (0.77; 1.84) 
 
1.00 (ref)             0.474 
0.97 (0.62; 1.52) 
1.21 (0.78; 1.88) 
0.81 (0.39; 1.67) 
 
1.00 (ref)             0.145 
1.36 (1.02; 1.83) 
1.20 (0.90; 1.61) 
1.48 (0.96; 2.30) 
 
1.00 (ref)             0.361 
1.01 (0.75; 1.36) 
0.83 (0.61; 1.13) 
1.08 (0.69; 1.69) 
 
1.00 (ref)             0.978 
1.04 (0.72; 1.49) 
1.01 (0.70; 1.45) 
0.93 (0.53; 1.62) 
Age at diagnosis (years) 
  <5 
  5-9 
  10-14 
  15-20 
 
1.00 (ref)             0.155 
0.54 (0.31; 0.94) 
0.93 (0.58; 1.49) 
0.77 (0.41; 1.42) 
 
1.00 (ref)             0.481 
1.12 (0.85; 1.47) 
1.11 (0.85; 1.45) 
1.30 (0.93; 1.82) 
 
1.00 (ref)             0.066 
0.57 (0.37; 0.90) 
0.99 (0.68; 1.46) 
0.80 (0.49; 1.33) 
 
1.00 (ref)             0.737 
1.06 (0.81; 1.38) 
0.98 (0.76; 1.28) 
0.87 (0.62; 1.22) 
 
1.00 (ref)             0.510 
0.94 (0.70; 1.25) 
1.11 (0.84; 1.47) 
0.89 (0.63; 1.26) 
 
1.00 (ref)             0.579 
0.85 (0.62; 1.16) 
0.82 (0.59; 1.12) 
0.83 (0.53; 1.28) 
Time since diagnosis (years) 
  <15 
  ≥15 
 
1.00 (ref)              0.643 
1.11 (0.72; 1.71) 
 
1.00 (ref)              0.920 
0.99 (0.78; 1.25) 
 
1.00 (ref)              0.830 
1.04 (0.73; 1.47) 
 
1.00 (ref)              0.074 
1.24 (0.98; 1.56) 
 
1.00 (ref)              0.606 
1,07 (0.83; 1.37) 
 
1.00 (ref)              0.617 
1.07 (0.81; 1.43) 
History of relapse 
  No 
  Yes 
 
1.00 (ref)             0.286 
1.33 (0.79; 2.24) 
 
1.00 (ref)             0.508 
1.11 (0.82; 1.50) 
 
1.00 (ref)             0.607 
1.12 (0.72; 1.76) 
 
1.00 (ref)             0.292 
1.18 (0.87; 1.59) 
 
1.00 (ref)             0.888 
1.02 (0.75; 1.40) 
 
1.00 (ref)             0.161 
1.29 (0.90; 1.83) 
CI: confidence interval; CNS: central nervous system; CVD: cardiovascular disease; ICCC3: International Classification of Childhood Cancer, 3rd edition; OR: odds ratio; RT: radiotherapy; 
a: Multivariable analysis for adherence to nutritional recommendations were adjusted for: 1) socio-demographic variables: gender, age category, education level, parental education level, migration background, and language 
region in Switzerland and 2) lifestyle factors: BMI category, smoking status, alcohol intake, and sport participation; 
b: global p-value for an association between high/frequent dietary intake and the variable as a whole (Wald test comparing models with and without the variable); 
c: Including the following clinics with paediatric oncology units Kantonsspital Aarau AG, Universitäts-Kinderspital Basel, Ospedale S. Giovanni Bellinzona, Universitäts-Kinderklinik Bern, Hôpital des Enfants Genève, CHUV 
Lausanne, Kantonsspital Luzern, Ostschweizer Kinderspital St. Gallen, Universitäts-Kinderspital Zurich; 
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d: Other chemotherapeutic agents and radiotherapy than anthracyclines and chest radiotherapy; 
e: Chest radiotherapy includes direct radiation applied to the chest, including total body irradiation, mantlefield irradiation or irradiation to the thorax, mediastinum, or thoracic spine.
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Figure S1. Swiss Childhood Cancer Survivor Study questionnaire, French and German version  
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Figure S2. Participants of the Swiss Childhood Cancer Survivor Study 
Flow diagram of our study population starting from those eligible in the Swiss Childhood Cancer Registry to those included in the 
analysis. 
  
513 (13%) no valid address available 
 
850 (24%) did not respond 
216 (6%) refused 
143 (4%) did not provide data on diet 
1864 (52%) available for analyses 
520 (14%) excluded because <16 years or 
>45 years 
10 (<1%) had died  
2527 (70%) returned questionnaire 
 
4116 survivors eligible for the SCCSS  
3593 (100%) traced and sent 
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INTRODUCTION 
An unhealthy dietary intake is seen as a modifiable factor that can prevent or delay the 
development of chronic diseases like type II diabetes, metabolic syndrome, and CVD [1-3]. It 
is therefore widely recommended in populations suffering from these comorbidities to consume 
a diet rich in fruit, vegetables, fibre, and complex carbohydrates, low in saturated and trans-
fatty acids, and moderate in alcohol consumption. Accumulating research among childhood 
cancer survivors (CCSs) shows that chronic diseases secondary to childhood cancer or its 
treatment can be reduced, with diet adaptations, weight management, and physical activity [4-
7]. This makes nutrition particularly relevant for CCSs with an increased risk to develop chronic 
diseases, but few studies have evaluated the dietary intake or quality of CCSs [8, 9]. Within 
the St. Jude Lifetime cohort a poor dietary adherence to the 2010 Dietary Guidelines for 
Americans and a poor diet quality based on the Healthy Eating Index-2010 (HEI-2010, 58% of 
the maximum score) were found in 2570 adult long-term CCSs [10]. They found an even poorer 
dietary quality for those CCSs diagnosed young and treated with abdominal radiation therapy. 
Similar results were observed in other smaller studies from the United States (US), CCSs 
poorly adhered to dietary recommendations and diet quality ranged from 33-56% of the 
maximum score [5, 6, 11-13].  
Studies outside the US, with different lifestyle and eating habits, are limited and suffer 
from methodological shortcomings, e.g. small sample sizes, short follow-up times, poorly 
detailed dietary descriptions, and only focus on specific cancer diagnoses. Almost all studies 
performed to date lack control groups to compare dietary intake between CCSs and the 
general population. Therefore, we analyzed data from the Swiss Childhood Cancer Survivor 
Study (SCCSS) to assess dietary intake and quality of CCSs in comparison to the general 
population and whether clinical characteristics have an impact on CSSs long-term dietary 
intake. 
 
METHODS  
Study populations  
The Swiss Childhood Cancer Survivor Study (SCCSS)  
The SCCSS is a population-based, long-term follow-up study in all childhood cancer patients 
registered in the Swiss Childhood Cancer Registry (SCCR; available from: 
www.childhoodcancerregistry.ch) who have been diagnosed with leukemia, lymphoma, central 
nervous system (CNS) tumors, malignant solid tumors, or Langerhans cell histiocytosis; who 
survived ≥5 y after initial diagnosis of cancer; who were under the age of 21 y; and who were 
alive at the time of the study [14-16]. Ethical approval of the SCCR and the SCCSS was 
granted by the Ethics Committee of the Canton of Bern (KEK-BE: 166/2014). This study was 
registered at clinicaltrials.gov as NCT03297034.  
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As part of the SCCSS, we traced all addresses of CCSs diagnosed between 1976 and 
2005, who filled in a baseline questionnaire between 2007 and 2013 [14], and who were at 
time of the follow-up questionnaire in 2017 at least 20 y. Nonresponders received a reminder 
of the follow-up questionnaire 6 wks later. If they again did not respond, we contacted them 
again by sending a second questionnaire reminder. Our questionnaire included core questions 
from the US and UK CCS studies [17, 18], with added questions about dietary intake [19, 20], 
health behaviors, and sociodemographic measures from the Swiss Health Survey (SHS) [21] 
and the Swiss Census [22]. 
 
Comparison groups  
We used 3 random samples of the general Swiss population represented by data from Bus 
Santé, CoLaus, and the Swiss National Nutrition Survey.  
Bus Santé is a cross-sectional, on-going population based study in the canton of 
Geneva, as previously described [23]. Every year since 1993, a representative sample of non-
institutionalized men and women aged 35-74 y are recruited. Eligible participants are identified 
with a standardized procedure using a residential list established by the local government. 
Random sampling in age and sex-specific strata is proportional to the corresponding 
frequencies in the population. Non-responders after 3 mailings and 7 phone calls were 
replaced using the same selection protocol as above, but those who refused to participate 
were not replaced. Included participants were not eligible for future recruitments and surveys. 
Participants received a self-administered questionnaire to collect data on socio-demographic 
characteristics, health behaviors, and dietary intake at home before receiving an invite for a 
health examination in a clinic or a mobile medical unit. During the examination, trained staff 
checked the questionnaires for completion.  
The “Cohorte Lausannoise” (CoLaus) study is a prospective, population-based study 
conducted in the city of Lausanne to identify biological and genetic determinants of 
cardiovascular disease. From June 2003 until May 2006 participants aged 35-75 y were 
recruited for the baseline study. Participants were invited to the outpatient clinic of the 
University Hospital of Lausanne for an interview, physical assessment, and blood and urine 
collections. Those who participated in the baseline study were asked to participate in the 
follow-up study between April 2009 and September 2012 [24]. In the follow-up study, dietary 
intake was assessed with a food frequency questionnaire (FFQ).  
The Swiss National Nutrition Survey is a cross-sectional nutrition survey conducted 
from January 2014 till February 2015 in 18-75 y old adults living in one of the 3 main linguistic 
regions of Switzerland (German, French, and Italian) [20]. Trained dieticians collected the data. 
Each participant got 2 24-hour dietary recalls (24HDR), the first was face-to-face and the 
second by phone 2-6 wk later. Prior to the face-to-face interview, participants received a 49-
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item questionnaire including e.g. questions on socio-demographic characteristics and health 
behaviors. Interviews were carried out in either German, French or Italian. 
 
Measurements  
Dietary intake  
In CCSs and among participants of the Bus Santé and CoLaus survey, dietary intake was 
assessed with the same self-administered, semi quantitative FFQ including portion sizes [25, 
26]. The FFQ was originally developed and validated for the French-speaking Swiss adult 
population [19, 23, 25, 27]. It provides information on consumption frequency and portion sizes 
during the 4 previous wk for 97 fresh and prepared food items organized in 12 different food 
groups (dietary supplements not accounted for). Consumption frequencies ranges from “never 
during the last 4 wk” to “2 or more times per day” and portions are dived in 3 sizes: smaller, 
equal, or larger than the reference size. The reference portions were defined as common 
household measures representing the median portion size of a previous validation study [19]. 
The “smaller” and “larger” portions represented the first and third quartiles of this distribution. 
The French Centre d’Information sur la Qualité des Aliments food-composition table was used 
to convert the portions into macro- and micronutrients.  
In the Swiss National Nutrition Survey (www.menuch.ch) dietary intake was assessed 
by 2 non-consecutive 24HDR during all seasons, weekdays and weekends. The GloboDiet 
software [28, 29] was used which was complemented with a comprehensive picture book [30] 
and a set of real dishes adapted to the Swiss specific food market to support survey 
participants in quantifying amounts of consumed foods. Conversion into macro- and 
micronutrients was performed on the basis of the Swiss Food Composition Database (SFCDB) 
[31]. We took the average dietary intake of the 2 24HDRs per participant. To account for non-
response and national population representativeness all data was corrected by sample weights 
[20]. 
In CCSs we extended the used FFQ with 15 additional food products, based on data 
of the Swiss National Nutrition Survey [20]. Since CCS could live in whole Switzerland we 
investigate if most frequent dietary products consumed in the German and Italian-speaking 
part of Switzerland were also included in the FFQ, as the original FFQ was developed for the 
French-speaking part of Switzerland. The 15 additional food products were all reported more 
than 70 times (>2%) during the 24h recall assessments. 
 
Data collected  
For all CCSs and comparison groups, we collected self-reported data on sex, age at survey, 
educational level, country of birth, language region in Switzerland, living situation, physical 
activity, smoking status, and BMI at survey. Physical activity was differently assessed in CCSs 
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and comparison groups. In the SCCSS and the Swiss National Nutrition Survey we 
dichotomized physical activity according the WHO guidelines of physical activity for adults: 
lower (inactive) or equal or more (active) than 150 minutes of moderate intense or 75 minutes 
of vigorous intense or a combination of moderate and vigorous intense physical activity per 
week [32]. In Bus Santé and CoLaus physical activity were assessed with a self-administered 
validated physical activity frequency questionnaire (PAFQ) [33] and dichotomized in lower 
(inactive) or equal or more than the first quartile of total weekly physical activity time excluding 
sleep (active). For all CCSs we had information on weight and height at time of survey from 
the self-administered questionnaires. We asked CCSs to report their weight without clothes 
and their height without shoes. Within the 3 random samples of the general Swiss population, 
body weight and height were measured with participants standing without shoes in light indoor 
clothes. Body weight was measured in kilograms to the nearest 100 g using a calibrated 
electronic scale (Seca®, Hamburg Germany). Height was measured to either the nearest 5 or 
10 mm using a Seca® height gauge. We calculated BMI by dividing weight in kilograms by 
height in meters squared (kg/m2) in all groups. BMI in adults was classified as underweight 
(<18.5 kg/m2), normal weight (≥18.5 to <25 kg/m2), overweight (≥25 to <30 kg/m2), or obesity 
(≥30 kg/m2) [34]. For the CCSs population, we extracted additional clinical information from the 
Swiss Childhood Cancer Registry (SCCR). This included information on cancer diagnosis and 
the age at diagnosis. Diagnosis was classified according to the International Classification of 
Childhood Cancer, 3rd Edition [35]. Radiotherapy was classified as “any”, “cranial”, “chest”, 
“total body irradiation and/or abdominal” or “no radiotherapy”. Cranial radiation was considered 
if the survivor had received direct radiation to the brain and/or skull. Chest radiotherapy was 
considered direct radiation applied to the chest including total body irradiation, mantlefield 
irradiation, or irradiation to the thorax, mediastinum, or thoracic spine. Cumulative dosage of 
radiotherapy was obtained from medical records and categorized based on the Children’s 
Oncology Group Long-Term Follow-up (COG-LTFU) Guidelines for cranial into: <18 Gray (Gy) 
versus ≥18 Gy; chest: <30 Gy versus ≥30 Gy, and total body irradiation and/or abdominal 
versus neither [36]. Chemotherapy was divided into “glucocorticoids”; “anthracyclines”; or 
“alkylating agents”. Glucocorticoids, prednisone and/ or dexamethasone, intake was based on 
cancer protocol adherence as described previously [37]. We also retrieved records on 
hematopoietic stem cell transplantation (HSCT) and relapse during follow-up time. 
 
Statistical Analyses  
We included all CCSs and the participants of the general population (Bus Santé, CoLaus, 
Swiss National Nutrition Survey), who were aged ≤50 years at time of survey, who provided 
reliable dietary intake information, and were not pregnant nor lactating during the survey 
(Supplemental Figure 1). For better comparison between CCSs and peers, we standardized 
comparison groups for sex, age at survey, and language region as previously described [38-
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40]. The first step in our analyses was to evaluate if CCS and their peers met the dietary 
recommendations for Germany (D), Austria (A), and Switzerland (CH) (DACH) [41]. We 
compared the mean intake to the recommended intake or, when not available, the adequate 
intake. We calculated the mean intake based on age and sex recommendations, weighted by 
the age and sex distribution of the study population. Nutritional goals were set at 100 when the 
mean intake met the recommended or adequate intake. Total energy intake was calculated 
including calories from alcohol consumption. To estimate the diet quality of CCS and peers we 
used the Alternative Healthy Eating Index (AHEI) [42]. All AHEI score components score from 
zero (worst) to 10 (best), and the total AHEI score ranges from zero (nonadherence) to 100 
(perfect adherence). We compared whether the AHEI score differed between CCS and peers. 
Furthermore, we assessed if CCSs’ dietary quality differed by cancer diagnosis and treatment 
with the use of ANCOVA while adjusting for sex and age. Because education level attained, 
smoking habits, physical activity, and BMI can be affected by cancer diagnosis, treatment 
exposures, and late effects occurrence (i.e., intermediates on the causal pathway), these 
covariates were not adjusted in the analysis to avoid over adjustment. We used Stata software 
(version 14, Stata Corporation, Austin, Texas) for all statistical analysis. 
 
FIRST RESULTS 
Response rate of the study populations  
Among 1832 eligible CCSs, we traced and contacted 1578, of whom 918 (58%) returned a 
questionnaire. We excluded 29 survivors who were over 50 y old, 11 who were pregnant or 
lactating, 34 who did not reported their dietary intake, and a further 70 who had unreliable 
dietary intake. We thus included 774 CCSs in this study (Supplemental Figure S1). Of 20,125 
participants within the Bus Santé survey, 10,851 were over 50 y old, and 310 who had 
unreliable dietary intake information. Participation rates ranged from 55 to 75% [43]. Of 5064 
participants (41% response rate) within the CoLaus survey, 3616 were over 50 y old, 126 had 
no dietary intake information, and 46 had unreliable dietary intake. Within the Swiss National 
Nutrition Survey we excluded from 2085 participants (38% response rate), 857 who were older 
than 50 y and 39 who were younger than 20 y, 27 who were pregnant or lactating, one 
participant who did not reported his dietary intake, and 27 participants with unreliable dietary 
intake information (Table I).  
 Among CCSs, the most common cancers were leukemia, lymphoma, and central 
nervous system tumors (Table II). The median age at diagnosis was 9 y (IQR: 4-14 y). The 
median time from diagnosis to survey was 26 y (IQR: 20-31 y).  
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Table I. Characteristics of childhood cancer survivors and comparison groups1 
 CCSs 
(n = 774) 
Bus Santé2 
(n = 8964) 
CoLaus2 
(n = 1276) 
Menu.CH2 
(n = 1134) 
Characteristics  n (%std) P3 n (%std) P3 n (%std) P3 
Sex, n (%)        
  Men 386 (50) 4345 (55) NA 628 (49) NA 498 (51) NA 
Age at survey, n (%)        
  20-24 y 69 (9) - NA - NA 169 (9) NA 
  25-29 y 179 (23) -  -  188 (23)  
  30-34 y 163 (21) -  -  150 (22)  
  35-39 y 156 (20) 3027 (45)  -  146 (20)  
  40-44 y 123 (16) 2997 (32)  552 (62)  211 (16)  
  45-50 y 84 (11) 2940 (23)  724 (38)  270 (11)  
Language region, n (%)        
  German speaking 554 (72) - NA - NA 740 (71) NA 
  French speaking 202 (26) 8964 (100)  1276 (100)  280 (27)  
  Italian speaking 18 (2) -  -  114 (2)  
Country of birth, n (%)        
  Switzerland 737 (95) 4811 (54) <0.001 750 (58) <0.001 934 (81) <0.001 
  Other 37 (5) 4153 (46)  526 (42)  200 (19)  
Education (highest degree), n (%)        
  Lower than university 537 (69) 5336 (59) <0.001 916 (71) 0.817 741 (61) <0.001 
  University 237 (31) 3628 (41)  360 (29)  393 (39)  
Living situation, n (%)        
  Alone 161 (21) 2192 (24) 0.038 237 (19) 0.526 170 (16) 0.012 
  Other 613 (79) 6772 (76)  1039 (81)  964 (84)  
Physical activity4, n (%)        
  Inactive 159 (21) 662 (8) <0.001 267 (21) <0.001 220 (19) 0.051 
  Active 613 (79) 2700 (33)  905 (71)  900 (80)  
  Missing 2 (<1) 5602 (58)  104 (8)  14 (1)  
Smoking status, n (%)        
  Never  523 (68) 4005 (44) <0.001 567 (46) <0.001 521 (44) <0.001 
  Former 129 (17) 2460 (27)  398 (30)  320 (28)  
  Current 122 (16) 2499 (29)  311 (24)  293 (28)  
BMI at survey, n (%)        
  Underweight 17 (2)5 241 (3) <0.001 19 (2) <0.001 34 (3) 0.023 
  Normal 513 (66) 5536 (62)  649 (51)  687 (60)  
  Overweight 170 (22) 2491 (28)  451 (36)  306 (28)  
  Obese 74 (10) 696 (8)  157 (12)  107 (9)  
1 BMI, body mass index; CCS, childhood cancer survivors; NA, not applicable; std, standardized. 
2 Standardized on sex, age at survey, and language region according to CCSs. 
3 P value calculated from Chi-Square statistics comparing comparison groups with CCSs (2-sided test). 
4 CCSs and Swiss National Nutrition Survey (Menu.CH): < or ≥150 minutes of moderate intense or 75 minutes of vigorous intense or a combination of 
moderate and vigorous intense physical activity per week. Bus Santé and CoLaus: < or ≥ 1st quartile of total weekly physical activity time excluding sleep. 
5 Self-reported BMI in CCSs. 
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Table 2. Dietary intake in childhood cancer survivors and the general Swiss population: Bus Santé, CoLaus and Menu.CH compared to the DACH 
dietary recommendations1 
1 CCS, childhood cancer survivors, DACH, Dietary recommendations for Germany (D), Austria (A) and Switzerland (CH).  
2 Standardized on sex, age at survey, and language region according to CCSs. 
3 DACH recommendations for the general population age 20-50 y, excluding pregnant and lactating women. 
4 Percentage of mean intake in relation to the DACH recommended intake level * 100. Recommended intake is estimated on the basis of the age-sex groups of the DACH guidelines, weighted by the 
age and sex distribution of the study population. For alcohol intake the maximum tolerated dosage was taken. 
5 Depending on physical activity level (PAL, 1.4-1.8) and age.   
6 Federal Food Safety and Veterinary Office FSVO, www.naehrwertdaten.ch. 
7 BLV (2009). Kohlenhydrate in unserer Ernährung – Empfehlungen des BLV. www.blv.admin.ch.  
8 BLV (2012). Fett in unserer Ernährung – Empfehlung des BLV. www.blv.admin.chv, Recommendations as a percentage of the daily energy demand and based on a daily energy intake of 2000 kcal. 
9 Total vitamin A= retinol + carotene/12, expressed in μg RAE. 
10 Maximum tolerated dosage. 
 DACH  
recommendations3 
CCSs 
(n = 774) 
Bus Santé2 
(n = 8964) 
CoLaus2 
(n = 1276)  
Menu.CH2 
(n = 1134) 
Nutrients men women mean ± SD % DACH4 mean ± SD % DACH4 mean ± SD % DACH4 mean ± SD % DACH4 
Total energy, kcal5 2300-3400 1800-2600 1639 ± 582 65 2022 ± 688 79 1885 ± 658 75 2283 ± 720 90 
Macronutrients           
  Protein, g 57 48 66.1 ± 29.5 126 78.7 ± 29.5 149 73.3 ± 29.1 140 86.9 ± 37.2 165 
    % of energy6 10-20 10-20 16.1 ± 3.6 108 15.7 ± 3.1 105 15.6 ± 3.4 104 15.4 ± 4.6 103 
    Vegetal, g    18.1 ± 7.6  23.6 ± 10.0  21.8 ± 9.6    
    Animal, g   48.0 ± 26.9  55.1 ± 24.8  51.4 ± 24.3    
  Carbohydrates, g7 225-275 225-275 180 ± 74 72 230 ± 91 92 220 ± 88.9 88 246 ± 89 98 
    % of energy6, 7 45-55 45-55 43.9 ± 8.8 88 45.5 ± 8.6 91 46.6 ± 8.2 93 43.2 ± 8.1 86 
  Mono/disaccharides, g   86 ± 46  105 ± 52  107 ± 53  110 ± 54  
  Polysaccharides, g   94 ± 44  124 ± 60  113 ± 57  83 ± 49  
  Total fiber, g7 ≥30 ≥30 12.2 ± 6.4 41 15.7 ± 8.0 52 15.0 ± 8.1 50 20.3 ± 8.9 68 
  Total fat, g   68.2 ± 28.2  79.0 ± 31.1  72.2 ± 28.2  91.8 ± 35.1  
  Total fat, % of energy6 30-40 30-40 37.4 ± 6.9 107 35.2 ± 6.8 101 34.6 ± 6.3 99 36.1 ± 6.9 103 
  Saturated fat, g   25.2 ± 11.6  29.4 ± 13.4  26.8 ± 12.2  33.6 ± 14.8  
  Saturated fat, % of energy8 <10 <10 13.7 ± 3.2 137 13.0 ± 3.3 130 12.8 ± 3.1 128 13.2 ± 3.6 132 
  Monounsaturated fat, g   28.6 ± 12.7  31.4 ± 13.0  29.0 ± 11.7  23.2 ± 12.6  
  Polyunsaturated fat, g   8.6 ± 3.8  11.6 ± 5.3  10.2 ± 4.6  8.6 ± 5.3  
  Cholesterol, mg6 300 300 343 ± 208 114 343 ± 167 114 316 ± 141 106 261 ± 194 87 
Micronutrients           
Vitamins           
  A, mg-RE9 1.0 0.8 0.7 ± 0.7 79 0.9 ± 0.7 99 0.8 ± 0.7 89 0.7 ± 1.1 77 
  D, μg  20 20 2.4 ± 2.0 12 2.8 ± 2.1 14 2.6 ±  1.9 13 2.3 ± 2.2 11 
Minerals           
  Calcium, mg 1000 1000 889 ± 471 89 1079 ± 563 108 1021 ± 529 102 732 ± 391 73 
  Iron, mg 104 15 9.0 ± 3.6 72 11.2 ± 3.9 91 10.6 ± 3.9 85 7.4 ± 3.5 59 
  Alcohol, g10 20 10 5.7 ± 7.8 38 11.7 ± 16.4 75 8.7 ± 12.2 58 11.8 ± 18.0 78 
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Table 3. Diet quality in childhood cancer survivors by clinical characteristics (retrieved from 
ANCOVA)1, 2  
 CCS 
(n = 774) 
Characteristics n (%) AHEI score (95%CI) P 
ICCC-3 diagnosis    
  I: Leukemia 237 (31) 48.3 (46.8, 49.8) 0.078 
  II: Lymphoma 163 (21) 49.6 (47.8, 51.4)  
  III: CNS tumor 79 (10) 45.5 (42.9, 48.2)  
  Other 295 (38) 47.5 (46.2, 48.9)  
Age at diagnosis, y    
  <5 251 (32) 47.2 (45.5, 48.8) 0.390 
  5-9 163 (21) 48.7 (46.9, 50.6)  
  10-14 224 (29) 47.6 (46.0, 49.2)  
  15-20 136 (18) 49.3 (47.0, 51.5)  
Time since diagnosis    
  ≤25 366 (47) 49.1 (47.6, 50.6) 0.092 
  >25 408 (53) 47.0 (45.6, 48.4)  
History of relapse    
  No 691 (89) 47.9 (47.0, 48.8) 0.711 
  Yes 83 (11) 48.4 (45.9, 51.0)  
Cranial radiation    
  No 654 (85) 48.2 (47.3, 49.1) 0.247 
  Yes 120 (16) 46.8 (44.5, 49.0)  
Chest radiation    
  No 688 (89) 47.9 (47.0, 48.8) 0.748 
  Yes 86 (11) 48.4 (45.6, 51.2)  
TBI and/or abdominal radiation    
  No 707 (91) 48.0 (47.2, 48.9) 0.746 
  Yes 67 (9) 47.5 (44.6, 50.5)  
Glucocorticoids    
  No 444 (57) 47.5 (46.1, 48.9) 0.420 
  Yes 330 (43) 48.6 (46.8, 50.4)  
Anthracyclines    
  No 482 (62) 47.6 (46.5, 48.7) 0.345 
  Yes 292 (38) 48.6 (47.1, 50.0)  
Alkylating agents    
  No 455 (59) 47.6 (46.5, 48.8) 0.372 
  Yes 319 (41) 48.5 (47.1, 49.8)  
Hematopoietic stem cell transplantation    
  No 744 (96) 48.1 (47.2, 48.9) 0.246 
  Yes 30 (4) 45.5 (41.2, 49.8)  
1 CNS, central nervous system; CCS, childhood cancer survivors; ICCC3, International Classification of Childhood Cancer, 3rd 
edition. 
2 Adjusted for sex, age at survey, and ICCC-3 diagnosis. 
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Figure 1. Dietary intakes of nutrients compared with DACH recommended intakes or limits in 
childhood cancer survivors and the general Swiss population: Bus Santé, CoLaus, and 
Menu.CH. 
The length of the bar per nutrient corresponds to the percentage of mean intake (95% CIs) to the recommended intake level * 
100. Recommended intake is estimated on the basis of age and sex according to dietary recommendations for Germany (D), 
Austria (A) and Switzerland (CH) (DACH), weighted by the age and sex distribution per study population. For alcohol intake the 
maximum tolerated dosage was taken. Nutritional goals were set at 100 when the mean intake met the recommended intake or 
limit.  
All P values were calculated from ANOVA. 
  
 73 
 
Figure 2. Percentage of mean Alternate Healthy Eating Index1,2 scores with 95% CIs to the 
maximum scores in childhood cancer survivors and the general population (Menu.CH)3 by sex 
1 Adapted from Chiuve et al. J Nutr 2012 142(6):1009-18. 
2 Intermediate food intake was scored proportionately between the minimum score 0 and the maximum score 10. 
3 Adjusted for sex, age at survey, and ICCC-3 diagnosis, Menu.CH standardized on sex, age at survey, and language region according to 
CCSs. 
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SUPPLEMENTARY MATERIAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Response rates in the follow-up Swiss Childhood Cancer Survivor Study1 
1 FU, follow-up; SCCSS, Swiss Childhood Cancer Survivor Study. 
1832 survivors eligible for the FU SCCSS 
240 no valid address available 
14 died 
 
1578 (100%) traced and sent questionnaires 
645 (41%) did not respond 
15 (<1%) refused 
918 (58%) returned questionnaire  
774 (49%) available for analyses 
11 (<1%) were pregnant or lactating 
29 (2%) excluded because <16 y or >50 y  
70 (4%) had unreliable dietary data  
34 (2%) had missing dietary data  
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Table S1. Clinical characteristics of childhood cancer survivors1  
 
Characteristics 
CCSs 
(n = 774) 
ICCC3 diagnosis, n (%)  
  I: Leukemia 237 (31) 
  II: Lymphoma 163 (21) 
  III: CNS tumor 79 (10) 
  IV: Neuroblastoma 28 (4) 
  V: Retinoblastoma 12 (2) 
  VI: Renal tumor 52 (7) 
  VII: Hepatic tumor 6 (1) 
  VIII: Bone tumor 49 (6) 
  IX: Soft tissue sarcoma 64 (8) 
  X: Germ cell tumor 40 (5) 
  XI & XII: Other tumor 25 (3) 
  Langerhans cell histiocytosis 19 (2) 
Age at diagnosis, n (%)  
  <5 y 251 (32) 
  5-9 y 163 (21) 
  10-14 y 224 (29) 
  15-20 y 136 (18) 
Time since diagnosis,2 y 25.7 (20.1-31.1) 
History of relapse, n (%) 83 (11) 
Radiation, n (%)   
  Any 276 (36) 
  Cranial 120 (16) 
    <18 Gy 27 (3) 
    ≥18 Gy 93 (12) 
  Chest 86 (11) 
    <30 Gy 33 (4) 
    ≥30 Gy 53 (7) 
  TBI and/or abdominal 67 (9) 
Glucocorticoids, n (%) 330 (43) 
Anthracyclines, n (%) 292 (38) 
Alkylating agents, n (%) 319 (41) 
Hematopoietic stem cell transplantation, n (%) 30 (4) 
1 CCS, childhood cancer survivor; CNS, central nervous system; Gy, gray; ICCC3, International Childhood Cancer Classification, 3rd edition. 
2 Values are medians (IQRs). 
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Table S2. Dietary intake in childhood cancer survivors by sex compared to the DACH dietary recommendations1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 CCS, childhood cancer survivors, DACH, Dietary recommendations for Germany (D), Austria (A) and Switzerland (CH).  
2 DACH recommendations for the general population age 20-50 y, excluding pregnant and lactating women. 
3 Depending on physical activity level (PAL, 1.4-1.8) and age. 
4 Percentage of mean intake to the DACH recommended intake level * 100. Recommended intake is estimated on the basis of the age-sex groups of the DACH guidelines, weighted by the age and sex 
distribution of the study population. For alcohol intake the maximum tolerated dosage was taken. 
5 Federal Food Safety and Veterinary Office FSVO, www.naehrwertdaten.ch.  
6 BLV (2009). Kohlenhydrate in unserer Ernährung – Empfehlungen des BLV. www.blv.admin.ch.  
7 BLV (2012). Fett in unserer Ernährung – Empfehlung des BLV. www.blv.admin.chv, Recommendations as a percentage of the daily energy demand and based on a daily energy intake of 2000 kcal. 
8 Total vitamin A= retinol + carotene/12, expressed in μg RAE. 
9 Maximum tolerated dosage.  
 DACH recommendations2 CCSs 
(n = 774) 
Nutrients men women men (n = 386) women (n = 388) 
   mean ± SD % DACH4 mean ± SD % DACH4 
Total energy, kcal3 2300-3400 1800-2600 1743 ± 632 61 1535 ± 508 70 
Macronutrients       
  Protein, g 57 48 73.8 ± 33.8 129 58.5 ± 22.1 122 
    % of energy5 10-20 10-20 16.9 ± 3.7 112 15.4 ± 3.4 103 
    Vegetal, g   18.3 ± 7.7  18.0 ± 7.5  
    Animal, g   55.5 ± 30.7  40.6 ± 19.9  
  Carbohydrates, g6 225-275 225-275 187 ± 76.2 75 174 ± 71 70 
    % of energy5, 6 45-55 45-55 42.8 ± 8.4 86 45.2 ± 9.1 90 
  Mono/disaccharides, g   87 ± 46  84 ± 46  
  Polysaccharides, g   98 ± 46  90 ± 42  
  Total fiber, g6 ≥30 ≥30 11.5 ± 5.8 38 12.9 ± 6.9 43 
  Total fat, g   72.2 ± 30.2  64.2 ± 25.4  
  Total fat, % of energy5 30-40 30-40 37.2 ± 6.6 106 37.5 ± 7.2 107 
  Saturated fat, g   27.3 ± 12.5  23.1 ± 10.4  
  Saturated fat, % of energy7 <10 <10 14.0 ± 2.9 140 13.5 ± 3.4 135 
  Monounsaturated fat, g   29.9 ± 13.3  27.3 ± 11.9  
  Polyunsaturated fat, g   9.0 ± 3.9  8.2 ± 3.6  
  Cholesterol, mg5 300 300 376 ± 209 125 310 ± 202 103 
Micronutrients       
Vitamins       
  A, mg-RE8  1.0 0.8 0.7 ± 0.7 71 0.7 ± 0.7 89 
  D, μg  20 20 2.5 ± 2.0 12 2.3 ± 2.0 12 
Minerals       
  Calcium, mg 1000 1000 908 ± 502 91 869 ± 437 87 
  Iron, mg 104 15 9.7 ± 3.9 97 8.3 ± 3.1 56 
  Alcohol, g9 20 10 7.5 ± 7.9 37 4.0 ± 7.2 40 
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Table S3. Scoring method and mean scores (95%CI) of components of the modified Alternate Healthy Eating Index1,2 in childhood cancer survivors 
and the general population (Menu.CH) by sex 
1 Adapted from Chiuve et al. J Nutr 2012 142(6):1009-18. 
2 Intermediate food intake was scored proportionately between the minimum score 0 and the maximum score 10. 
3 One serving was equal to 118.3g of raw or cooked vegetables or 250g of vegetable soup. Dried vegetables were not included. 
4 One serving was equal to 118.3g of raw or cooked fruit. Dried fruit was not included. 
5 Whole grain products like whole grain bread and muesli were included. 
6 One serving was equal to 226.8g. 
7 One serving was equal to 28.4g. 
8 One serving was equal to 113.4g of red meat or 42.5g of processed meat. 
9 Consumption was estimated based on the assumption that each food contains max. 2g of trans fat per 100g of total fat, as defined in the Swiss regulation. 
10 The highest score was given to individuals with ≥10% of total energy intake from poly-unsaturated fatty acids (PUFA). 
11 One drink was 113.4g of wine, 340.2g of beer or 42.5g of liquor. A score of 2.5 was given to non-drinkers. 
12 Adjusted for age at survey and ICCC-3 diagnosis  
13 Adjusted for age at survey and standardized on sex, age at survey, and language region according to CCSs. 
Components Criteria for  
minimum score (0) 
Criteria for 
maximum score (10) 
Score in CCSs12 
mean (95%CI) 
Score in Menu.CH13 
mean (95%CI) 
   men 
(n = 386) 
women  
(n = 388) 
men 
(n = 498) 
women 
(n = 636) 
Vegetables, excluding potatoes (servings/day)3 0 ≥ 5 4.6 (4.4, 4.9) 5.5 (5.3, 5.7) 3.2 (3.2, 3.2) 3.3 (3.3, 3.3) 
Fruit, excluding juice (servings/day)4 0 ≥ 4 2.9 (2.6, 3.2) 3.9 (3.6, 4.2) 2.9 (2.9, 2.9) 3.4 (3.4, 3.5) 
Whole grains (g/day)5 
    
  
   Men 0 ≥ 90 3.3 (3.0, 3.6)  3.4 (3.4, 3.4)  
   Women 0 ≥ 75  4.7 (4.4, 5.0)  4.0 (4.0, 4.0) 
Sugar-sweetened beverage and fruit juice (servings/day)6 ≥ 1 0 3.8 (3.4, 4.2) 4.9 (4.5, 5.3) 3.8 (3.7, 3.9) 4.8 (4.7, 4.9) 
Nuts, seeds, legumes, and tofu (servings/day)7 0 ≥ 1 1.9 (1.6, 2.2) 2.6 (2.3, 2.9) 1.7 (1.6, 1.7) 2.5 (2.5, 2.6) 
Red and processed meat (servings/day)8 ≥ 1.5 0 3.5 (3.2, 3.8) 5.8 (5.5, 6.1) 2.3 (2.3, 2.4) 5.2 (5.2, 5.2) 
Trans fat (% of total energy intake)9 ≥ 4 ≤ 0.5 9.6 (9.5, 9.7) 9.5 (9.5, 9.6) 9.5 (9.5, 9.5) 9.4 (9.4, 9.4) 
Fish, excluding processed products (g/day) 0 32.4 5.2 (4.8, 5.5) 4.9 (4.6, 5.3) 2.6 (2.6, 2.6) 2.6 (2.6, 2.6) 
PUFA (% of total energy intake)10 ≤2 ≥10 4.8 (4.6, 5.1) 5.2 (4.9, 5.5) 4.4 (4.3, 4.4) 4.3 (4.3, 4.3) 
Alcohol (drinks/day)11 
    
  
   Men ≥ 3.5 0.5 - 2.0 5.4 (5.0, 5.7)  5.0 (4.9, 5.0)  
   Women ≥ 2.5 0.5 - 1.5  3.9 (3.6, 4.3)  4.0 (4.0, 4.1) 
Total 0 100 45.0 (43.8, 46.2) 50.9 (49.7, 52.1) 38.7 (38.4, 38.9) 43.8 (43.6, 44.0) 
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SUMMARY 
 
Background: Urine analyses are an objective way to quantify intake of different nutrients, and 
can therefore complement self-reported information on nutrition from food frequency 
questionnaires (FFQs). We compared urine spot sample outcomes 1:1 with FFQs and 
evaluated the study conduct to investigate the possibility for a future national study.  
 
Methods: In an observational multicentre pilot study, we determined dietary intake with a FFQ. 
First and second morning urine spot samples were asked of patients hospitalised in the 
university hospitals of Lausanne (CHUV) or Geneva (HUG) and first morning spot samples of 
outpatients previously treated in CHUV or HUG. We analyse the content of sodium, potassium, 
urea, urate, creatinine, and phosphate in urinary samples. Currently, analyses are ongoing to 
compare the urine spot sample outcomes 1:1 with the FFQ dietary assessment tool. 
 
Results: We included 6 patients (response rate 75%) and 119 outpatients (response rate 
50%). The recruitment target was not met for patients (6 out of 50), but was met for outpatients 
(119 out of 100). Study recruitment in patients was difficult for several reasons, e.g. patient 
was too young, too sick, or did not needed an overnight stay, or recruitment was impossible 
due to understaffed paediatric oncology departments. 
 
Conclusions: Study feasibility in childhood cancer patients is poor if there is not a direct 
patient benefit. With the current information we recommend a future study only in outpatients 
as the response rate was relatively high. The quality of outpatients’ samples still need to be 
investigated.  
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BACKGROUND 
Biochemical indicators are an objective way to quantify intake of different nutrients, and can 
therefore complement self-reported information on nutrition from food frequency 
questionnaires (FFQs). This can be done by direct assays of the nutrient or the metabolic 
product in tissue or fluid, e.g. nails, faeces, blood, or urine. 24h urinary assessment of alkali 
minerals (sodium, potassium), halide ions (chloride, iodine and fluorine) and protein intakes 
are potential more valid indicators of nutrition than questionnaire-based data [1]. However, 
collection of 24h urine involves a considerable burden for subjects, and may introduce bias 
due to undetected incomplete sample collection and low response rate. Recently, research 
has therefore focused on the utility of single spot urines to estimate 24h urinary assessments 
[2, 3]. This is less burdensome for subjects, potential under- or over-collection is irrelevant and 
it is easier to incorporate in nutritional studies, as collection can be done during a single 
encounter. By adjusting for parameters such as age, sex, height and weight, and by taking 
urinary creatinine into account, samples can be converted into interpretable results. This 
makes spot urine samples a practical and costs saving alternative to 24h urine excretion to 
estimate population levels.  
This pilot study was set up to: 
1) compare the urine spot sample outcomes 1:1 with the FFQ dietary assessment tool. This 
will give more information about the reliability of the FFQ, the actual dietary intake of CCS and 
help to investigate if there is an association between diet and somatic late effects occurrence. 
2) evaluate the pilot study, e.g. 
• to determine feasibility (response rate, costs, quality) of analysing objective dietary 
markers in spot urine of CCS. 
• to observe if there are potential differences in study conduct, response rate and 
quality of the samples among two categories of participants:  
- patients followed at the oncology clinic, and 
- outpatients, former patients of CHUV or HUG 
• based on this experience, define the feasibility of a future national study to 
determine objectively dietary intake.  
 
METHODS 
Study population 
Inclusion criteria 
This multicentre observational pilot study was performed in the paediatric cancer centre in 
Lausanne (CHUV) and Geneva (HUG). For this pilot study we aimed to recruit 50 patients and 
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100 outpatients (Figure 1). This was perceived as the maximal feasible sample size within the 
study period of 2 years, both because of logistical reasons and patient availability. 
 
Participants were eligible to participate if they were: 1) childhood cancer patients (i.e. cancer 
diagnosed before the age of 21 years) newly diagnosed or in treatment, aged ≥8 years, and 
who were at time of the pilot study hospitalised in the oncology department of CHUV or HUG 
or 2) SCCSS study participants ≥16 years who visited in the past the oncology department of 
CHUV or HUG and filled in the FFQ as part of the SCCSS follow-up questionnaire. If the 
informed consent was signed and the urine specimen was sufficient to fulfil the pilot study 
protocol, participants were automatically enrolled. Study participants were excluded if they had 
end stage renal disease, or were pregnant or lactating. 
 
Figure 1. Pilot study flowchart.  
Recruitment and Screening 
Patients received a verbal briefing, and/or an information letter and informed consent in person 
from the project leader or their treating oncologist to ask for their willingness to participate. 
During recruitment it was made clear that this study would not lead to a direct benefit for the 
patient, but could benefit childhood cancer survivors in an attempt to reduce treatment related 
late effects. In case the patient and/or the legal representative signed the informed consent, 
the urine collection kit was handed over to collect a first and second morning urine sample the 
following day. It was hypothesized that the urine spot samples of this group would have the 
highest quality compared to outpatients. A high quality was expected as these patients 
received supervision of hospital staff during the pilot study, samples were considered to be 
stored quicker under the protocol storage procedures, and it was ensured that first and second 
morning urine spot samples were collected. Therefore, the urine spot samples of outpatients 
were compared to the ones of patients. The urine samples of patients were transferred as soon 
as possible, preferably within 1h to 1 day after collection handed over to the CHUV laboratory 
for analyses. 
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Outpatients received by post mail an information letter signed by the project leader. If 
the patient did not rejected to participate, an urine collection kit and informed consent were 
shipped to the participant’s home address to collect a first morning sample within 2 weeks. 
After sample collection, the urine spot was asked to be transferred by mail within 24 hours to 
the CHUV laboratory for analyses.  
Information about medication and type of treatment was extracted from clinical records 
for all participants. 
 
Measurements 
Up to 70 ml of a fresh first morning urine sample was asked to an eligible recruited participant 
during hospitalisation (patients) or via post mail (outpatients) (Figure 1). Second morning urine 
samples were asked only during hospitalisation. Response rate, feasibility, quality of samples, 
and correspondence between self-reported nutrition and objective measurements were 
assessed (Table I).  
For analyses, levels of potassium, sodium, phosphate, urate, urea, and creatinine were 
measured using routine laboratory procedures (Table I). Urinary potassium-to-creatinine ratio 
was used to estimate dietary potassium intake; similar calculations were done for sodium, 
phosphate, urate, and protein intakes (estimated by urea excretion, Table II). The central 
laboratory of CHUV, performed all biochemical analyses of all samples coming from both 
CHUV and HUG. Urine samples were frozen and stored in a biobank for further analyses 
corresponding to the topic of research, and to complete and increase the power of a possible 
further similar investigation within the larger cohort of the SCCCS.   
Table I. Primary and secondary endpoint/ outcomes of interest in the urine spot pilot study 
Endpoints/outcomes Method: Quality promotion (Expected) time point/window 
Detailed dietary 
intake, macro- and 
micronutrients 
Dietary intake was assessed using 
a validated FFQ which provided 
information on consumption 
frequency and portion sizes during 
the 4 previous wks for 97 fresh and 
prepared food items organized in 12 
different food groups.  
 
-The FFQ was not validated and 
adapted to children- 
A validated FFQ 
earlier used in the 
Bus Santé and 
CoLaus study was 
slightly adapted to 
meet study 
objectives 
Participants were expected to fill in 
and return the FFQ within +/- 10 
wks. After 4-6 wks, the participants 
received their 1st reminder by 
sending the FFQ again. In case of 
non-response, they received a 2nd 
reminder. The FFQ was sent before 
the start of this pilot study to all 
SCCSS participants (≥16 yrs). 
Urinary 
measurements, e.g. 
Na, K, urea, urate, 
creatine, PO4 
Laboratory tests Standard 
laboratory 
procedures 
Measurements were done at the 
same time the routine analyses 
were performed in the hospital 
laboratory. Measurements were 
performed during the whole time 
period of the pilot study 
General response 
rate and in subgroups 
- Patients: the investigator kept track 
of the number of CCS that were not 
willing to participate.  
- Outpatients: the SCCSS tracking 
system kept track of the number of 
CCS that did not responded or were 
not willing to participate.  
n.a. 
 
 
 
After finalising the pilot study 
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Costs 
 
All costs were recorded, e.g. 
laboratory, mailing, printing, urine 
collection sample kits. 
 Mid-term evaluation and after 
finalising the pilot study 
Quality of obtained 
urine spots 
FFQ vs. urine spots were compared 
between subgroups. To investigate 
if storage circumstances among 
subgroups did not substantially 
impact the quality of urine 
measurements, a subset of 10 
patients 1st morning samples (20%) 
mimicked to potential outpatients’ 
conditions. This means, that 1st 
morning samples of 10 patients 
were split into 2 subsamples. The 
1st subsample (3 x 3ml) was kept 4 
hrs at room temperature before 
urine chemistry and final storage at 
-80°C. The 2nd subsample (9 x 3ml) 
followed standard protocol storage 
procedures. The outcomes of the 
urine chemistry analyses of the 2 
subsamples were 1:1 compared. 
Standard 
laboratory 
procedures 
Mid-term evaluation and after 
finalising the pilot study 
Study feasibility for 
both hospital and 
study participants 
Difficulties in the study conduct 
among study participants or at the 
study centres (CHUV and HUG) 
were recorded for final evaluation. 
n.a. Mid-term evaluation and after 
finalising the pilot study 
CCS, childhood cancer survivor; CHUV, Centre Hospitalier Universitaire Vaudois; FFQ, food frequency questionnaire; HUG, 
Hôpital Universitaire de Genève; K, potassium; Na, sodium; PO4, phosphate; SCCSS, Swiss Childhood Cancer Survivor Study    
Table II. Performed urinary measurements and their estimated dietary intake 
Urinary measurement Estimation of dietary intake 
sodium (Na) • Dietary sodium intake  
• Na/Cr ratio 
potassium (K) • Dietary potassium intake (fruit and vegetables) 
• K/Cr ratio 
urea • Protein intake. Main end-product of the catabolism of amino acids 
• Protein/Cr ratio 
urate • Production of uric acid – diet rich in protein 
creatinine (Cr) • Completeness of urine collection 
phosphate (PO4) • Phosphate intake (dairy products, meat, whole grain, nuts, eggs, 
additives in processed food) 
• PO4/Cr ratio 
 
STATUS 
The urine pilot study includes in total 125 participants: 6 patients and 119 outpatients (Figure 
2). The study was terminated prematurely on 01.04.2018 (Table III). Currently, data analyses 
are ongoing. 
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Table III. Pilot study elements and duration  
Pilot study duration Date 
Ethical approval  
   CER-VD 
   CCER 
 
15.03.2016 
21.07.2017 
Date first participant in 03.02.2017 
Date last participant in 10.12.2017 
FFQ data entered 23.03.2018 
End of study 01.04.2018 
CCER, Commission Catonale d’éthique de la recherche Genève; CER-VD, Commission  
Catonale d’éthique de la recherche sur l’être humain Vaud 
 
 
Figure 2. Response rates per study arm in the Swiss Childhood Cancer Survivor Study 
(SCCSS) Urine Pilot Study  
 
STUDY CHALLENGES 
This study has not met its initial target number of participants due to difficulties with patient 
recruitment. Initially this study contained three study arms:  
1. Patients: childhood cancer patients hospitalised in the paediatric oncology department 
of CHUV or HUG 
2. Clinical visit: CCS with regular clinical visits at CHUV or HUG, meaning at least one 
planned visit during study duration 
3. Outpatients: CCS with unregularly clinical visits in CHUV or HUG, meaning no planned 
visit during study duration 
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The original target participant number was 200 (patients N=50, clinical visit N=50, outpatients 
N=100) of which we enrolled 125 (patients N=6, clinical visit N=0, outpatients N=119).  
 
Patients 
Reasons why the target for the study arm ‘patients’ was not met were: 
• patients did not met the inclusion criteria. Hospital staff often had difficulties with the 
age limitation of ≥ 8 years as a high proportion of patients were younger;   
• patients were too sick; 
• patients resigned sooner than expected (no overnight stay); 
• under staffed paediatric oncology departments, no time for recruitment, sample 
collection etc., and because of 
• refusal of patient and/or legal guardian(s) (minority) 
Clinical visit and outpatients 
Because of recruitment difficulties, understaffed paediatric oncology departments, and time 
restrictions we decided to include a second study centre (HUG) and drop the study arm: 
‘clinical visit’. This gave us the opportunity to include more eligible ‘outpatients’ due to the 
overlap between the study arms ‘clinical visit’ and ‘outpatients’. We aimed for an as high as 
possible eligible outpatients number as we expected potential recruitment difficulties. 
Outpatients were asked to collect and send their urine samples during the week and bring the 
sample to the post office as the sample did not fitted the opening of a mailbox. Although a low 
response rate was expected we managed to recruit more outpatients than planned. Due to 
good response, we did not send the planned reminder. The recruitment target for ‘outpatients’ 
was met due to the: 
• high number of eligible CCS, national coverage of SCCR;  
• direct contact possibilities with the potential participants; 
• up to date address list, personal information etc. of SCCR, and  
• because CCS were more often capable to participate to the study (less restricted to 
illness) compared to patients and highly motivated. 
 
CONCLUSION 
We can conclude that the study feasibility in childhood cancer patients is poor if there is not a 
direct patient benefit. With the current information we recommend a future study only in 
outpatients as the response rate was relatively high. The quality of outpatients’ samples still 
need to be investigated. 
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SUMMARY 
 
Background: Childhood cancer patients (CCP) have been reported to be at increased risk of 
becoming overweight during treatment. We assessed prevalence of overweight in CCP at 
diagnosis and at the end of treatment, determined risk factors, and identified weight change 
during treatment by type of cancer. 
 
Objective: In a multicentre cohort study, we collected height and weight measurements of 
CCP at diagnosis and repeatedly during treatment. We calculated age- and sex-adjusted BMI 
Z-scores using references of the International Obesity Taskforce for children. Risk factors were 
described by multivariable linear regression, and weight change during treatment by multilevel 
segmented linear regression. 
 
Results: The study included 327 CCP with a median age of 7 years (IQR 3-12) at diagnosis 
(55% boys), who had been diagnosed with acute lymphoblastic leukaemia (ALL, 29%), 
lymphoma (16%), central nervous system (CNS) tumours (13%), sarcoma (18%), and other 
types of cancer (24%). At diagnosis, 27 CCP (8%) were overweight. This increased to 43 (13%) 
at end of treatment, on average 0.7 years after diagnosis. Being a boy (p=0.005) and having 
been diagnosed with ALL or lymphoma (p<0.001) were risk factors for weight gain during 
treatment. During the first half of treatment, BMI Z-scores increased in ALL (regression slope 
β=0.4, 95% CI 0.1–0.7) and lymphoma (β=1.5, 95% CI 0.2–2.9) patients, whereas for patients 
with CNS tumours (β=-1.4, 95% CI -2.7 to -0.2), sarcoma (β=-1.4, 95% CI -2.0 to -0.7), or other 
types of cancer (β=-0.3, 95% CI -1.5–0.9) BMI Z-scores tended to drop initially. During the 
second half of treatment BMI Z-scores of all patients tended to increase. Exploratory analyses 
showed that BMI Z-scores of younger ALL patients (<7 years at diagnosis) increased during 
induction (β= 3.8, 95% CI 0.5–7.0). The inverse was seen for older ALL patients (≥7 years at 
diagnosis), in whom BMI Z-scores tended to decrease during induction (β= -1.5, -5.1–2.2), 
both groups tended to increase afterwards. 
 
Conclusions: CCP diagnosed with ALL or lymphoma are at increased risk of weight gain 
during treatment, and might particularly benefit from early lifestyle interventions. 
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INTRODUCTION  
Childhood cancer survival has substantially improved in recent decades, but chronic health 
problems are common in survivors [1]. Overweight is reported as a frequent late effect, 
particularly in patients with acute lymphoblastic leukaemia (ALL) and brain tumours [2, 3]. 
Some studies have suggested that patients diagnosed with other cancers such as sarcomas 
and lymphomas are also affected [2, 4]. The consequences of overweight and obesity in 
childhood cancer patients (CCP) are manifold: reduced health-related quality of life, more 
comorbidities in later life, and increased risk for relapse, second primary tumours, and mortality 
[4, 5].  
Studies of overweight or obesity during treatment have been conducted mainly in ALL 
and brain tumour patients, and have reported varying results. At diagnosis, 10-36% of ALL 
patients were reported to be overweight and 2-19% obese [4, 6-9]. At the end of treatment, 19-
49% were reported as overweight and 9-48% as obese [4, 6-9]. In patients with 
craniopharyngiomas, obesity was reported in 50% of the patients after tumour resection [10, 
11].  
Data on risk factors for overweight in CCP are inconclusive [4, 12]. A meta-analysis 
has concluded that childhood ALL patients have substantial weight gain from diagnosis to start 
of maintenance treatment and beyond, independent of gender, cranial radiation therapy, and 
weight status at diagnosis [13]. For brain tumour patients, female gender and younger age 
were described as risk factors for obesity [10, 14]. Yet few studies have covered the whole 
diagnostic spectrum of childhood cancer. Comparable information on overweight prevalence 
at diagnosis, during, and at the end of cancer treatment between diagnostic groups in CCP is 
also lacking, but is crucial for initiating individualised preventive measures at an early stage.  
The goals of this multicentre cohort study were to 1) determine overweight prevalence 
of CCP at diagnosis and at the end of treatment, 2) determine potential risk factors for weight 
change from diagnosis until the end of treatment, and 3) describe weight change during 
treatment by type of cancer, with a focus on ALL patients during the different treatment phases.  
 
METHODS  
Study population  
Eligible patients for this retrospective cohort study were CCP aged <18 years at diagnosis who 
were diagnosed 2003–2006 and treated with chemotherapy and/or percutaneous radiotherapy 
in three tertiary care centres for paediatric haematology/oncology in Basel, Bern, and Zürich 
in the German-speaking part of Switzerland. Prospectively collected data on type of cancer, 
treatment, and demographic information were extracted from the Swiss Childhood Cancer 
Registry (SCCR, www.childhoodcancerregistry.ch) [15, 16]. Height and weight measurements 
were obtained from a retrospective chart review. Detailed information on our study design was 
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published previously [17]. Ethical approval of the SCCR was granted by the Ethics Committee 
of the Canton of Bern (KEK-BE: 166/2014).  
 
Measurements  
Body weight and BMI Z-scores  
Body mass index (BMI), expressed in kg/m2 was used to define overweight. BMI Z-scores were 
calculated according to Cole’s LMS method [18] based on the reference values of the 
International Obesity Taskforce (IOTF). For children under two years of age, we used the 
standards of the World Health Organization [19]. Underweight (thinness grade I-III), normal 
weight, and overweight (including obesity and morbid obesity) was classified according to BMI 
cut-offs recommended by the IOTF (Supplementary Table S1) [20]. The observation period 
started with the first measurement at diagnosis and ended with the last measurement before 
the end of anticancer treatment or when the patient died, relapsed, or was transferred to a 
nonparticipating hospital for ongoing anticancer treatment [17]. This study used all weight and 
height measurements available from medical charts.  
We obtained birth weights from medical records and by using probabilistic record 
linkage of the SCCR and birth records from the Swiss Federal Statistical Office, as described 
previously [21]. Birth weight was classified into three categories: low (<2500 g), normal (2500-
4000 g), and high (>4000 g) [22].  
 
Sociodemographic and clinical characteristics  
Participants who were not Swiss citizens at birth, not born in Switzerland, or had at least one 
parent who was not a Swiss citizen were classified as having a migration background. 
Diagnosis was classified according to the International Classification for Childhood Cancer, 
3rd edition (ICCC-3) [23], and grouped into five main categories: ALL, lymphomas, CNS 
tumours, sarcomas, and other types of cancer. These categories were chosen in accordance 
with other studies [2, 4]. Radiotherapy was classified as cranial radiation therapy (CRT) if the 
patient had received direct radiation to the brain and/or skull. Cumulative dosage of CRT was 
obtained from medical records and categorized as <20 Gray (Gy) or ≥20 Gy. We also extracted 
information on parenteral and/or enteral nutritional support during treatment. 
 
Statistical Analyses  
We first compared the changes in prevalence of overweight and BMI Z-scores between 
diagnosis and the end of treatment by sociodemographic and clinical characteristics. The time 
of end of treatment was replaced with time at relapse, death, or end of data collection if these 
occurred during treatment.  
Second, we used linear regression to determine risk factors associated with change in 
BMI during treatment, from diagnosis till end of treatment. We selected the following potential 
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risk factors a priori based on a literature review: gender, age at diagnosis, ICCC-3 diagnosis, 
cumulative CRT, parenteral/enteral nutrition support, birthweight, and BMI Z-score at 
diagnosis. Variables with p-values <0.05 in univariable models were jointly included in a 
multivariable model. F-tests were used to test the association between the outcome and the 
covariates. Age at diagnosis and BMI Z-scores at diagnosis were included as continuous 
variables after testing for linearity of their association with BMI-change using likelihood ratio 
tests.  
Third, to assess whether the slope of BMI change was different between early and late 
treatment phases we fit multilevel segmented linear regression models with BMI Z-score as 
dependent variable and therapy duration in years as independent variable. We separated 
analyses for each diagnostic group. The piecewise linear regression line allowed for a change 
in trend at a specified breakpoint set to the median treatment duration among patients of the 
given diagnostic group. For ALL patients, we performed separate analyses with breakpoints at 
the end of the induction period (33 days, 0.09 years) and the start of the maintenance period 
(99 days, 0.27 years), based on the cancer protocols used in the study. All regression models 
included a random effect term on patient level, allowing for intra-individual correlation. The 
models were adjusted for gender, age at diagnosis, cumulative CRT, parenteral/enteral 
nutrition support, and BMI Z-score at diagnosis. For these analyses, we included only 311 CCP 
who had at least five height and weight measurements available.  
BMI Z-score curves of individual patients were highly variable, and fitting a single trend by 
diagnostic group is clearly an oversimplification. In additional exploratory analyses in ALL 
patients, we therefore fit separate segmented linear regressions with a flexible breakpoint to 
the BMI Z-score of each patient. We then grouped patients according to whether the initial 
slope was positive or negative and compared groups according to gender and age (below and 
above median of 7 years) at diagnosis using chi-square tests. We found that BMI Z-scores 
tended to initially increase in younger patients, but decreased in older patients (p=0.002). The 
groups differed little in gender composition (p=0.117). In post hoc analyses we therefore 
repeated our main analysis for ALL (with specified breakpoints at the end of the induction 
period and the start of the maintenance period), stratifying patients by these age groups. We 
used Stata (version 14, Stata Corporation, Austin, Texas) and R (version 3.2.0) for all analyses. 
The command xtmixed was used for multilevel segmented linear regression analysis.  
 
RESULTS  
We included 327 patients in the analysis whose median age at diagnosis of 7 years 
(interquartile range [IQR] 3-12). ALL was the most common diagnosis among CSS with 95 
patients (29%), followed by sarcomas (18%), lymphoma (16%), CNS tumours (13%), other 
types of cancer (24%) including acute myeloid leukaemia, nephroblastoma, and 
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neuroblastoma (Table I). The median time from diagnosis until the end of treatment was 0.7 
years (IQR 0.4-1.8) for all patients and varied by type of cancer: ALL 2.0 (IQR 2.0-2.3), 
lymphoma 0.4 (IQR 0.3-0.6), CNS tumours 0.7 (IQR 0.3-1.2), sarcomas 0.7 (IQR 0.5-0.9), and 
other types of cancer 0.6 (IQR 0.4-0.7) years. Median time interval between successive weight 
and height measurements was 13 days (IQR 10-19 days), and 267 patients were observed 
until the end of their anticancer treatment (82%), 23 patients (7%) relapsed during therapy, 12 
patients (4%) died, and 25 patients (8%) were lost to follow up. Other patient and clinical 
characteristics are shown in Table I. 
 
Overweight prevalence and BMI Z-scores at diagnosis and at the end of treatment  
At diagnosis, 27 patients (8%) were overweight. This proportion increased to 43 (13%) at the 
end of treatment (Table I). Mean BMI Z-score was -0.1 (SD 1.1) at diagnosis and -0.1 (SD 1.3) 
at the end of treatment (Table II). Prevalence of overweight at diagnosis increased during 
treatment in boys and girls, all age groups, all types of cancer except “other types,” and patients 
with and without parenteral or enteral nutrition support (Figure 1). BMI Z-scores tended to 
increase during treatment in boys, patients below the age of five years, those diagnosed with 
ALL or lymphoma, with no or <20 Gy CRT, no parenteral or enteral nutrition support, and those 
who were underweight at diagnosis (Table II).  
 
Risk factors for weight change during treatment among childhood cancer patients  
In adjusted models, risk factors for weight gain during treatment were being a boy (β=0.3; 
95%CI: 0.1, 0.5) and being diagnosed with ALL (β=0.5; 0.2, 0.8) or lymphoma (β=0.6; 0.2, 1.0). 
Weight loss was associated with older age at diagnosis (β=-0.03; -0.05, 0.01, per year 
increase), ≥20 Gy CRT (β=-0.6; -1.0, 0.1), receiving parenteral/enteral nutrition support (β=-
0.3; -0.5, 0.1), and a higher BMI at diagnosis (β=-0.3; -0.4, 0.2, per BMI Z-score) (Table III). 
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Table I. General characteristics of the study population (n=327)  
 Total 
 
(n=327) 
Overweight at 
diagnosis 
(n=27) 
Overweight at the end of 
treatment 
(n=43) 
Characteristics n (%) n (%) n (%) 
Sociodemographic characteristics    
Gender 
  Girl 
  Boy 
 
146 (45) 
181 (55)  
 
15 (56) 
12 (44) 
 
17 (40) 
26 (60) 
Age at diagnosis, median years (IQR)  
  <5 
   5-9 
   10-14 
   ≥15 
6.8 (2.9, 12.0) 
132 (40) 
86   (26) 
71   (22) 
38   (12) 
9.2 (1.5, 13.0) 
11 (41) 
5   (19) 
6   (22) 
5   (19) 
7.0 (3.9, 13.7) 
18 (42) 
9   (21) 
8   (19) 
8   (19) 
Migration  
  No migration background 
  Migration background 
 
239 (73) 
88   (27) 
 
19 (70) 
8   (30) 
 
31 (72) 
12 (28) 
Clinical characteristics    
ICCC-3 diagnosis 
  Ia: ALL 
  II: Lymphoma 
  III: CNS tumour 
  VIII-IX: Sarcoma 
  Other 
 
95 (29) 
53 (16) 
42 (13) 
59 (18) 
78 (24) 
 
7   (26) 
2   (7) 
5   (19) 
4   (15) 
9   (33) 
 
17 (40) 
7   (16) 
6   (14) 
7   (16) 
6   (14) 
Treatment centre 
  Centre 1 
  Centre 2 
  Centre 3 
 
152 (46) 
113 (35) 
62   (19) 
 
19   (70) 
6     (22) 
2     (7) 
 
22   (51) 
14   (33) 
7     (16) 
Time from dx until end of treatment, median 
years (IQR) 
 
0.7 (0.4, 1.8) 
 
- 
 
- 
Cranial radiation therapy  
  No  
  <20 Gy 
  ≥20 Gy 
 
284 (87) 
16   (5) 
27   (8) 
 
20 (74) 
4   (15) 
3   (11) 
 
38 (88) 
3   (7) 
2   (5) 
Chemotherapy 
  No  
  Yes  
 
3     (1) 
324 (99) 
 
2   (7) 
25 (93) 
 
2   (5) 
41 (95) 
Parenteral/ enteral nutrition support 
  No 
  Yes 
 
229 (70) 
98   (30) 
 
21 (78) 
6   (22) 
 
32 (74) 
11 (26) 
BMI at diagnosis 
  Underweight 
  Normal 
  Overweight 
  Obese 
 
63   (19) 
237 (72) 
20   (6) 
7     (2) 
 
- 
- 
20 (74) 
7    (26) 
 
- 
24 (56) 
13 (30) 
6   (14) 
BMI at end of treatment 
  Underweight 
  Normal 
  Overweight 
  Obese 
 
72   (22) 
212 (65) 
35   (11) 
8     (2) 
 
- 
8   (30) 
13 (48) 
6   (22) 
 
- 
- 
35 (81) 
8   (19) 
Birthweight, gram 
  Low: <2500 
  Normal: 2500-4000 
  High: >4000 
  Missing  
 
18   (6) 
239 (73) 
29   (9) 
41   (13)  
 
- 
18 (67) 
2   (7) 
7   (26) 
 
2   (5) 
31 (72) 
3   (7) 
7   (16) 
ALL, acute lymphoblastic leukaemia; BMI, body mass index; CNS, central nervous system; Gy, gray; ICCC-3, International 
Classification of Childhood Cancer, 3rd edition; IQR, interquartile range 
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Table II. BMI Z-scores at diagnosis and at the end of treatment  
 BMI Z-score mean (SD) 
 Diagnosis 
(n=327) 
End of treatment 
(n=327) 
Difference between diagnosis 
and end of treatment 
All CCS -0.10 (1.1) -0.08 (1.3)  0.02 (1.1) 
Gender 
    Girl  
    Boy 
 
-0.13 (1.2) 
-0.08 (1.1) 
 
-0.30 (1.3) 
 0.10 (1.3) 
 
-0.17 (1.1) 
 0.18 (1.0) 
Age at diagnosis 
  <5 
   5-9 
   10-14 
   ≥15 
 
-0.19 (1.2) 
-0.18 (1.0) 
-0.05 (1.0) 
 0.26 (1.1) 
 
 0.02 (1.3) 
-0.19 (1.4) 
-0.18 (1.2) 
 0.03 (1.4) 
 
 0.21 (1.2) 
-0.01 (1.1) 
-0.14 (0.9) 
-0.23 (0.9) 
ICCC-3 diagnosis 
    Ia: ALL 
    II: Lymphoma 
    III: CNS tumour 
    VIII-IX: Sarcoma 
    Other 
 
-0.14 (1.2) 
-0.07 (1.0) 
-0.25 (1.4) 
-0.08 (0.9) 
-0.02 (1.1) 
 
 0.28 (1.1) 
 0.22 (1.1) 
-0.60 (1.6) 
-0.32 (1.2) 
-0.26 (1.3) 
 
 0.42 (1.0) 
 0.29 (0.9) 
-0.35 (1.3) 
-0.24 (0.8) 
-0.24 (1.2) 
Cranial radiation therapy 
    No  
    <20 Gy 
    ≥20 Gy 
 
-0.14 (1.1) 
 0.41 (1.6) 
-0.05 (1.1) 
 
-0.04 (1.3) 
 0.55 (1.4) 
-0.84 (1.3) 
 
 0.10 (1.1) 
 0.14 (0.9) 
-0.79 (1.0) 
Parenteral/ enteral nutrition support 
    No 
    Yes 
 
-0.04 (1.1) 
-0.24 (1.1) 
 
 0.06 (1.2) 
-0.41 (1.4) 
 
 0.11 (1.0) 
-0.17 (1.3) 
BMI at diagnosis 
  Underweight 
  Normal 
  Overweight 
 
-1.64 (0.6) 
 0.07 (0.6) 
 1.98 (0.7) 
 
-0.98 (1.1) 
-0.04 (1.1) 
 1.70 (1.3) 
 
 0.66 (1.0) 
-0.11 (1.1) 
-0.29 (0.9) 
ALL, acute lymphoblastic leukaemia; BMI, body mass index; CCS, childhood cancer survivors; CNS, central nervous system; Dx, 
diagnosis; Gy, gray; ICCC-3, International Classification of Childhood Cancer, 3rd edition; OW, overweight; SD, standard deviation 
 
 
Figure 1. Prevalence of overweight at diagnosis and end of treatment for childhood 
cancer patients by gender, age at diagnosis, type of cancer, and nutritional support 
CI, confidence interval; ALL, acute lymphoblastic leukaemia; CNS, central nervous system  
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Table III. Risk factors for change in BMI per Z-score from diagnosis until end of treatment 
(retrieved from univariable and multivariable linear regression models) 
 β (95% CI) for change in BMI per Z-score from diagnosis until end 
of treatment 
 Univariable Multivariablea 
 β (95% CI) p-valueb β (95% CI) p-valueb 
Gender 
  Girl 
  Boy  
 
 Ref 
 0.35 (0.12–0.59) 
 
 
0.003 
 
 Ref 
 0.30 (0.09–0.51) 
 
 
0.005 
Age at diagnosis, years -0.03 (-0.05 to 0.01) 0.007 -0.03 (-0.05 to 0.01) 0.010 
ICCC-3 diagnosis 
  Other 
  Ia: ALL 
  II: Lymphoma 
  III: CNS tumour 
  VIII-IX: Sarcoma 
 
 Ref  
 0.66 (0.35–0.98) 
 0.53 (0.17–0.90) 
-0.11 (-0.50 to 0.28) 
 0.01 (-0.35 to 0.36) 
 
 
 
 
 
<0.001 
 
 Ref 
 0.54 (0.24–0.84) 
 0.57 (0.20–0.95) 
 0.10 (-0.30 to 0.50) 
 0.11 (-0.24 to 0.46) 
 
 
 
 
 
<0.001 
Cranial radiotherapy 
  No 
  <20 Gy 
  ≥20 Gy 
 
 Ref 
 0.05 (-0.49 to 0.58) 
-0.88 (-1.30 to 0.46) 
 
 
 
<0.001 
 
 Ref 
 0.30 (-0.20 to 0.80) 
-0.58 (-1.02 to 0.14) 
 
 
 
0.015 
Parenteral/ enteral nutrition support 
  No 
  Yes 
 
 Ref  
-0.28 (-0.53 to 0.02) 
 
 
0.035 
 
 Ref  
-0.29 (-0.53 to 0.06) 
 
 
0.016 
Birthweight 
  Low: <2500 
  Normal: 2500-4000 
  High: >4000 
 
 0.03 (-0.50 to 0.55) 
 Ref 
 0.06 (-0.36 to 0.49) 
 
 
 
0.992 
 
- 
 
- 
BMI at diagnosis (BMI Z-scores) -0.29 (-0.40 to 0.19) <0.001 -0.29 (-0.39 to 0.20) <0.001 
ALL, acute lymphoblastic leukaemia; BMI, body mass index; CI, confidence interval; CNS, central nervous system; Gy, gray; 
ICCC3, International Classification of Childhood Cancer, 3rd edition; OR, odds ratio 
a: Adjusted for gender, age at diagnosis, ICCC-3, CRT, parenteral/enteral nutrition support, and weight at diagnosis 
b: p-value calculated from F-test 
 
Weight change during treatment by type of cancer  
Using multilevel segmented linear regressions, we found that BMI Z-scores tended to increase 
throughout treatment in ALL patients (β0-0.6 yrs: 0.4; 95%CI: 0.1, 0.7; β≥0.6 yrs: 0.3; 0.2, 0.5) (Table 
IV), especially during early treatment from diagnosis until end of the induction phase (β0-0.1 yrs: 
2.3; 95%CI: -0.2, 4.8) (Figure 2, Supplementary Table S2). BMI Z-score also tended to 
increase throughout the whole treatment period in lymphoma patients (β0-0.2 yrs: 1.5; 0.2, 2.9; 
β≥0.2 yrs: 0.6; 0.2, 1.1). In patients with CNS tumours, sarcoma, and other types of cancer BMI 
Z-scores tended to drop during the first half of the treatment period (βCNS: -1.4; -2.7, 0.2; βsarcoma: 
-1.4; -2.0, 0.7; βother: -0.3; -1.5, 0.9), but tended to increase thereafter (coefCNS: 0.2; -0.5, 0.9; 
coefsarcoma: 1.2; 0.7, 1.7, coefother: 0.6; 0.1, 1.1) (Table IV).  
In post hoc analyses of ALL patients, BMI Z-scores of ALL patients who were <7 years 
at diagnosis tended to increase during treatment (β0-33 days: 3.8; 0.5, 7.0; β34-99 days: -0.4; -1.9, 
1.0; β≥100 days: 0.2; 0.1, 0.3) (Supplementary Table S2, Supplementary Figure S1A). BMI Z-
scores of older ALL patients tended to drop during the induction phase of their cancer treatment 
protocol (β0-33 days: -1.5; -5.1, 2.2), and increase thereafter (β34-99 days: 0.5; -1.3, 2.2; β≥100 days: 
0.3; 0.2, 0.4) (Supplementary Table S2, Supplementary Figure S1B).  
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Table IV. Slopes of change in BMI Z-score from multilevel segmented linear regression 
modelsa for childhood cancer patients by cancer type  
ICCC-3 diagnosis slope 1  
β (95%CI) 
slope 2  
β (95%CI) 
Break point, 
yearsb 
ALL   0.38 (0.08–0.69)  0.32 (0.19–0.45) 0.61  
Lymphoma  1.53 (0.18–2.87)  0.62 (0.17–1.07) 0.22 
CNS -1.44 (-2.73 to 0.16)  0.22 (-0.46 to 0.89) 0.37 
Sarcoma -1.39 (-2.04 to 0.74)  1.18 (0.72–1.65) 0.34 
Other -0.28 (-1.50 to 0.89)  0.61 (0.09–1.14) 0.27 
ALL, acute lymphoblastic leukaemia; BMI, body mass index; CI, confidence interval; CNS, central nervous system; ICCC-3, 
International Classification of Childhood Cancer, 3rd ed.  
a Adjusted for gender, age, cumulative cranial radiation therapy, parenteral/enteral nutrition support, and BMI at diagnosis with a 
random effect on patient level. 
b Breakpoint defined at the median treatment duration within each diagnostic group 
 
 
 
Figure 2. Slope of change in BMI Z-score from a multilevel segmented linear 
regression modela for childhood acute lymphoblastic leukaemia patients (n=95)  
a Adjusted for gender, age at diagnosis, cranial radiation therapy, parenteral/enteral nutrition support, and BMI at 
diagnosis with a random effect on patient level. Breakpoints defined at the end of the induction period (33 days, 0.09 
years) and the start of the maintenance period (99 days, 0.27 years). 
 
DISCUSSION  
The prevalence of overweight at diagnosis of Swiss CCP increased from 8% at diagnosis to 
13% at the end of treatment. Being a boy and being diagnosed with ALL or lymphoma were 
risk factors for weight gain during treatment. Patients with ALL and lymphoma showed a 
continuously increasing trend in BMI Z-scores over the treatment period. The increase was 
particularly steep during early treatment in ALL patients, from diagnosis until end of induction. 
However, in older ALL patients (≥7 years at diagnosis) BMI initially tended to drop and increase 
later.  
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Prevalence of overweight and BMI Z-scores in comparison with other studies  
Direct comparison with other studies is limited due to the lack of studies including all types of 
cancers and different overweight definitions that were used. A Dutch prospective study in 133 
CCP with a median age of 8 years, found that 5% of the children were overweight at diagnosis, 
and 10% one year later [12]. They used higher cut-offs to define overweight than we did, which 
might explain the lower prevalence. We found similar overweight prevalence in the general 
Swiss population; 12% in the general population versus 8% in CCP at diagnosis to 13% at the 
end of treatment [24]. In a study in the US, 55% of 183 patients were overweight at diagnosis 
and 69% at the end of treatment [6] while in another US-based study 21% of 83 ALL patients 
were overweight and this rose to almost 40% at the end of treatment [8]. The BMI Z-scores of 
these respective ALL patients increased between diagnosis and end of treatment from 0.2 to 
0.8 and 0.6 to 1.1 respectively [6, 8]. These studies are in accord with the higher prevalence 
of overweight seen in the general US population, with around 33% of the children being 
overweight [25]. We observed a lower prevalence of overweight, 7%, at diagnosis, and 18% 
at the end of treatment. In our study mean BMI Z-score in ALL patients increased from -0.1 to 
0.3 during the observation period, with an accentuated weight increase during early treatment 
potentially due to the high doses of glucocorticoids given during this treatment period in all 
patients with ALL. Glucocorticoids may also effect linear growth suppression which could be 
associated with a BMI increase [26, 27]. The overall increase in BMI we observed in ALL 
patients is in line with previous literature [6-8, 13, 28, 29].  
Patients with CNS tumours, especially those diagnosed with craniopharyngioma, 
astrocytoma, or ependymoma have been reported to be at increased risk of overweight after 
treatment [2, 4]. We could not confirm this. We found that the BMI Z-score of CNS patients 
dropped during the first four months of treatment, but tended to increase afterwards. These 
results are in contrast to 36 CNS patients in the Dutch study mentioned above in whom a rapid 
increase in BMI Z-scores was observed after diagnosis [12]. The differences in these results 
might be due to the higher proportion of medulloblastoma patients in our study who are often 
undernourished [17], whereas the opposite is seen for patients diagnosed with astrocytoma 
and craniopharyngioma.  
 
Risk factors for weight gain during treatment in relation to other studies  
Mixed results are reported in literature. Female gender [4, 7, 10, 14], and male gender have 
been associated with becoming overweight during treatment [9, 30, 31], while no gender 
association has also been observed [13]. We found that boys were more likely to gain weight 
than girls, which is in line with the gender differences found in the general Swiss child 
population [32]. Furthermore, we found that ALL patients who were older at diagnosis (≥7 
years) tended to show a decline in BMI during the induction treatment phase, after which BMI 
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tended to increase. This initial drop may reflect the physiological and psychosocial burden of 
a cancer diagnosis among children who are old enough to fully understand its consequences 
and hazards. We observed the same tendency for all cancer diagnosis groups combined. 
Weight at diagnosis was associated with overweight at the end of treatment in other studies 
[8, 9, 33]. This has not been seen, however, in meta-analysis: weight gain during treatment 
was independent of weight at diagnosis, but patients who were underweight at diagnosis 
showed a greater BMI increase than normal and overweight patients [13]. We saw an inverse 
association between BMI at diagnosis and change of BMI during treatment with an overall 
increase in BMI Z-scores in underweight patients and a decrease in overweight patients; 
however, the majority of overweight patients at diagnosis stayed overweight at end of treatment 
(70%). 
 
Limitations and strengths of the study  
Our study is limited by its retrospective study design. Weight and height measurements were 
based on routine, clinically indicated measurements, documented in charts, and were not 
taken at specific times during patients’ treatments. Second, BMI Z-scores do not measure the 
ratio of lean to fat mass or the fat distribution. Although BMI Z-scores are an easy, low cost, 
and appropriate method to assess overweight, they correlate less with body fat than other 
methods such as skinfold measurements, underwater weighing, dual energy X-ray, or 
magnetic resonance imaging [34], and are not recommended as a sole overweight indicator in 
childhood cancer patients [35]. Third, we did not collect data on lifestyle and social factors like 
diet, physical activity, and parenting style that could potentially affect weight gain during 
treatment. Finally, the multilevel segmented linear regression models were a poor fit to the 
highly variable BMI Z-score curves of individual patients. More complex analyses are required 
to take this heterogeneity into account among patients.  
Despite these limitations, our study is among the few to have captured weight at 
diagnosis and end of treatment in childhood cancer patients of all diagnoses. We chose the 
IOTF cut-off values [20], which are stricter than national cut-offs [6-8], to define overweight for 
international comparability. Finally, we had access to detailed clinical information of patients 
from the SCCR.  
 
Implications for future recommendations  
Overweight plays a significant role in childhood cancer treatment [3, 4, 33] and has been 
reported to affect treatment-related toxicity, relapse rates, and (event-free) survival rates [3, 4, 
36]. Weight gain during treatment tends to persist in ALL patients beyond treatment completion 
[13]. Early weight management should therefore be emphasized. Furthermore, in overweight 
CCP lower emotional, cognitive, and social functioning has been reported compared to 
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children with a normal weight [5]. This can reveal new target areas for overweight interventions 
because awareness of influential factors can help to proactively introduce and specifically 
review current methods. Since early overweight is a risk factor for overweight later in life, 
weight management interventions should be individually tailored and provided especially to 
patients who have a high risk of developing overweight during treatment. Overweight later in 
life is associated with development of chronic cardiac disorders and type II diabetes [37]. As 
CCP already have an increased risk of developing these disorders, early overweight 
management could prevent long-term consequences [1]. Purposeful prevention and treatment 
measures should be developed and implemented with regard to encouraging a balanced diet 
and sufficient physical exercise. Focus should lie on the prevention of overweight and 
underweight as 19% of the patients were underweight at diagnosis and 22% at end of 
treatment. Both overweight and underweight CCP have a reduced health-related quality of life 
compared to normal weight CCP [5]. Therefore, future research needs to focus on testing 
interventions that aim to improve the nutritional status of children with cancer and behavioural 
interventions should be well grounded in theory and empirical evidence as they are complex.  
 
CONCLUSION  
This multicentre cohort study found that overall prevalence of overweight markedly increased 
in CCP within an average treatment duration of less than one year. Lifestyle interventions to 
prevent overweight development should start early during treatment, particularly for patients 
diagnosed with ALL or lymphoma.  
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SUPPLEMENTARY MATERIAL 
 
Table S1. Cut-off valuesa by gender for BMI, Z-scores, and percentiles for thinness, normal 
weight, overweight, obesity, and morbid obesity [20] 
 BMI at age 18 
(kg/m2) 
BMI Z-score Percentile 
 Girls Boys Girls Boys Girls Boys 
Thinness (grade I-III) <18.5 <18.5 <-0.975 <-1.014 <16.5 <15.5 
Normal 18.5 18.5 -0.975 -1.014 16.5 15.5 
Overweight 25 25 1.244 1.310 89.3 90.5 
Obesity 30 30 2.192 2.288 98.6 98.9 
Morbid obesity 35 35 2.822 2.930 99.76 99.83 
a upper cut-off value for thinness and lower cut-off values for normal, overweight, obesity, and morbid obesity   
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Table S2. Slopes of change in BMI Z-score from multilevel segmented linear regression modelsa for 
childhood acute lymphoblastic leukaemia patients by age at diagnosis  
ICCC-3 diagnosis slope 1  
β (95%CI) 
slope 2  
β (95%CI) 
slope 3 
β (95%CI) 
Break points, daysb 
ALL  2.28 (-0.22; 4.78) -0.02 (-1.14; 1.09) 0.33 (0.22; 0.45) 33 (=induction) 
99 (=maintenance) 
   <7 years  3.75 (0.48; 7.03) -0.41 (-1.86; 1.04) 0.20 (0.13; 0.27) 33 (=induction) 
99 (=maintenance) 
   ≥7 years -1.47 (-5.14; 2.21)  0.48 (-1.29; 2.24) 0.28 (0.17; 0.39) 33 (=induction) 
99 (=maintenance) 
ALL, acute lymphoblastic leukaemia; BMI, body mass index; CI, confidence interval 
a Adjusted for gender, age, cumulative cranial radiation therapy, parenteral/ enteral nutrition, and BMI at diagnosis with a random effect on 
patient level. 
b Breakpoints defined at end of induction (33 days, 0.09 years) and start of maintenance period (99 days, 0.27 years). 
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Figure S1A. Observed individual BMI Z-score curves of random samples (N=5) of ALL patients age <7 years (N=5) at diagnosis and estimated trend from 
multilevel segmented linear regression models with fixed breakpointsa  
BMI Z-score per patient since diagnosis over time shown in solid line and fitted multilevel segmented linear regression based on predicted random effects on patient level shown in dashed line. 
a Adjusted for gender and age at diagnosis with a random effect on patient level. Breakpoints were defined at end of induction (33 days, 0.09 years) and start of maintenance period (99 days, 0.27 years).
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Figure S1B. Observed individual BMI Z-score curves of random samples (N=5) of ALL patients age ≥7 years (N=5) at diagnosis and estimated trend from 
multilevel segmented linear regression models with fixed breakpointsa  
BMI Z-score per patient since diagnosis over time shown in solid line and fitted multilevel segmented linear regression based on predicted random effects on patient level shown in dashed line. 
a Adjusted for gender and age at diagnosis with a random effect on patient level. Breakpoints were defined at end of induction (33 days, 0.09 years) and start of maintenance period (99 days, 0.27 years).
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SUMMARY 
 
Background: An increased risk of becoming overweight has been reported for childhood 
cancer survivors (CCSs), in particular leukemia survivors, although the evidence is 
inconclusive. 
 
Objective: We assessed the prevalence of overweight in CCSs, with a focus on leukemia 
survivors, compared it with their peers, and determined potential risk factors. 
 
Design: As part of the Swiss Childhood Cancer Survivor Study, we sent a questionnaire 
between 2007 and 2013 to all Swiss resident CCSs aged <21 y at diagnosis who had survived 
≥5 y. We calculated body mass index (BMI) from medical records at diagnosis and self-
reported heights and weights at survey. We calculated BMI z scores by using Swiss references 
for children and compared overweight prevalence in CCSs, their siblings, and the general 
population with the use of the Swiss Health Survey (SHS) and assessed risk factors for being 
overweight by using multivariable logistic regression. 
 
Results: The study included 2365 CCSs, 819 siblings, and 9591 SHS participants. At survey, 
at an average of 15 y after diagnosis, the prevalence of overweight in CCSs overall (26%) and 
in leukemia survivors (26%) was similar to that in siblings (22%) and the general population 
(25%). Risk factors for being overweight in CCSs were male sex (OR: 1.8; 95% CI: 1.5, 2.1), 
both young (OR for ages 5–14 y: 1.6; 95% CI: 1.2, 2.3) and older (range—OR for ages 25–29 
y: 1.7; 95% CI: 1.2, 2.4; OR for ages 40–45 y: 4.0; 95% CI: 2.5, 6.5) age at study, lower 
education (OR: 1.4; 95% CI: 1.1, 1.8), migration background (OR: 1.3; 95% CI: 1.1, 1.7), and 
no sports participation (OR: 1.4; 95% CI: 1.1, 1.7). Risk factors for overweight were similar in 
peers. CCSs treated with cranial radiotherapy (≥20 Gy) were more likely to be overweight than 
their peers (OR: 1.6; 95% CI: 1.2, 2.2). 
 
Conclusions: The prevalence of and risk factors for being overweight are similar in long-term 
CCSs and their peers. This suggests that prevention methods can be the same as in the 
general population. An important exception is CCSs treated with cranial radiotherapy ≥20 Gy 
who may need extra attention during follow-up care. This study was registered at 
clinicaltrials.gov as NCT03297034. 
 
  
 113 
 
INTRODUCTION 
Overweight and obesity are well-known risk factors for chronic diseases, such as diabetes, 
dyslipidemia, hypertension, and cardiovascular disease [1]. Fortunately, these risk factors are 
modifiable: primary- and secondary-prevention methods can reduce morbidity and mortality. 
Childhood cancer survivors (CCSs) already have an elevated burden of chronic diseases due 
to cancer treatment, which increases with age [2, 3]. It is thus important to avoid additional, 
preventable risk factors such as obesity by identifying CCSs at high risk and offering them 
targeted interventions. 
 
Whether CCSs are more overweight in the long term after treatment is not clear. Two meta-
analyses suggested that obesity was more common in childhood acute lymphoblastic leukemia 
(ALL) survivors within 5 y of treatment (BMI z score: 0.89), but obesity diminished 5–9 y post-
treatment (BMI z score: 0.64) compared with their healthy peers [4, 5]. Results are inconclusive 
for those ≥10 y post-treatment, although overweight prevalence (34–46%) in these long-term 
ALL survivors seemed to be similar to that in noncancer comparison groups [4]. Risk factors 
for overweight in the general population are sedentary lifestyle, low (≤2.5 kg) and high (>4 kg) 
birth weights [6, 7], and overweight during early childhood [8]. In CCSs, most risk factors were 
the same as in the general population, but no study has considered birth weight. ALL and 
lymphoma survivors who were overweight at diagnosis were substantially more likely to be 
overweight or obese 12 y after treatment [9]. The same was true for cranial radiation therapy 
(CRT); ALL survivors treated with CRT were more likely to be overweight or obese than their 
siblings 21–25 y after diagnosis [10, 11]. 
 
Studies of overweight conducted to date have been of somewhat limited relevance to CCSs. 
Research on overweight prevalence has involved mostly ALL survivors [9–19], whereas study 
of risk factors has led to inconsistent conclusions [4]. Studies conducted in the United States 
reflect the lifestyles and eating habits of CSSs in that country [10–13, 16, 17, 19–22], whereas 
the duration of follow-up in other studies has been only short to medium term [4, 5], and many 
have had small (<250 participants) sample sizes [4, 11, 13–15, 17–19]. With this background 
of research in mind, we analyzed data from the Swiss Childhood Cancer Survivor Study 
(SCCSS) to 1) assess overweight prevalence in CCSs overall and for specific, different 
diagnoses; 2) compare overweight prevalence in CCSs with that in their siblings and the Swiss 
general population; and 3) identify sociodemographic and clinical risk factors for excessive 
weight. 
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METHODS 
Study populations 
The SCCSS 
The SCCSS is a population-based, long-term follow-up study in all childhood cancer patients 
registered in the Swiss Childhood Cancer Registry (SCCR; available from: 
www.childhoodcancerregistry.ch) who have been diagnosed with leukemia, lymphoma, central 
nervous system (CNS) tumors, malignant solid tumors, or Langerhans cell histiocytosis; who 
survived ≥5 y after initial diagnosis of cancer; who were under the age of 21 y; and who were 
alive at the time of the study [23–25]. Ethical approval of the SCCR and the SCCSS was 
granted by the Ethics Committee of the Canton of Bern (KEK-BE: 166/2014). This study was 
registered at clinicaltrials.gov as NCT03297034. 
 
As part of the SCCSS, we traced all addresses of CCSs diagnosed between 1976 and 2005 
and sent them a questionnaire between 2007 and 2013. Nonresponders received a second 
copy of the questionnaire 4–6 wk later. If they again did not respond, we contacted them by 
phone. Our questionnaire included core questions from the US and UK CCS studies [26, 27], 
with added questions about health behaviors and sociodemographic measures from the Swiss 
Health Survey (SHS) [28] and the Swiss Census [29]. The main domains covered by the 
questionnaire were quality of life, somatic health, fertility, current medication and health 
services use, psychological distress, health behaviors, and socioeconomic status. Detailed 
information on our study design was published previously [23]. 
 
Comparison groups 
We used 2 comparison groups for this study: siblings of the CCSs and a random sample of the 
general Swiss population represented by data from the SHS. The sibling survey was conducted 
from 2009 to 2012. We asked CCSs for consent to contact siblings and for their contact 
information. We sent siblings the same questionnaire as CCSs, omitting questions about 
cancer history. Siblings who did not respond received another copy of the questionnaire 4–6 
wk later, but were not contacted by phone [23]. The second comparison group consisted of 
participants in the 2012 SHS [30]. The SHS is a representative national telephone survey 
repeated every 5 y. The SHS compiled a randomly selected representative sample of Swiss 
households with landline telephones and attempted to contact 1 person/household. Sampling 
was stratified by region and conducted in a stepwise manner. Households were selected first, 
and then the survey was administered to anyone aged ≥15 y who answered the phone. 
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Measurements 
Body weight and BMI 
We obtained information on participants’ weight and height. For all CCSs and both comparison 
groups, we had information on weight and height at time of survey from the self-administered 
questionnaires. Study participants were instructed to record height without shoes and weight 
without clothes. For leukemia survivors diagnosed between 1990 and 2005 and treated in a 
specialized pediatric cancer clinic, we also had information on weight and height at diagnosis 
and at birth. Weight and height at diagnosis were obtained via a retrospective medical record 
audit. We obtained 98% of birth weights by using a probabilistic linkage procedure (G-LINK 
2.3; Statistics Canada) to link CCSs and anonymous birth statistics with no personal identifiers, 
which was collected by the Swiss Federal Statistical Office. Information on sex, date of birth, 
first name, nationality, municipality of residence at birth, and parental birth dates was used for 
linking. The remaining birth weights (2%) were obtained from medical records. We calculated 
BMI by dividing weight in kilograms by height in meters squared (kg/m2). BMI in adults was 
classified as underweight (<18.5), normal weight (≥18.5 to <25), or overweight (≥25) [1]. As 
recommended for children aged ≤19 y, we calculated BMI z scores by using the latest available 
Swiss growth curves [31]. BMI z scores were classified as underweight (<–2), normal weight 
(–2 to 1), or overweight (>1 for age >5 y, >2 for age ≤5 y) [32]. Birth weight was classified into 
3 categories: low (<2500 g), normal (2500–4000 g), and high (>4000 g) [33]. 
 
Risk factors for being overweight at time of survey 
For all 3 study populations, we assessed sex, age at survey, educational level, migration 
background, language region in Switzerland, and participation in sports at time of survey as 
potential sociodemographic risk factors for being overweight. Participants who were not Swiss 
citizens at birth, not born in Switzerland, or had ≥1 parent who was not a Swiss citizen were 
classified as having a migration background. We classified education into 3 categories: primary 
education (compulsory schooling only; ≤9 y), secondary education (vocational training; 10–
13 y), and tertiary education (higher vocational training, college, or university degree). Sports 
participation was classified as sports if respondents reported engaging in a specific gym or 
sports activity for ≥1/wk, or no sports with less or no such participation. 
 
For the CCS population, we extracted additional clinical information from the SCCR. This 
included information on cancer diagnosis and age at diagnosis. Diagnosis was classified 
according to the International Classification of Childhood Cancer, 3rd Edition [34]. 
Radiotherapy was classified as CRT if the survivor had received direct radiation to the brain, 
skull, or both. The cumulative dosage of CRT was obtained from medical records and 
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categorized as either <20 Gy or ≥20 Gy. We also retrieved records on hematopoietic stem cell 
transplantation, chemotherapy, and relapse during follow-up time. 
 
Statistical analyses 
We included all participants in the SCCSS (CCSs and their siblings) and the SHS (general 
population) who were aged ≤45 y at time of survey and who provided self-reported height and 
weight (Supplemental Figure S1). For better comparison between CCSs and peers, we 
standardized comparison groups for sex, age at survey, migration background, and language 
region, as previously described [35–37]. The first step in our analyses was to assess the overall 
prevalence of overweight in CSSs at survey and stratify diagnostic groups. We divided BMI 
into 2 categories: overweight (overweight and obesity) and nonoverweight (underweight and 
normal weight) as separate categories were small and logistic regression outcomes for the 
categories of overweight and obesity were in the same direction and magnitude as for the 
category of overweight or obesity combined. We then compared the prevalence of overweight 
between CCSs and comparison groups by using chi-square tests. Finally, we determined risk 
factors for being overweight at survey within each group separately by using multivariable 
logistic regression. We identified potential sociodemographic, lifestyle, and clinical risk factors 
and included them in uni- and multivariable logistic regressions. To test for statistical 
significance, we used likelihood ratio tests for unstandardized groups and Wald tests for 
standardized groups. We investigated whether birth weight and BMI at diagnosis were 
additional risk factors for overweight at survey in a subgroup of leukemia survivors who had 
been diagnosed between 1990 and 2005. Interaction terms were used to formally test 
differences in effects of risk factors between CCSs and comparison groups. We also included 
both CCSs and comparison groups in multivariable logistic regression models to investigate 
whether the risk of being overweight was similar between groups stratified for CRT. We used 
Stata software (version 14; StataCorp) for all statistical analysis. 
 
RESULTS 
Response rate and characteristics of the study populations 
Among 4116 eligible CCSs, we traced and contacted 3577, of whom 2527 returned a 
questionnaire. We excluded 119 questionnaires that did not report height and weight, and a 
further 43 from survivors who were >45 y old. We thus included 2365 CCSs in this study, of 
whom 770 were leukemia survivors and 461 of whom were diagnosed between 1990 and 2005 
(Supplemental Figure S1). We received consent to contact 1530 siblings, of whom 866 
returned the questionnaire. Twenty-seven were outside the age range and 20 did not report 
height and weight; thus, 819 siblings were finally included in the analyses. Of 41,008 
households surveyed in the general population (SHS), 21,597 households replied to the 
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survey. In those responding households, 9591 persons who were ≤45 y old were included in 
the analysis. 
 
Among CCSs, the most common cancers were leukemia (predominantly ALL; 88%), 
lymphoma, and CNS and renal tumors (Table I). The median age at diagnosis was 7 y (IQR: 
3–12 y) for CCSs overall and 5 y (IQR: 3–9 y) for leukemia. The median time from diagnosis 
to survey was 15 y (IQR: 10–21 y) for CCSs overall and 16 y (IQR: 11–22 y) for leukemia 
survivors. Most leukemia survivors received chemotherapy. Among the subgroup of leukemia 
survivors diagnosed between 1990 and 2005, 10% had a high birth weight and 6% were 
overweight at diagnosis (Supplemental Table S1). 
 
Table I. Clinical characteristics of CCSs and childhood leukemia survivors1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 CCS, childhood cancer survivor; CNS, central nervous system; CRT, cranial radiation therapy; HSCT, 
hematopoietic stem cell transplantation; ICCC3, International Classification of Childhood Cancer, 3rd edition 
2 Values are medians (IQRs) 
3 n=3 missing (<1%) 
 
Sociodemographic characteristics were mostly identical across CCSs and the comparison 
groups. Fewer CCSs than siblings had parents who completed tertiary education, however, 
 
Characteristics 
CCSs 
(n= 2365) 
Leukemia 
(n= 770) 
ICCC3 diagnosis, n (%) 
  I: Leukemia 
  II: Lymphoma 
  III: CNS neoplasm 
  IV: Neuroblastoma 
  V: Retinoblastoma 
  VI: Renal tumor 
  VII: Hepatic tumor 
  VIII: Malignant bone tumor 
  IX: Soft tissue sarcoma 
  X: Germ cell tumor 
  XI & XII: Other tumor 
  Langerhans cell histiocytosis 
 
770  (33) 
424  (18)  
341  (14) 
118  (5) 
72    (3) 
144  (6) 
20    (1) 
96    (4) 
137  (6) 
106  (4) 
54    (2) 
83    (4) 
 
770 (100) 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Age at diagnosis, n (%) 
  <5 y 
  ≥5 y 
 
1,413 (60) 
952    (40) 
 
389 (51) 
381 (49) 
Year of diagnosis, n (%) 
  Before 1990 
  1990-2000 
  After 2000 
 
762 (32) 
977 (41) 
626 (26) 
 
291 (38) 
299 (39) 
180 (23) 
Time since diagnosis,2 y 15.0 (10.0-20.9) 15.6 (10.7-22.0) 
Chemotherapy3, n (%) 
  No 
  Yes 
 
509    (22) 
1,856 (78) 
 
- 
767 (100) 
CRT, n (%) 
  None 
  <20 Gy 
  ≥20 Gy 
 
1,950 (82) 
157    (7) 
258    (11) 
 
599 (78) 
95   (12) 
76   (10) 
HSCT, n (%)  
  No 
  Yes 
 
2,248 (95) 
117    (5) 
 
709 (92) 
61   (8) 
History of relapse, n (%) 
  No 
  Yes 
 
2,081 (88) 
284    (12) 
 
670 (87) 
100 (13) 
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and the educational level of CCSs was slightly lower than that of their peers (Table II). CCSs 
engaged in fewer sports than their siblings but more than the general population. 
 
Overweight prevalence among CCSs and comparison groups 
Overall, the prevalence of overweight among CCSs was 26% (median BMI in those aged >19 
y: 27; IQR: 26–30; median BMI z score in those aged ≤19 y: 1; IQR: 1–2), which was similar 
to overweight prevalence in the comparison groups: 22% in siblings (P = 0.07; median BMI in 
those aged >19 y: 27; IQR: 26–29; median BMI z score in those aged ≤19 y: 1; IQR: 1–2), 25% 
in the general population (P = 0.64; median BMI in those aged >19 y: 27; IQR: 26–29; median 
BMI z score in those aged ≤19 y: 1; IQR: 1–2). However, CCS diagnostic groups differed: 31% 
of CNS neoplasm survivors were overweight, whereas only 13% of neuroblastoma and 18% 
of soft tissue sarcoma survivors were overweight; the prevalence differences were significant 
(P < 0.001, P < 0.001, and P = 0.04, respectively; Figure 1). The prevalence of overweight in 
leukemia survivors (26%) was similar to the average of all CCSs. 
 
 
Figure 1. Overweight in childhood cancer survivors and comparison groups.  
The BMI distribution of comparison groups is standardized on sex, age at survey, migration background, and language region 
according to childhood cancer survivors. The dotted line reflects the overweight prevalence of the general population. CCS, 
childhood cancer survivors; CNS, central nervous system; LCH, Langerhans cell histiocytosis; Malignant bone..., malignant bone 
tumor. 
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Table II. General characteristics of CCSs and comparison groups1 
 CCSs, n (%) Siblings2 
(n =819)  
General 
population2 
(n =9,591)  
 
Characteristics 
CCSs  
(n =2,365) 
Leukemia 
(n =770) 
 
n (%std)   p-value3 
 
n (%std)     p-value3 
Sex, n (%) 
  Female 
  Male 
 
1,086   (46) 
1,279   (54)  
 
367 (48) 
403 (52) 
 
473 (45) 
346 (55)       n.a. 
 
4,946 (46) 
4,645 (54)       n.a. 
Age at survey, n (%) 
  5-14 y 
  15-19 y 
  20-24 y 
  25-29 y 
  30-34 y 
  35-39 y 
  40-45 y 
 
329   (14) 
541   (23) 
530   (22) 
401   (17) 
277   (12) 
185   (8) 
102   (4) 
 
121 (16) 
184 (24) 
167 (22) 
136 (18) 
87   (11) 
47   (6) 
28   (4) 
 
94   (18) 
142 (20) 
162 (19) 
168 (19) 
115 (12) 
84   (8) 
54   (5)         n.a. 
 
- 
1,518 (33) 
1,440 (23) 
1,174 (13) 
1,424 (11) 
1,601 (9) 
2,434 (10)      n.a. 
Parents’ education (highest degree)4, n 
(%) 
  Primary schooling 
  Secondary education 
  Tertiary education 
 
 
62   (7) 
469 (54) 
339 (39) 
 
 
26   (9) 
165 (54) 
114 (37) 
 
 
8     (3) 
115 (47) 
113 (50)    0.007 
 
 
n.a. 
Personal education5, n (%) 
  Primary schooling 
  Secondary education 
  Tertiary education 
 
117    (8) 
1,010 (68) 
368    (25) 
 
36   (8) 
337 (72) 
92   (20) 
 
24   (4) 
359 (61) 
200 (35)  <0.001 
 
691    (8) 
4,549 (62) 
2,833 (30)  <0.001 
Migration, n (%)  
  No migration background 
  Migration background 
 
1,762 (75) 
603    (26) 
 
573 (74) 
197 (26) 
 
657 (75) 
162 (25)       n.a. 
 
6,137 (77) 
3,454 (23)       n.a. 
Language region of Switzerland, n (%) 
  German speaking 
  French speaking 
  Italian speaking 
 
1,658 (70) 
630    (27) 
77      (3) 
 
571 (74) 
172 (22) 
27   (4) 
 
650 (70) 
143 (27) 
26   (3)         n.a. 
 
6,300 (70) 
2,620 (27) 
671    (3)         n.a. 
Sports participation, n (%) 
  Yes 
  No 
 
1,623 (69) 
742    (31) 
 
544 (71) 
226 (29) 
 
593 (75) 
226 (25)    0.002 
 
5,598 (64) 
3,993 (36)  <0.001 
BMI at survey6, n (%) 
  Underweight 
  Normal 
  Overweight 
 
127    (5) 
1,632 (69) 
606    (26) 
 
43   (6) 
525 (68) 
202 (26) 
 
20   (2) 
602 (76) 
197 (22)  <0.001 
 
349    (3) 
6,354 (72) 
2,888 (25)   <0.001 
1 CCS, childhood cancer survivor; n.a., not applicable, std, standardized 
1 Standardized on sex, age at survey, migration background and language region according to CCSs 
2 p-value calculated from Chi-Square statistics comparing comparison group to CCSs (2-sided test) 
3 Highest parental education level of CCSs and siblings <20 y at time of survey 
4 Highest personal education level of CCSs, siblings, and the general population ≥20 y at time of survey 
5 BMI Z-scores were calculated for CCSs, siblings, and the general population ≤19 y, BMI scores (kg/m2) were calculated for adults (>19 y) 
 
Risk factors for being overweight among CCSs and comparison groups 
In a multivariable regression, we found associations between all sociodemographic factors and being 
overweight. In all 3 study populations, male participants, those who were older at survey, and those 
who did not take part in sports activities were more likely to be overweight (Table III). Also associated 
with being overweight were lower education (CCSs, leukemia survivors), migration background (CCSs, 
the general population), and living in the German-speaking part of Switzerland (siblings, the general 
population). Results of univariable logistic regression are shown in Supplemental Table S2. 
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Table III. Overweight prevalence and risk factors associated with overweight in CCSs or comparison groups (from multivariable logistic 
regression)1  
 CCSs Siblings2 
(n =819) 
General population2 
(n =9,591) 
 CCSs  
(n =2,365) 
Leukemia 
(n =770) 
  
Sociodemographic characteristics %ow  OR (95% CI)   p-value3 %ow  OR (95% CI)  p-value3 %ow   OR (95% CI)    p-value4 %ow OR (95% CI)    p-value4 
  Sex 
    Female 
    Male 
 
(20) 1.00 (ref)          <0.001 
(30) 1.76 (1.45, 2.14) 
 
(20) 1.00 (ref)          <0.001 
(32) 1.95 (1.38, 2.76) 
 
(17) 1.00 (ref)             <0.001 
(27) 2.20 (1.51, 3.18) 
 
(17) 1.00 (ref)            <0.001 
(32) 2.42 (2.16, 2.71) 
  Age at survey 
    5-14 y 
    15-19 y 
    20-24 y 
    25-29 y 
    30-34 y 
    35-39 y 
    40-45 y 
 
(25) 1.64 (1.16, 2.32) <0.001 
(17) 1.00 (ref)  
(21) 1.30 (0.94, 1.78) 
(25) 1.71 (1.24, 2.38) 
(34) 2.76 (1.94, 3.91) 
(43) 3.80 (2.58, 5.60) 
(41) 4.03 (2.50, 6.48) 
 
(29) 2.05 (1.16, 3.64) <0.001 
(16) 1.00 (ref)  
(21) 1.25 (0.71, 2.20) 
(23) 1.62 (0.90, 2.90) 
(40) 3.64 (1.97, 6.70) 
(53) 6.13 (2.94, 12.78) 
(39) 3.81 (1.54, 9.42) 
 
(12) 1.48 (0.65, 3.36) <0.001 
(11) 1.00 (ref)  
(20) 2.17 (1.07, 4.40) 
(25) 2.87 (1.49, 5.54) 
(34) 4.64 (2.33, 9.25) 
(43) 7.04 (3.40, 14.58) 
(46) 8.53 (3.65, 19.94) 
 
-                                 <0.001 
(16) 1.00 (ref)  
(23) 1.58 (1.30, 1.92) 
(28) 2.07 (1.70, 2.52) 
(31) 2.39 (1.98, 2.88) 
(37) 3.00 (2.50, 3.60) 
(41) 3.73 (3.15, 4.42) 
  Age at diagnosis 
    ≥5 y 
    <5 y 
 
(26) 1.00 (ref)            0.107 
(25) 1.20 (0.96, 1.49) 
 
(26) 1.00 (ref)            0.161 
(27) 1.29 (0.90, 1.86) 
 
n.a 
 
n.a 
  Education5 
    Primary schooling 
    Secondary education 
    Tertiary education  
 
(28) 1.45 (0.98, 2.15) 0.008 
(27) 1.42 (1.13, 1.78) 
(22) 1.00 (ref) 
 
(31) 2.06 (1.03, 4.12) 0.010 
(29) 1.88 (1.22, 2.89) 
(18) 1.00 (ref) 
 
(31) 1.75 (0.65, 4.72)   0.268 
(24) 1.36 (0.90, 2.05) 
(19) 1.00 (ref) 
 
n.a. 
  Migration 
    No migration background 
    Migration background 
 
(25) 1.00 (ref)            0.011 
(29) 1.34 (1.07, 1.68) 
 
(26) 1.00 (ref)            0.368 
(27) 1.21 (0.80, 1.81) 
 
(22) 1.00 (ref)               0.189 
(23) 1.37 (0.86, 2.18) 
 
(23) 1.00 (ref)            <0.001 
(31) 1.34 (1.19, 1.50) 
  Language region of 
Switzerland 
    German speaking 
    French speaking 
    Italian speaking 
 
(26) 1.00 (ref)            0.287 
(24) 0.84 (0.67, 1.05) 
(25) 0.94 (0.55, 1.63) 
 
(27) 1.00 (ref)            0.638 
(25) 0.95 (0.63, 1.44) 
(19) 0.62 (0.22, 1.74) 
 
(25) 1.00 (ref)               0.017 
(16) 0.46 (0.27, 0.79) 
(18) 0.69 (0.19, 2.46) 
 
(26) 1.00 (ref)              0.019 
(23) 0.85 (0.74, 0.96) 
(24) 0.84 (0.67, 1.04) 
  Sports participation 
    Yes  
    No 
 
(23) 1.00 (ref)            0.004 
(31) 1.35 (1.10, 1.66) 
 
(24) 1.00 (ref)            0.427 
(31) 1.17 (0.80, 1.70) 
 
(19) 1.00 (ref)               0.002 
(34) 1.90 (1.27, 2.85) 
 
(23) 1.00 (ref)            <0.001 
(30) 1.42 (1.27, 1.60) 
1 CCS, childhood cancer survivor; na, not applicable; ref, reference 
2 Standardized on sex, age at survey, migration background, and language region according to CCSs; multivariable logistic regressions are separately for each study population 
3 p-values were calculated from likelihood ratio test 
4 Global p-values for an association between prevalence of overweight/obesity and the variables as a whole (Wald test comparing models with and without the variable) 
5 Highest parental (aged <20 y at time at survey) or personal (aged ≥20 y at time of survey) education
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Interaction tests (Supplemental Table S3) showed that most effects of sociodemographic 
factors did not differ between CCSs and the comparison groups (all P-interaction ≥ 0.05), 
suggesting that the direction and strength of the associations between these risk factors and 
overweight were similar. The only difference was the effect of sex, which was weaker in CCSs 
(OR: 1.7; 95% CI: 1.45, 2.14) than in the general population (OR: 2.42; 95% CI: 2.16, 2.71; 
Table III, Supplemental Table S3). Among clinical factors, only ≥20 Gy CRT was associated 
with overweight. After combining all diagnostic groups, we saw that CCSs who received ≥20 
Gy CRT, of whom 29% were diagnosed with leukemia and 45% with CNS neoplasms, were 
around 1.5 times more likely to be overweight in comparison to their peers (OR for CCSs 
compared with siblings: 1.5; 95% CI: 1.1, 2.2; OR for CCSs compared with the general 
population: 1.6; 95% CI: 1.2, 2.2; Figure 2). 
 
 
Figure 2. CRT-specific ORs (95% CIs) for overweight in childhood cancer survivors and 
comparison groups (from multivariable logistic regression).  
Both comparison groups were standardized on sex, age at survey, migration background, and language region according to 
childhood cancer survivors. Values were adjusted for sex, age, education, migration background, language region of Switzerland, 
and sports participation. CCS, childhood cancer survivors; CRT, cranial radiation therapy; Gy, Gray. 
 
We found no association between being overweight at survey and birth weight (P = 0.523) in 
a subgroup of 461 leukemia survivors diagnosed between 1990 and 2005. However, being 
overweight at diagnosis was associated with being overweight at survey (OR: 9.86; 95% CI: 
3.97, 24.51) (Supplemental Table S4). Results of univariable logistic regression are shown in 
Supplemental Table S5. Of 27 leukemia survivors who were overweight at diagnosis, 18 
(67%) remained overweight at survey. 
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DISCUSSION 
Principal findings 
At a median of 15 y after cancer diagnosis, 26% of all CCSs were overweight. This prevalence 
is comparable to that of their healthy peers, but there were differences between diagnostic 
groups. Survivors of CNS neoplasms were most likely to be overweight, whereas survivors of 
neuroblastoma and soft tissue sarcoma were least likely to be overweight. Sociodemographic 
factors for being overweight were similar in CCSs, their siblings, and the general population. 
Among clinical factors, we confirmed that receiving ≥20 Gy CRT was associated with being 
overweight. 
 
Strengths and limitations 
Height and weight at survey were self-reported; both under- and overreporting could have 
occurred. However, because height and weight were self-reported in all study populations we 
expected the degree of nondifferential error of BMI assessment to be similar across CCSs and 
comparison groups. BMI calculations are practical and inexpensive measures of overweight 
and are therefore widely used in population-based studies, and BMI values derived from self-
reported height and weight can be as reliable as measured values in the estimation of health 
risks [38]. The prevalence of overweight might be underestimated because having a higher 
BMI at diagnosis is associated with poorer survival. This could have resulted in excluding more 
overweight CCSs due to our exclusion criteria of ≥5 y of survival after initial diagnosis of cancer 
[39]. Furthermore, our results could have been biased by reverse causation (e.g., a lack of 
sports participation could have been due to overweight). 
 
Long-term follow-up is a strength of this study, as are the national coverage of the SCCSS and 
our high CCS response rate, which makes this the largest such study in Europe to date. We 
also had access to high-quality clinical information extracted from the SCCR, including 
extended information about clinical factors, birth weight, and height and weight at diagnosis 
for a large subgroup of leukemia patients. The questionnaire also allowed us to assess a wide 
variety of sociodemographic factors. Finally, we included not 1 but 2 comparison groups: 
siblings of CCSs (who share environmental factors with CCSs) and the general population with 
data derived from a population-based study performed simultaneously in Switzerland. 
 
Overweight prevalence: results in relation to other studies 
Studies investigating overweight or obesity among CCSs other than ALL survivors are scarce. 
Meta-analyses have suggested that overweight or obesity is common among short-term ALL 
survivors who are still in childhood or early adolescence compared with reference populations 
[4, 5], and potentially increased among late-adolescent and adult long-term ALL survivors aged 
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≥15 y at survey [40]. In our study, the prevalence of overweight among CCSs overall and 
leukemia survivors was similar to that in the general population but increased for CNS 
neoplasms. CNS neoplasm survivors are exposed to several risk factors (e.g., CRT, 
hypothalamic tumors, and surgical damage) that might lead to hypothalamic obesity, and more 
research on adequate management is needed [41, 42]. 
 
A contributor to differences in overweight prevalence between our results and those of 
pertinent studies across the literature included in meta-analyses may be the lack of detailed 
treatment information on CRT and dose-dependent associations with overweight in those 
studies. Our findings do agree with those of a recent US-based study in 14,290 CCSs [median 
of 24 y (5–39 y) after diagnosis] and 4031 siblings in which self-reported obesity in CCSs and 
siblings was similar to our results, and the 4100 survivors treated with ≥18 Gy of CRT were 
more likely to be obese [20]. In contrast, a study in 7195 survivors of a variety of cancer types 
≥5 y after diagnosis reported underweight in CCSs treated for different cancers, including 
neuroblastoma and soft tissue sarcoma, when compared with the general population [22], and 
an increased likelihood of obesity was observed in both male and female ALL survivors who 
received CRT ≥20 Gy [12, 22]. 
 
Potential mechanisms and risk factors: results in relation to other studies 
CRT affects the hypothalamic-pituitary axis, which may lead to growth hormone deficiency and 
leptin insensitivity, which could, in turn, place CCSs at risk of neuroendocrine abnormalities 
such as obesity [13]. However, previous studies of overweight in CCSs and CRT have shown 
mixed results that vary from weak to strong associations [4]. Older studies usually showed a 
clear association between overweight and CRT [9, 10, 12, 14], whereas those with children 
treated more recently with no or lower-dose CRT have shown a smaller effect [15–17, 43]. We 
found an association only between ≥20 Gy CRT and overweight. Overall, CCSs and leukemia 
survivors treated with ≥20 Gy CRT were more likely to be overweight, which suggests that ≥20 
Gy CRT is a risk factor for obesity in all CCSs irrespective of the diagnosis. The positive 
association between CRT and obesity has also been seen in adult survivors of a variety of 
different childhood cancer types [22, 44]. Although CRT was not stratified by dose amount, 
survivors in these studies were diagnosed between 1970–1986 [22] and 1966–1996 [44], and 
the majority might have received high-dose CRT. 
 
Female sex also has been reported as a risk factor for obesity in ALL adult survivors [10, 12, 
22]. We could not confirm this. On the contrary, we found that men were more likely to be 
overweight or obese. This was the same in our comparison groups. Two systematic reviews 
on overweight in CCSs published in 2014 and 2015 reported no conclusive effect due to sex 
 124 
 
[4, 5]. This suggests that sex differences mainly reflect social and cultural differences. We also 
found that leukemia survivors who are overweight at diagnosis have a substantially higher risk 
of being overweight later in life. This is in line with previous observations of survivors of 
leukemia [11, 17–19] and other childhood cancers [44] and the general population, in all of 
whom overweight tends to track strongly throughout life [45]. As in our study, others have found 
that more than two-thirds of ALL survivors who were overweight at diagnosis remained 
overweight at the end of, or after, treatment [18, 19]. 
 
Implications and recommendations 
Overweight and obesity are associated with chronic diseases that are frequently seen among 
CCSs, such as type 2 diabetes and cardiovascular disease [46, 47]. Poor diet and a sedentary 
lifestyle could further increase these already elevated risks. Personal counseling should be 
offered to childhood cancer patients and their parents throughout treatment and beyond, and 
special attention should be given to patients with an increased BMI [48]. However, counseling 
during this period, when patients and families face the crisis of a life-threatening illness and 
nutritional status is not a first priority, is challenging. In addition, children may receive high 
steroid doses, which increase appetite and fatty tissue, and they may experience fatigue or be 
immobilized for some time, which reduces their physical activity. During clinical follow-up, 
special attention should focus on CNS tumor and leukemia survivors treated with ≥20 Gy CRT, 
who have the highest risk of becoming overweight. Follow-up services with multi-profession 
teams, including physicians, dieticians, nurses, and physiotherapists, might be a promising 
approach. 
 
Conclusions 
This national survey in Switzerland found that the prevalence of and risk factors for overweight 
were similar in CCSs overall and in healthy peers, suggesting that prevention methods and 
interventions can be the same as in the general population. Important exceptions are CCSs 
treated with ≥20 Gy CRT who may need extra attention during follow-up care. 
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SUPPLEMENTARY MATERIAL 
 
Table S1. Sociodemographic and clinical characteristics of childhood leukemia survivors, 
subgroup diagnosed between 1990-2005  
 
Characteristics 
Leukemia 
(n =461) 
Sociodemographic characteristics  
Sex, n (%)  
  Female 212 (46)  
  Male 249 (54) 
Age at survey, n (%)   
  5-14 y 121 (26) 
  15-19 y 183 (40) 
  ≥20 y 157 (34) 
Parents’ education (highest degree)1, n (%)  
  Primary schooling 26   (9) 
  Secondary education 165 (54) 
  Tertiary education 113 (37) 
Personal education2, n (%)  
  Primary schooling 23   (15) 
  Secondary education 115 (73) 
  Tertiary education 19   (12) 
Migration, n (%)  
  No migration background 309 (67) 
  Migration background 152 (33) 
Language region of Switzerland, n (%)  
  German speaking 333 (72) 
  French speaking 113 (25) 
  Italian speaking 15   (3) 
Sports participation, n (%)  
  Yes 350 (76) 
  No 111 (24) 
BMI at survey3, n (%)  
  Underweight 24   (5) 
  Normal 336 (73) 
  Overweight 101 (22) 
Birth weight4, n (%)  
  Low: <2500 g 28   (6) 
  Normal: 2500-4000 g 337 (73) 
  High: >4000 g 45   (10) 
Clinical characteristics  
BMI at diagnosis5, n (%)  
  Underweight 24   (5) 
  Normal 366 (79) 
  Overweight 27   (6) 
Age at diagnosis, n (%)  
  ≥5 y 228 (49) 
  <5 y 233 (51) 
Year of diagnosis, n (%)  
  1990-2000 287 (62) 
  After 2000  174 (38) 
CRT, n (%)  
  None 366 (79) 
  <20 Gy 65   (14) 
  ≥20 Gy 30   (7) 
CRT, cranial radiation therapy 
1 Highest parental education level reported for CCS <20 y at time of survey 
2 Highest personal education level of CCS ≥20 y at time of survey 
3 BMI Z-scores were calculated for CCS ≤19 y, BMI scores (km/m2) were calculated for adults (>19 y) 
4 n=51 missing (11%) 
5 n=44 missing (10%).
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Table S2. Overweight prevalence and risk factors associated with overweight in CCSs and comparison groups (from univariable logistic regression)1 
 CCSs Siblings2  
(n =819) 
General population2 
(n =9591) 
 CCS 
(n =2365) 
Leukemia 
(n =770) 
  
Sociodemographic characteristics %ow  OR (95% CI)      p-value3 %ow  OR (95% CI)      p-value3 %ow  OR (95% CI)      p-value4 %ow  OR (95% CI)      p-value4 
  Gender     
    Female (20) 1.00 (ref)                 <0.001 (20) 1.00 (ref)                 <0.001 (17) 1.00 (ref)                  0. 001 (17) 1.00 (ref)                 <0.001 
    Male (30) 1.70 (1.41, 2.06) (32) 1.90 (1.36, 2.64)  (27) 1.80 (1.28, 2.53) (32) 2.20 (1.97, 2.45) 
  Age at survey     
    5-14 y (25) 1.58 (1.13, 2.21)     <0.001 (29) 2.09 (1.20, 3.64)     <0.001 (12) 1.08 (0.48, 2.45)     <0.001 -                                      <0.001 
    15-19 y (17) 1.00 (ref) (16) 1.00 (ref) (11) 1.00 (ref) (16) 1.00 (ref) 
    20-24 y (21) 1.27 (0.94, 1.73) (21) 1.36 (0.79, 2.34) (20) 2.03 (1.01, 4.07) (23) 1.58 (1.30, 1.91) 
    25-29 y (25) 1.62 (1.18, 2.23) (23) 1.52 (0.87, 2.65) (25) 2.66 (1.36, 5.17) (28) 2.07 (1.70, 2.51) 
    30-34 y (34) 2.48 (1.78, 3.46) (40) 3.46 (1.93, 6.17) (34) 4.02 (2.02, 7.99) (31) 2.44 (2.03, 2.93) 
    35-39 y (43) 3.54 (2.46, 5.11) (53) 5.83 (2.91, 11.67) (43) 5.87 (2.86, 12.06) (37) 3.09 (2.59, 3.69) 
    40-45 y (41) 3.33 (2.12, 5.23) (39) 3.32 (1.41, 7.80) (46) 6.66 (2.97, 14.97) (41) 3.70 (3.14, 4.36) 
  Education5     
    Primary schooling (28) 1.36 (0.94, 1.97)     <0.001 (31) 1.95 (1.03, 3.72)       0.009 (31) 1.91 (0.79, 4.57)        0.170 n.a 
    Secondary education (27) 1.29 (1.05, 1.60) (29) 1.80 (1.20, 2.68) (24) 1.34 (0.93, 1.94)  
    Tertiary education  (22) 1.00 (ref) (18) 1.00 (ref) (19) 1.00 (ref)  
  Migration     
    No migration background (25) 1.00 (ref)                   0.047 (26) 1.00 (ref)                   0.664 (22) 1.00 (ref)                   0.819 (23) 1.00 (ref)                 <0.001 
    Migration background (29) 1.23 (1.00, 1.52) (27) 1.08 (0.75, 1.56)  (23) 1.05 (0.69, 1.61) (31) 1.48 (1.33, 1.64) 
  Language region of Switzerland     
    German speaking (26) 1.00 (ref)                   0.574 (27) 1.00 (ref)                   0.552 (25) 1.00 (ref)                   0.046 (26) 1.00 (ref)                   0.101 
    French speaking (24) 0.89 (0.72, 1.11) (25) 0.90 (0.61, 1.34) (16) 0.55 (0.34, 0.89) (23) 0.88 (0.78, 0.99) 
    Italian speaking (25) 0.92 (0.54, 1.56) (19) 0.62 (0.23, 1.65) (18) 0.67 (0.22, 2.06) (24) 0.93 (0.75, 1.15) 
  Sports participation     
    Yes (23) 1.00 (ref)                 <0.001 (24) 1.00 (ref)                   0.083 (19) 1.00 (ref)                 <0.001 (23) 1.00 (ref)                 <0.001 
     No (31) 1.45 (1.19, 1.76) (31) 1.36 (0.96, 1.92) (34) 2.22 (1.54, 3.20) (30) 1.45 (1.31, 1.62) 
Clinical characteristics     
  ICCC-3 diagnosis     
    I: Leukemia (26) 1.00 (ref)                   0.003 n.a n.a n.a 
    II: Lymphoma (27) 1.06 (0.81, 1.38)    
    III: CNS neoplasm (31) 1.29 (0.97, 1.70)    
    IV: Neuroblastoma (13) 0.41 (0.23, 0.72)    
    V: Retinoblastoma (24) 0.87 (0.49, 1.53)    
    VI: Renal tumor (20) 0.71 (0.46, 1.10)    
    VII: Hepatic tumor (25) 0.94 (0.34, 2.61)    
    VIII: Malignant bone tumor (24) 0.89 (0.54, 1.45)    
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1 CCS, childhood cancer survivor; CNS, central nervous system; HSCT, hematopoietic stem cell transplantation; ICCC3, International Classification of Childhood Cancer, 3rd edition  
2 Standardized on gender, age at survey, migration background and language region according to CCS 
3 p-value calculated from likelihood ratio test 
4 Global p-value for an association between prevalence of overweight/obesity and the variables as a whole (Wald test comparing models with and without the variable) 
5 Highest parental (<20 years at time at survey) or personal education (≥20 years at time of survey) 
    IX: Soft tissue sarcoma (18) 0.60 (0.37, 0.95)    
    X: Germ cell tumor (26) 1.01 (0.64, 1.60)    
    XI & XII: Other tumor (24) 0.89 (0.47, 1.70)    
    Langerhans cell histiocytosis (33) 1.36 (0.83, 2.21)    
  Age at diagnosis     
    ≥5 y (26) 1.00 (ref)                   0.339 (26) 1.00 (ref)                   0.749 n.a n.a 
    <5 y (25) 0.91 (0.75, 1.10) (27) 1.05 (0.76, 1.45)   
  Year of diagnosis     
    Before 1990 (32) 1.00 (ref)                   0.001 (34) 1.00 (ref)                 <0.001 n.a n.a 
    1990-2000 (23) 0.62 (0.50, 0.77) (19) 0.47 (0.33, 0.69)   
    After 2000 (22) 0.60 (0.47, 0.77) (26) 0.68 (0.45, 1.02)   
  CRT     
    None (24) 1.00 (ref)                 <0.001 (24) 1.00 (ref)                 <0.001 n.a n.a 
    <20 Gy (26) 1.13 (0.78, 1.63) (17) 0.63 (0.36, 1.11)   
    ≥20 Gy (38) 1.98 (1.51, 2.60) (53) 3.45 (2.12, 5.61)   
  HSCT      
    No (26) 1.00 (ref)                   0.270 (27) 1.00 (ref)                   0.212 n.a n.a 
    Yes (21) 0.78 (0.50, 1.23) (20) 0.67 (0.35, 1.29)   
  Chemotherapy     
    No (29) 1.00 (ref)                   0.060 n.a n.a n.a 
    Yes (25) 0.81 (0.65, 1.01)    
  History of relapse     
    No (25) 1.00 (ref)                   0.299 (26) 1.00 (ref)                   0.504 n.a n.a 
    Yes (28) 1.16 (0.88, 1.53) (29) 1.17 (0.74, 1.87)    
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Table S3. Interaction of study group with sociodemographic determinants (retrieved from 
multivariable logistic regressions1)  
 
 
 
 
 
 
 
 
 
 
CCS, childhood cancer survivors; n.a., not applicable 
1 Adjusted for sex, age category, education level, migration background, language region in Switzerland, sports participation; the 
model including only CCSs, is additionally adjusted for age at diagnosis, year of diagnosis, and cranial radiation therapy 
2 Standardized on sex, age at survey, migration background, and language region according to CCSs 
3 p-value for interaction (study group, CCSs versus comparison group x determinant) was calculated with the likelihood ratio test 
  
 
 
Sociodemographic determinants 
CCS except 
leukemia vs. 
leukemia3 
CCS vs. 
siblings2,3 
CCS vs.  
general 
population2,3 
Gender 0.446 0.381 <0.001 
Age at survey, year 0.723 0.438 0.156 
Education  0.471 0.807 0.500 
Migration  0.708 0.457 0.249 
Language region 0.497 0.193 0.806 
Sports 0.400 0.075 0.828 
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Table S4. Overweight prevalence and risk factors associated with overweight in childhood 
leukemia survivors, subgroup diagnosed between 1990-2005 (from multivariable logistic 
regression)  
 Leukemia 
(n =461) 
Characteristics (%ow) OR (95% CI) p-value1 
Sociodemographic characteristics    
Sex    
  Female (17) 1.00 (ref) 0.026 
  Male (26) 1.76 (1.06, 2.90)  
Age at survey    
  5-14 y (29) 1.61 (0.74, 3.50) 0.049 
  15-19 y (16) 1.00 (ref)   
  ≥20 y (23) 2.18 (1.08, 4.38)  
Education    
  Primary education (27) 1.50 (0.61, 3.38) 0.242 
  Secondary education (24) 1.67 (0.91, 3.09)  
  Tertiary education (17) 1.00 (ref)  
Migration    
  No migration background (19) 1.00 (ref) 0.066 
  Migration background (27) 1.66 (0.97, 2.84)  
Language region in Switzerland    
  German speaking (22) 1.00 (ref)  0.233 
  French speaking (23) 1.04 (0.58, 1.84)  
  Italian speaking (7) 0.22 (0.03, 1.84)  
Sports participation    
  Yes (23) 1.00 (ref) 0.854 
  No (19) 0.94 (0.51, 1.73)  
Clinical characteristics    
Birth weight2    
  Low: <2500 g (32) 1.68 (0.65, 4.35) 0.523 
  Normal: 2500-4000 g (22) 1.00 (ref)  
  High: >4000 g (18) 0.70 (0.30, 1.66)  
BMI at diagnosis3    
  Underweight (13) 0.49 (0.14, 1.78)  <0.001 
  Normal (20) 1.00 (ref)  
  Overweight/Obese (67) 9.86 (3.97, 24.51)  
Age at diagnosis    
  ≥5 y (21) 1.00 (ref) 0.338 
  <5 y (23) 1.36 (0.73, 2.54)  
Year of diagnosis    
  1990-2000 (19) 1.00 (ref) 0.278 
  After 2000 (26) 1.48 (0.73, 2.99)  
CRT    
  None (23) 1.00 (ref) 0.057 
  <20 Gy (15) 0.45 (0.22, 0.95)  
  ≥20 Gy (25) 1.53 (0.43, 5.37)  
1 p-value calculated from likelihood ratio test 
2 n=51 missing (11%) 
3 n=44 missing (10%) 
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Table S5. Overweight prevalence and risk factors associated with overweight in childhood 
leukemia survivors, subgroup diagnosed between 1990-2005 (from univariable logistic 
regression)  
 Leukemia 
(n =461) 
Characteristics (%ow) OR (95% CI) p-value1 
Sociodemographic characteristics    
Sex    
  Female (17) 1.00 (ref) 0.018 
  Male (26) 1.73 (1.09, 2.73)  
Age at survey, year    
  5-14 y (29) 2.08 (1.19, 3.61) 0.033 
  15-19 y (16) 1.00 (ref)   
  ≥20 y (23) 1.52 (0.88, 2.60)  
Education    
  Primary education (27) 1.81 (0.83, 3.95) 0.193 
  Secondary education (24) 1.54 (0.90, 2.63)  
  Tertiary education (17) 1.00 (ref)  
Migration    
  No migration background (19) 1.00 (ref) 0.068 
  Migration background (27) 1.53 (0.97, 2.42)  
Language region in Switzerland    
  German speaking (22) 1.00 (ref)  0.258 
  French speaking (23) 1.05 (0.63, 1.74)  
  Italian speaking (7) 0.25 (0.03, 1.93)  
Sports    
  Yes (23) 1.00 (ref) 0.376 
  No (19) 0.79 (0.46, 1.35)  
Clinical characteristics    
Birth weight2    
  Low: <2500 g (32) 1.71 (0.74, 3.95) 0.562 
  Normal: 2500-4000 g (22) 1.00 (ref)  
  High: >4000 g (18) 0.78 (0.35, 1.75)  
BMI at diagnosis3    
  Underweight (13) 0.58 (0.17, 2.01)  <0.001 
  Normal (20) 1.00 (ref)  
  Overweight/Obese (67) 8.17 (3.52, 18.93)  
Age at diagnosis    
  ≥5 y (21) 1.00 (ref) 0.645 
  <5 y (23) 1.11 (0.71, 1.73)  
Year of diagnosis    
  1990-2000 (19) 1.00 (ref) 0.069 
  After 2000 (26) 1.52 (0.97, 2.37)  
CRT    
  None (23) 1.00 (ref) 0.257 
  <20 Gy (15) 0.59 (0.31, 1.15)  
  ≥20 Gy (25) 1.10 (0.35, 3.51)  
HSCT     
  No (23) 1.00 (ref) 0.190 
  Yes (14) 0.57 (0.23, 1.39)  
History of relapse    
  No (22) 1.00 (ref) 0.828 
  Yes (21) 0.93 (0.46, 1.87)  
1 p-value calculated from likelihood ratio test 
2 n=51 missing (11%) 
3 n=44 missing (10%) 
  
 135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Response rates in the Swiss Childhood Cancer Survivor Study (SCCSS) 
CCS, childhood cancer survivor 
  
4116 survivors eligible for the SCCSS  
     
     529 no valid address available 
10 had died 
 
3577 (100%) traced and sent questionnaires 
850 (24%) did not respond 
200 (6%) refused 
2527 (71%) returned full questionnaire 
119 (3%) had missing data on self-reported 
height and weight at survey 
2365 (66%) available for analyses 
770 leukemia survivors  1595 CCSs with other tumors: 
• II: Lymphoma (424) 
• III: CNS neoplasm (341) 
• IV: Neuroblastoma (118) 
• V: Retinoblastoma (72) 
• VI: Renal tumor (144) 
• VII: Hepatic tumor (20) 
• VIII: Malignant bone tumor (96) 
• IX: Soft tissue sarcoma (137) 
• X: Germ cell tumor (106) 
• XI & XII: Other tumor (54) 
• Langerhans cell histiocytosis (83) 
 
43 (2%) were older than 45 years 
461 leukemia survivors 
diagnosed 1990-2005 
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SUMMARY 
 
BACKGROUND: Glucocorticoids can lead to weight gain during cancer treatment, but we know little 
about their long-term effects in childhood cancer survivors (CCS).  
 
METHODS: As part of the Swiss Childhood Cancer Survivor Study, we sent a questionnaire to CCS 
residing in Switzerland aged <21 years at diagnosis, who survived ≥5 years and were 15-45 years old 
at survey. We assessed cumulative doses of glucocorticoids from medical records and study protocols 
and calculated BMI from self-reported height and weight at survey. We compared prevalence of 
overweight between CCS, their siblings, and the general population (Swiss Health Survey, SHS) and 
investigated the association of overweight with treatment-related risk factors using multivariable logistic 
regression.  
 
RESULTS: The study included 1936 CCS, 546 siblings, and 9591 SHS participants. Median 
(interquartile range) age of the CCS at survey was 24 (20-31) years and median time since diagnosis 
was 17 (12-22) years. At survey, 26% of CCS were overweight, a proportion comparable to that among 
siblings (24%) and the SHS participants (25%). Prevalence of overweight was 24% in CCS treated with 
glucocorticoids only (n=686), 37% in those with cranial radiation therapy (CRT) (n=127), and 49% in 
those with both glucocorticoids and CRT (n=101), p<0.001. We found no evidence for a dose-response 
relationship between cumulative glucocorticoid doses and overweight and no evidence that CRT 
modified the effect of cumulative glucocorticoid dose treatment on overweight.  
 
CONCLUSION: This study suggests that glucocorticoids used for the treatment of childhood cancer are 
not associated with long-term risk of overweight. 
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INTRODUCTION  
The glucocorticoids prednisone and dexamethasone are currently part of the standard 
treatment of acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and Hodgkin 
lymphoma (HL). Type of glucocorticoid, dose, and duration of treatment can differ by cancer 
treatment protocol [1]. Cancer treatment with glucocorticoids can lead to weight gain 
originating in physiological e.g. altered cortisol concentrations and adipose tissue metabolism 
and psychological changes that among others may influence appetite and lower energy 
expenditure due to physical inactivity [1, 2]. An excess of dietary intake and physical inactivity 
during treatment could be the base for behavioural changes in the long-term leading to 
continues weight gain during survivorship. Prednisone and dexamethasone have similar 
mechanisms of action, but dexamethasone in the dose range commonly used causes more 
adverse effects such as acute metabolic side effects, infections, osteopenia, and behavioral 
abnormalities [1, 3]. Other treatments for childhood cancer can also affect the development of 
overweight and obesity in particular cranial radiation therapy (CRT). CRT impairs the 
hypothalamic-pituitary axis, which in turn can lead to growth hormone deficiency and leptin 
insensitivity [4]. ALL treatment protocols have not routinely prescribed CRT since the 1980s, 
and overall cumulative CRT doses have decreased [5]. In contrast, cumulative glucocorticoid 
doses have increased in the US, and prednisone has been partly replaced by the more potent 
dexamethasone [6, 7]. Many CCS are overweight, especially in the US, despite decreased 
doses of CRT [8].  
 
Glucocorticoids might, therefore, be implicated in excessive weight gain during cancer 
treatment [3, 7]. But whether glucocorticoids have a longer-lasting effect on weight is uncertain, 
and any such effect may depend on the dose and duration of treatment. Research has yielded 
contradictory results. One small (N=169) study of ALL survivors reported a six-fold increased 
risk of being overweight or obese in ALL survivors with the highest cumulative doses of 
glucocorticoids (≥10,000 mg/m2) compared to the lowest doses (<7500 mg/m2) five years after 
diagnosis [9], while another US study found no dose-response effects ≥10 years after 
diagnosis [10]. In an US study glucocorticoid treatment was associated with obesity 25 years 
after diagnosis in 776 CCS who were treated with CRT, but cumulative dose and type of 
glucocorticoid were not assessed [11]. Previous studies have mainly focused on acute effects 
of glucocorticoids during or shortly after treatment [9, 12-16], have not assessed cumulative 
glucocorticoid dose [11, 13], and often have relatively low numbers of participants (<200) [9, 
12-18]. Thus it remains unclear whether glucocorticoids affect overweight in CCS long after 
treatment.  
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We analyzed data from the Swiss Childhood Cancer Survivor Study (SCCSS) to investigate 
whether 1) overweight in long-term CCS (on average 17 years after diagnosis) is associated 
with the cumulative glucocorticoid dose received, 2) there is a dose-response relationship 
between cumulative glucocorticoid dose and BMI, and 3) the respective effects of prednisone 
and dexamethasone differ. We studied the entire group of CCS, and separately the three 
cancer types treated most frequently with glucocorticoids (ALL, NHL, and HL).  
 
METHODS  
Sampling  
The Swiss Childhood Cancer Survivor Study  
The Swiss Childhood Cancer Survivor Study (SCCSS) is a long-term follow-up study of 
patients registered in the Swiss Childhood Cancer Registry (SCCR, 
www.childhoodcancerregistry.ch) who have been diagnosed since 1976 and survived ≥5 years 
after cancer diagnosis [19]. The SCCR is a population-based registry that includes all children 
and adolescents under age 21 in Switzerland who are diagnosed with leukemia, lymphoma, 
central nervous system (CNS) tumors, malignant solid tumors, or Langerhans cell histiocytosis 
[20, 21]. Ethical approval of the SCCR and the SCCSS has been given by the Ethics 
Committee of the Canton of Bern to (KEK-BE: 166/2014).  
 
As part of the SCCSS, we traced addresses of all CCS diagnosed between 1976-2005, who 
we sent questionnaires between 2007-2013. A second questionnaire was sent to 
nonresponders four to six weeks later. If they again did not respond, we contacted them by 
phone. Our questionnaire included core questions from the US and UK CCS studies [22, 23], 
with added questions about health behaviors and sociodemographic measures from the Swiss 
Health Survey (SHS) [24] and the Swiss Census [25]. Detailed information on our study design 
has been published previously [19, 26].  
 
Comparison groups  
We used two comparison groups in this study: siblings of the CCS and a random sample of 
the general Swiss population represented by data from the Swiss Health Survey (SHS). The 
sibling survey was conducted from 2009 to 2012. We asked CCS for consent to contact siblings 
and for contact information. We sent siblings the same questionnaire as CCS, omitting 
questions about cancer history. Siblings who did not respond received another copy of the 
questionnaire four to six weeks later, but were not contacted by phone [19].  
 
The second comparison group consisted of participants in the SHS questionnaire 2012 [24]. 
This is a nationally representative telephone survey repeated every five years. The SHS 
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compiled a randomly selected sample of Swiss households with telephone landlines and 
attempted to contact someone in each household. Sampling was stratified by region and in the 
selected households the survey was administered to the consenting household member, age 
15 years or older, who first answered the phone.  
 
Measurements  
Body weight and BMI  
Body weight and height at the time of survey were collected from the questionnaires. We 
instructed all study participants and control groups to record height without shoes and weight 
without clothes. We calculated BMI by dividing weight by height in meters squared (kg/m2). 
Adult BMI <18.5 kg/m2 was classified as underweight, ≥18.5 to <25 kg/m2 as normal weight, 
and ≥25 kg/m2 as overweight including obesity [27]. For adolescents 15-19 years at survey, 
we standardized BMI into z-scores for age and gender using the latest available Swiss 
references [28]. BMI z-scores lower than -2 were classified as underweight, from -2 to 1 as 
normal weight, and >1 as overweight including obesity [29].  
 
Glucocorticoids  
We calculated prednisone and/or dexamethasone doses based on the intended doses in the 
cancer treatment protocol and, if applicable, the treatment arm. Glucocorticoid tapering was 
taken into account if protocols indicated this. In the event tapering information on duration and 
dosage was missing, we assumed that the dosage decreased by 50% of the prior dose in three 
steps over three days. The few protocols (3%) that prescribed glucocorticoids by body weight 
(mg/kg) were converted into dose per body surface area (mg/m2) by multiplying the dose in 
mg/kg by a conversion factor of 30, which represents an average of the factors for persons 
weighing 20 and 60 kg [30]. Glucocorticoids administered by intrathecal route and for 
supportive care or immunosuppression, were not taken into consideration [1]. Treatment 
protocols that were included came from the Swiss Pediatric Oncology Group (31%), Pediatric 
Oncology Group (29%), Berlin/Frankfurt/Muenster study group (24%), German Society of 
Pediatric Oncology and Hematology (7%), and others (9%) (Supplementary Table S1). In 67 
cases in which the study arm was unknown, survivors were assigned to the protocol arm with 
the lowest glucocorticoid dosage. We calculated the total cumulative glucocorticoid dose in 
equivalent of prednisone for each patient using the formula cumulative glucocorticoid dose = 
cumulative prednisone dose + (cumulative dexamethasone dose x 6.67) in mg/m2 [31]. The 
recommended cumulative glucocorticoid doses dropped over time when all cancer types were 
combined, and specifically for each type of cancer with the exception of ALL protocols, in which 
doses increased (Supplementary Figure S1). We assessed other clinical and 
sociodemographic variables as described previously [26].  
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Statistical analysis  
We included all SCCSS survivors and their siblings, and the SHS participants in the general 
population, who were aged 15-45 years at time of survey and provided self-reported height 
and weight (Supplementary Figure S2). We excluded CCS with hematopoietic stem cell 
transplantation (HSCT); this specific group is at substantial risk of underweight due to chronic 
graft-versus-host disease and long-term immunosuppression with recurrent infections [32]. For 
better comparison between CCS and peers, we standardized comparison groups for gender, 
age at survey, migration background, and language region as described previously [26]. First, 
we assessed whether overweight at survey was associated with the cumulative glucocorticoid 
dose during treatment. We determined these associations using multivariable logistic 
regression within all CCS, and within patients with the three cancer types frequently treated 
with glucocorticoids. We divided BMI into two categories: overweight (overweight and obesity) 
versus non-overweight (underweight and normal) because the group of obese people was 
small and the glucocorticoids and CRT risk estimates for the two categories overweight and 
obesity had the same direction and comparable magnitude. Cumulative prednisone and 
glucocorticoid usage was divided into three categories: lower than the median intake of all 
CCS, median to third quartile, and equal to or higher than the third quartile. Cumulative 
dexamethasone was divided into two categories: lower than the median intake of all CCS, and 
equal to or higher than the median. We adjusted the models for gender, age at diagnosis, time 
since diagnosis, and cumulative CRT and/or glucocorticoid dose. We used interaction terms 
to test whether age, gender, and the clinical variables e.g. age at diagnosis, year of diagnosis, 
time since diagnosis, and CRT modified the effect of cumulative glucocorticoid dose treatment 
on overweight since these variables are related to the total dose. Second, we illustrated the 
dose-response relationship by comparing the distribution of BMI by cumulative glucocorticoid 
dose in steps of 1000 mg/m2 (prednisone and total glucocorticoids) or 100 mg/m2 
(dexamethasone) with boxplots. Because 26% of CCS were 15-19 years at survey, we used 
BMI Z-scores for all CCS. We used trend tests to test for an ordered relationship between 
cumulative glucocorticoid dose categories and BMI Z-scores. Third, we examined whether 
effects differed between dexamethasone and prednisone treatment again using multivariable 
logistic regression models. Finally, we performed sensitivity analyses to compare standardized 
data for gender, age, migration background, and language region in all comparison groups 
according to the distribution in CCS to non-standardized data. For the 67 survivors for whom 
the study arm was unknown we performed sensitivity analyses in which they were excluded or 
were assigned to the protocol arm with the highest glucocorticoid dose instead of the lowest. 
We used Stata (version 14, Stata Corporation, Austin, Texas) for all statistical analyses.  
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RESULTS  
Response rate and characteristics of the study populations  
Among 4116 eligible CCS we traced and contacted 3593 of whom 2527 returned the SCCSS 
questionnaire. We excluded 119 participants who did not report height and weight, 355 who 
were younger than 15 or older than 45 years, and a further 117 who had received HSCT. We 
thus included 1936 CCS in this study, of whom 546 had been treated for ALL, 114 NHL, 195 
HL, and 1081 for other types of cancer (Supplementary Figure S2).  
 
We received consent to contact 1530 siblings, of whom 866 returned the questionnaire; 300 
were outside the age range, and 20 did not report height and weight, thus 546 siblings were 
finally included in the analyses. Of 41,008 households surveyed in the general population 
(SHS), 21,597 replied to the survey. In those responding households, 9591 persons who were 
aged 15-45 years were included in the analysis.  
 
Among CCS, median age at diagnosis was 8 (IQR 4–13) years overall, 5 (3–9) years for ALL, 
11 (8–14) for NHL, and 14 (12–16) for HL survivors (Table I). The median time from diagnosis 
to survey was 17 (IQR 12–22) years for CCS overall, 18 (13–23) for ALL, 17 (12-22) for NHL, 
and 15 (10-21) for HL survivors. Most ALL survivors had received glucocorticoids (96% 
prednisone, and 34% dexamethasone). NHL and HL were less often treated with 
glucocorticoids (86% NHL, and 59% HL). Sociodemographic characteristics were mostly 
identical between CCS and the comparison groups after standardization, except that fewer 
CCS than both siblings and the general population completed tertiary education (Table II). 
CCS engaged in less sports than siblings, but were comparable to the general population.  
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Table I. Clinical characteristics of childhood cancer survivors  
 CCS 
(n=1936) 
ALL survivors 
(n=546) 
NHL survivors 
(n=114) 
HL survivors 
(n=195) 
Characteristics n       (%) n       (%) p-valuea n      (%) p-valuea n       (%) p-valuea 
Age at diagnosis, median (IQR) 7.8    (3.7-13.1) 5.1    (3.1-9.1) <0.001 11.1 (7.7-14.0) <0.001 14.2  (11.6-15.9) <0.001 
Time since diagnosis, median (IQR) 16.5  (11.8-22.1) 18.1  (13.3-23.3) <0.001 16.8 (11.6-22.0) 0.918 14.7  (9.5-21.4) <0.001 
Year of diagnosis  
  1976-1988 
  1989-1996  
  1997-2005  
 
667   (34) 
703   (36) 
566   (29) 
 
242   (44) 
187   (34) 
117   (21) 
 
<0.001 
 
41    (36) 
44    (39) 
29    (25) 
 
0.653 
 
50     (26) 
58     (30) 
87     (45) 
 
<0.001 
History of relapse 194   (10) 58     (11) 0.580 8       (7)  0.271 13     (7) 0.100 
Chemotherapy 1494 (77) 546   (100)  <0.001 111  (97)b <0.001 171   (88) <0.001 
Prednisone exposurec 
  Dose, median (IQR), mg/m2 
852   (44) 
2520 (1680-5824) 
524   (96)  
2880 (1680-5824) 
<0.001 84     (74)  
1836 (1836-3880) 
<0.001 116   (59) 
3060 (2340-4824) 
<0.001 
Dexamethasone exposurec 
  Dose, median (IQR), mg/m2 
239   (12) 
1260 (250-1260) 
183   (34)  
1260 (770-1260) 
<0.001 34     (30) 
236   (200-240) 
<0.001 - 
n.a. 
<0.001 
Glucocorticoidsc 
  Dose, median (IQR), mg/m2 
882   (46) 
3470 (1960-8100) 
528   (97)d 
5824 (3360-10084) 
<0.001 98     (86) 
2520 (1836-3516) 
<0.001 116 (59) 
3060 (2340-4824) 
<0.001 
CRT 
  Yes, <20 Gy 
  Yes, ≥20 Gy 
 
133   (7) 
228   (12) 
 
71     (13)  
65     (12) 
 
<0.001 
 
4      (4) 
11    (10) 
 
0.234 
 
17     (9) 
4       (2) 
 
<0.001 
Glucocorticoids and CRT 
  No glucocorticoids and No CRT 
  Glucocorticoids only 
  <20 Gy CRT only 
  ≥20 Gy CRT only  
  Glucocorticoids and <20 Gy CRT  
  Glucocorticoids and ≥20 Gy CRT 
 
889   (46) 
686   (35) 
38     (2) 
127   (7) 
95     (5) 
101   (5) 
 
17     (3)  
393   (72) 
1       (<1) 
- 
70     (13) 
65     (12) 
 
<0.001 
 
16     (14) 
83     (73) 
- 
- 
4       (4) 
11     (10) 
 
<0.001 
 
72   (37) 
102 (52) 
7     (4) 
- 
10   (5) 
4     (2) 
 
<0.001 
ALL, acute lymphoblastic leukemia; CCS, childhood cancer survivors; CRT, cranial radiation therapy; HL, Hodgkin lymphoma; IQR, interquartile range; NHL, non-Hodgkin lymphoma; 
a: p-value calculated from two-sample mean comparison test (t test) or chi-square statistics comparing separate diagnostic groups with remaining CCS (2-sided test); 
b: n=3 is missing (3%); 
c: Protocols with an unknown glucocorticoid dose were not taken into account. Survivors who were treated with unknown dose: 1st protocol: prednisone N=31 (2%), dexamethasone N=19 (<1%); 2nd 
protocol: prednisone N=7 (<1%), dexamethasone N=6 (<1%); and 3rd protocol: prednisone N=2 (<1%), dexamethasone N=2 (<1%). 
d: Of the 18 survivors who did not receive glucocorticoids during their treatment, N=13 (72%) had no protocol information in their medical records, N=5 (28%) got a classification protocol, after which 
no protocol information was given in their medical record, N=9 (50%) survivors were diagnosed before 1990.
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Table II. General characteristics of childhood cancer survivors, their siblings, and the general 
population (Swiss Health Survey)  
 CCS 
(n=1936) 
Siblingsa 
(n=725) 
General populationa 
(n=9591) 
Characteristics n       (%)  n     (%std)  p-valueb n       (%std)   p-valueb 
Gender 
  Male 
 
1034 (53)  
 
301 (54) 
 
n.a. 
 
4645 (54) 
 
n.a. 
Age at survey, y  
  15-19 
  20-24 
  25-29 
  30-34 
  35-45 
 
509   (26) 
504   (26) 
388   (20) 
259   (13) 
276   (14) 
 
142 (26) 
162 (24) 
168 (23) 
115 (13) 
138 (14) 
 
n.a. 
 
1518 (33) 
1440 (23) 
1174 (13) 
1424 (11) 
4035 (19) 
 
n.a. 
Parents’ education (highest degree)c 
  Primary  
  Secondary  
  Tertiary  
 
33     (6) 
302   (59) 
174   (34) 
 
6   (4) 
77 (54) 
59 (42) 
 
0.243 
 
n.a. 
 
Personal educationd 
  Primary  
  Secondary  
  Tertiary  
 
108   (8) 
966   (68) 
353   (25) 
 
24   (4) 
359 (62) 
200 (35) 
 
<0.001 
 
691   (8) 
4549 (62) 
2833 (30) 
 
<0.001 
Migration background 453   (23) 132 (23) n.a. 3454 (23) n.a. 
Sportse 1281 (66) 506 (71) 0.041 5598 (64) 0.051 
BMI at survey 
  Underweight 
  Normal 
  Overweight 
  Obese 
 
113   (6) 
1321 (68) 
372   (19) 
130   (7) 
 
19   (2) 
523 (74) 
149 (20) 
34   (4) 
 
<0.001 
 
349   (3) 
6354 (72) 
2285 (24) 
603   (6) 
 
<0.001 
BMI, body mass index; CCS, childhood cancer survivors; n.a., not applicable;  
a: Standardized on gender, age at survey, migration background, and language region according to CCS; 
b: p-value calculated from chi-square statistics comparing comparison group to CCS (2-sided test); 
c: Highest parental education level of participants <20 years at time of survey; 
d: Highest personal education level of participants ≥20 years at time of survey;  
e: Sports participation was classified as sports if respondents reported engaging in a specific gym or sports activity for at least one hour per 
week 
Overweight and glucocorticoid therapy  
The prevalence of overweight among all CCS was 26% at survey. This was similar to the 
overweight prevalence in the comparison groups after standardization according to CCS: 24% 
in siblings (p=0.34) and 25% in the general population (p=0.48) (Table II, Supplementary 
Figure S3). When we stratified CCS by treatment, we found that the prevalence of overweight 
was 23% in CCS treated with no glucocorticoids and no CRT (205 of 889), 24% in those treated 
with glucocorticoids alone (166 of 686), 37% in CCS treated with ≥20 Gy CRT (47 of 127, 
p<0.01), and 49% in those treated with both glucocorticoids and ≥20 Gy CRT (49 of 101, 
p<0.001) (Figure 1). There was a weak trend (p=0.08), suggesting an interaction that the effect 
of CRT tended to be higher in CCS also treated with glucocorticoids.  
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Figure 1. Prevalence of overweight in long-term childhood cancer survivors, by treatment with 
glucocorticoids and ≥20 Gray cranial radiation. 
CI, confidence interval; CRT, cranial radiation therapy; Gy, gray; 
Comparison groups were standardized on gender, age at survey, migration background, and language region according to CCS; 
All p-values were calculated from chi-square statistics comparing CCS who got no glucocorticoids and no CRT to other CCS and 
comparison groups; 
The dotted line reflects the overweight prevalence of the general population 
 
In multivariable logistic regression models we found that overweight was not associated with 
cumulative glucocorticoid dose either in CCS overall or in the three cancer types treated 
frequently with glucocorticoids (Table III). But, CCS and ALL survivors treated with ≥20 Gy 
CRT were more likely to be overweight. Interaction tests did not suggest that the cumulative 
effect of glucocorticoids differed by gender, age, year of diagnosis, time since diagnosis, 
chemotherapy, CRT, or history of relapse (Supplemental Table S2).  
 
Dose-response relationship between overweight and glucocorticoids  
We found no evidence supporting a dose-response relationship between cumulative 
prednisone, dexamethasone, or both combined and BMI Z-scores, either when stratifying for 
CRT (ptrend no CRT=0.994, ptrend <20Gy=0.510, and ptrend ≥20Gy= 0.174, Figure 2), or when analyzing 
the entire CCS group adjusted for cumulative CRT dose (ptrend prednisone=0.085, ptrend 
dexamethasone=0.176, and ptrend glucocorticoids =0.583 Supplementary Figure S4). CCS who got high 
prednisone doses (≥8000 mg/m2) tended to have higher BMI Z-scores. In ALL survivors we 
also observed no dose-response relationship (ptrend prednisone=0.223, ptrend dexamethasone=0.063, and 
ptrend glucocorticoids =0.512, Supplementary Figure S5). 
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Table III. Crude and adjusted odds ratios for being overweight in childhood cancer survivors treated with different doses of cumulative glucocorticoid and  
cranial radiation therapy 
ALL, acute lymphoblastic leukemia; CCS, childhood cancer survivors; CI, confidence interval; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; OR, odd ratio; 
a: Adjusted for gender, age at diagnosis, time since diagnosis, cumulative cranial radiation therapy, and glucocorticoid dose (prednisone only, dexamethasone only, or both); 
b: Global p-value calculated from the likelihood ratio test 
 
 CCS  
(n=1936) 
ALL survivors 
(n=546) 
NHL survivors 
(n=114) 
HL survivors  
(n=195) 
 now/ntotal Crude OR  
(95% CI) 
Adj OR  
(95% CI)a 
now/ntotal Crude OR  
(95% CI) 
Adj OR  
(95% CI)a 
now/ntotal Crude OR 
(95% CI) 
Adj OR  
(95% CI)a 
now/ntotal Crude OR  
(95% CI) 
Adj OR  
(95% CI)a 
Cumulative prednisone (mg/m2) 
  <2520 
  2520-5823 
  ≥5824 
p-valueb 
  375/1489 
54/220 
73/227 
1.00 (ref)  
0.97 (0.70-1.34) 
1.41 (1.04-1.90) 
                 0.081 
1.00 (ref) 
0.87 (0.62-1.22) 
1.24 (0.90-1.70) 
                 0.236 
60/255 
32/111 
54/180 
1.00 (ref)  
1.32 (0.80-2.18) 
1.39 (0.91-2.14) 
                  0.276 
1.00 (ref)  
0.69 (0.37-1.28) 
0.78 (0.45-1.34) 
                  0.481 
23/74 
6/25 
5/15 
1.00 (ref)  
0.70 (0.25-1.98) 
1.11 (0.34-3.61) 
                  0.754 
1.00 (ref)  
0.45 (0.13-1.56) 
0.51 (0.14-1.87) 
                  0.351 
34/119 
9/49 
10/27 
1.00 (ref)  
0.56 (0.25-1.28) 
1.47 (0.61-3.53) 
                  0.179 
1.00 (ref) 
0.61 (0.25-1.48) 
1.02 (0.37-2.84) 
                     0.506 
Cumulative dexamethasone (mg/m2) 
  <1260 
  ≥1260 
p-valueb 
478/1813 
24/123 
 
1.00 (ref)  
0.68 (0.43-1.07) 
                 0.084 
1.00 (ref)  
0.78 (0.49-1.24) 
                 0.286 
123/424 
23/122 
1.00 (ref) 
0.57 (0.34-0.94) 
                  0.022 
1.00 (ref) 
0.54 (0.31-0.93) 
                  0.025 
34/114 
   - 
 
1.00 (ref) 
- 
                   
1.00 (ref)  
- 
                      
53/195 
- 
1.00 (ref) 
- 
                   
1.00 (ref)  
- 
                      
Cumulative glucocorticoids (mg/m2) 
  <3470 
  3470-8099 
  ≥8100 
p-valueb 
381/1495 
60/219 
61/222 
1.00 (ref)  
1.10 (0.80-1.52) 
1.11 (0.81-1.52) 
                 0.715 
1.00 (ref) 
1.04 (0.75-1.45) 
1.07 (0.78-1.49) 
                 0.900 
60/214 
44/152 
42/180 
1.00 (ref)  
1.05 (0.66-1.66) 
0.78 (0.49-1.23) 
                   0.438 
1.00 (ref)  
1.15 (0.70-1.87) 
0.63 (0.39-1.03) 
                 0.073 
25/89 
5/15 
4/10 
 
1.00 (ref)  
1.28 (0.40-4.12) 
1.71 (0.44-6.56) 
                  0.710 
1.00 (ref)  
1.28 (0.33-5.04) 
1.01 (0.24-4.24) 
                  0.940 
38/138 
5/30 
10/27 
 
1.00 (ref)  
0.53 (0.19-1.47) 
1.55 (0.65-3.68) 
                  0.212 
1.00 (ref)  
0.44 (0.15-1.34) 
0.96 (0.34-2.68) 
                     0.300 
CRT 
  No CRT 
  <20 Gy 
  ≥20 Gy 
p-valueb 
371/1575 
35/133 
96/228 
1.00 (ref) 
1.16 (0.77-1.73) 
2.36 (1.77-3.15) 
               <0.001 
1.00 (ref) 
1.16 (0.76-1.77) 
2.28 (1.70-3.06) 
               <0.001 
97/410 
11/71 
38/65 
1.00 (ref) 
0.59 (0.30-1.17) 
4.54 (2.64-7.82) 
                <0.001 
1.00 (ref) 
0.63 (0.31-1.28) 
4.40 (2.45-7.89) 
                <0.001 
29/99 
1/4 
4/11 
1.00 (ref) 
- 
1.38 (0.37-5.07) 
                  0.871 
1.00 (ref) 
- 
0.84 (0.20-3.46) 
                  0.963 
46/174 
7/17 
-/4 
1.00 (ref) 
1.95 (0.70-5.42) 
- 
                 0.202 
1.00 (ref) 
1.93 (0.65-5.74) 
- 
                     0.237 
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Figure 2. Box-plot of the dose-response relationship between BMI Z-score and cumulative 
glucocorticoid dose stratified by cranial radiation therapy in childhood cancer survivors 
(N=1936) 
BMI, body mass index; CRT, cranial radiation therapy; Gy, gray 
p-values for trend for no CRT 0.658, <20 Gy CRT 0.937, and ≥20 Gy CRT 0.309 
 
Prednisone versus dexamethasone  
In unadjusted analyses, CCS who were treated with the highest cumulative dose of prednisone 
(≥5824 mg/m2) tended to be more overweight than those treated with the lowest dose (<2520 
mg/m2). This was not significant after adjustment for time since diagnosis. We made further 
adjustments for gender, age at diagnosis, cumulative cranial radiation therapy, and 
dexamethasone (Table III). In contrast, ALL survivors who were treated with at a higher 
dexamethasone dose (≥1260 mg/m2) were less likely to be overweight than those treated with 
a lower dose (<1260 mg/m2).  
 
DISCUSSION  
At a median 17 years after cancer diagnosis, 26% of CCS in Switzerland were overweight. 
This prevalence is comparable to that in siblings and healthy peers in the general population. 
Prevalence of overweight was 23% in those CCS treated with glucocorticoids, but higher for 
CCS treated with cranial radiation ≥20 Gy (37%), and yet higher among CCS treated with both 
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glucocorticoids and cranial radiation ≥20 Gy (49%). The effect of CRT on overweight tended 
to be higher if CCS were also treated with glucocorticoids, but power for interaction tests was 
low. There was no evidence for a dose-response relationship between the cumulative 
glucocorticoid dose and being overweight, except for a possible effect at the highest doses 
(prednisone ≥8000 mg/m2).  
 
Overweight and obesity during treatment is frequent in ALL patients who receive high doses 
of glucocorticoids [33], but the long-tern impact of glucocorticoids on overweight has not been 
well studied. An US study of 784 ALL survivors followed over 26 years found an association of 
obesity with CRT, but not cumulative glucocorticoid dose. That finding is similar to ours, but 
ALL survivors with low glucocorticoid doses in the US study received high CRT doses. This 
could have masked an association between glucocorticoids and obesity [34]. A Dutch study of 
113 ALL survivors 10 years after treatment found that higher cumulative prednisone doses led 
to higher BMI Z-scores at end of treatment and shortly thereafter, but not in the long-term [18]. 
The cumulative prednisone doses in the study were much higher than ours; of the 65 survivors 
who received only prednisone 60 (92%) survivors had received a cumulative dose of 9800 
mg/m2, or more. We also found post hoc evidence that higher cumulative prednisone doses 
(≥8000 mg/m2) lead to more overweight, but after multivariable adjustment this effect 
disappeared. A dose-response association between cumulative glucocorticoid dose and BMI 
was also seen in a longitudinal single-center study in the US of 165 ALL survivors. BMI was 
assessed five years after diagnosis and again, cumulative glucocorticoid doses were higher 
(around 50% had a cumulative dose of >9000 mg/m2) [9]. We found in univariable analyses 
that survivors who got the highest cumulative prednisone dose (≥5824 mg/m2) were more likely 
to be overweight. After adjustment, the association was similar in magnitude and direction, but 
was no longer significant. We did not find an association between cumulative dexamethasone 
and overweight in CCS. However, follow-up time was longer in CCS treated with prednisone 
because dexamethasone was introduced more recently. ALL survivors who got a cumulative 
dexamethasone dose of ≥1260 mg/m2 were even less likely to be overweight than those who 
were treated with a lower dosage. The dose-response relationship between cumulative 
dexamethasone and BMI Z-scores showed a dent with higher doses of dexamethasone. Given 
the wide confidence intervals this finding is most likely due to chance. The dint could also be 
a surrogate for more severe disease and more intense treatment, leading to less weight gain 
over time. Studies that look at the association between glucocorticoids and overweight in 
survivors of tumors other than ALL are limited. In 88 HL survivors in complete continuous 
remission for 16 years, no difference in BMI was found between those treated with and without 
prednisone [17]. The glucocorticoid dose is lower and chemotherapy duration is shorter in HL 
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compared to ALL survivors. We saw no association between glucocorticoids and overweight 
in either survivor group.  
 
This study is the largest of its kind to have looked at cumulative glucocorticoid dose and 
overweight in CCS long after end of treatment. It also had a specific focus on ALL, NHL, and 
HL survivors who usually receive high doses of glucocorticoids. Other strengths include its 
national coverage and high response rate, which increase confidence that the results are 
representative, as does its access to both socioeconomic factors and detailed treatment data. 
We also compared CCS with two other groups from whom contemporaneous data were 
collected: CCS siblings, and the general population in Switzerland. Among the study’s 
limitations was the unavailability of patient dose levels, which necessitated deriving cumulative 
glucocorticoid doses from cancer protocol information. This could have led to either under- or 
over estimation of the cumulative glucocorticoid dose when the protocol arm was unknown. 
But for only 67 survivors was the study arm unknown. Sensitivity analyses where we excluded 
those with unknown study arms or were we assigned them to the highest dose instead of the 
lowest dose found the same results. Only 239 CCS were treated with dexamethasone 
because, though we included CCS diagnosed since 1976, dexamethasone use has increased 
only recently [7]. Height and weight at survey were self-reported; both under- and over-
reporting could have occurred. However, since height and weight were self-reported in all study 
populations we expected the degree of nondifferential errors of BMI assessment to be similar 
across all CCS, the comparison groups, and across CCS treated with different glucocorticoid 
doses. Finally, we used BMI as a measure of overweight. BMI measures neither the ratio of 
lean to fat mass nor fat distribution. Since glucocorticoids have a catabolic effect on muscle, 
CCS could have less lean mass and more fat mass than the general population with a similar 
BMI [35]. However, BMI is a practical and inexpensive proxy measure of overweight that is 
widely used in population-based studies.  
 
Treatment of childhood cancer increases survivors’ risk of chronic diseases. Overweight can 
worsen disease burden, in particular when it involves development of endocrine complications 
such as type II diabetes. While our study does not suggest glucocorticoids are associated with 
long-term overweight, advice on weight control, a healthy lifestyle, and physical activity should 
always be part of survivorship care, with a special focus on patients who received CRT as well 
as potentially those who received very high doses of glucocorticoids.  
 
Essentially, however, the findings of our study are comforting: treatment with glucocorticoids 
leads to overweight at the time of treatment [9, 12-14, 16], but our results suggests that 
glucocorticoid treatment is not a reason for concern for long term overweight in CSS.   
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SUPPLEMENTARY MATERIAL 
 
Table S1. Protocols of clinical trials included 
Protocol CCS, n (%)  Dexamethasone Prednisonea 
BFM  234 (24%)   
  ALL-BFM 83 1 X X 
  ALL-BFM 86 2 X X 
  ALL-BFM 90 56 X X 
  ALL-BFM 95 64 X X 
  ALL-BFM 99 MRD Pilot 4 X X 
  ALL-BFM 2000 23 X X 
  ALL/NHL-BFM 86 2 X X 
  ALL-REZ-BFM 87 1 X X 
  ALL-REZ-BFM 90 8 X X 
  ALL-REZ-BFM P95/96 8 X X 
  ALL-REZ-BFM 2002 2 X X 
  AML-BFM 87 1  X 
  AML-BFM 93 7  X 
  AML-BFM 98 4  X 
  B-NHL-BFM 04 3 X  
  NHL-BFM 83 3 X X 
  NHL-BFM 90 18 X X 
  NHL-BFM 95 27 X X 
GPOH 64 (7%)   
  ALCL99 (GPOH) 1 X  
  GPOH HD 95 47  X 
  GPOH HD 2002 16  X 
POG 279 (29%)   
  POG-7376 2  X 
  POG-7837 3  X 
  POG-7909 4  X 
  POG-8036 27  X 
  POG-8101 5 X X 
  POG-8304 5  X 
  POG-8314 4  X 
  POG-8426 1  X 
  POG-8602 34  X 
  POG-8616 6  X 
  POG 8618 1  X 
  POG-8691 2  X 
  POG-8704 18  X 
  POG-8710 1  X 
  POG-8719 11  X 
  POG-9005 27  X 
  POG-9006 12  X 
  POG-9061 1 X  
  POG-9201 11  X 
  POG-9219 14  X 
  POG-9310 1  X 
  POG-9315 5  X 
  POG-9398 2  X 
  POG-9404 4  X 
  POG-9405 6  X 
  POG-9406 7  X 
  POG-9411 3 X X 
  POG-9412 4 X  
  POG-9425 2  X 
  POG-9605 16  X 
  POG 9900 12 X X 
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CCS could have received several protocols based on the cancer type, relapse etc.; 
ALL, acute lymphoblastic leukemia; ALCL, anaplastic large cell; AML, acute myelogenous leukemia lymphoma; BFM, 
Berlin/Frankfurt/Muenster study group; CALGB, Cancer and Leukemia Group B; CCG, Children’s Cancer Group; COG, Children’s 
Oncology Group; DAL, German-Austrian multicentre trial; EORTC, European Organisation for Research and Treatment of Cancer; 
EURO, European; GPOH, German Society of Pediatric Oncology and Hematology; HD, high dose / Hodgkin’s disease; HR, high 
risk; LB, lymphoblastic; LCH, Langerhans cell histiocytosis; LMB, B-cell non-Hodgkin’s lymphoma and B-ALL; LR, low risk; MRD, 
minimal residual disease; NHL, non-Hodgkin lymphoma; POG, Pediatric Oncology Group; R-CHOP, rituximab cyclophosphamide 
hydroxyl-doxorubicin vincristine prednisone; REZ, relapse; SAKK, Swiss Group for Clinical Cancer Research; SIOP, International 
Society of Pediatric Oncology; SPOG, Swiss Pediatric Oncology Group; 
a: Intrathecal prednisone is not taken into account 
  
  POG-9904 2 X X 
  POG-9905 7 X X 
  POG-9906 10 X X 
  POG-9917 7 X  
  POG-A5971 2 X X 
SPOG 299 (31%)   
  SPOG ALL 79/84 129  X 
  SPOG ALL LR 76 35  X 
  SPOG ALL HR 76 5  X 
  SPOG ALL HR 79 11  X 
  SPOG ALL REZ LR 77 1  X 
  SPOG ALL REZ HR 77 2  X 
  SPOG NHL (1977) 32  X 
  SPOG H77 26  X 
  SPOG H87 13  X 
  SPOG Hodgkin 1985 10  X 
  SPOG HT(Hirntumor) A76 7  X 
  SPOG HX 28  X 
Other 91 (9%)   
  CALGB 7111 9 X X 
  CALGB 7411 12  X 
  CALGB 7611 16  X 
  CALGB 7721 4  X 
  CCG-2961 1 X  
  COG-AALL0433 2 X X 
  DAL HD 90 4  X 
  DAL HX 90 6  X 
  EORTC 58881 1 X X 
  EURO LB 02 1 X X 
  HD 5 1  X 
  HD 9 1  X 
  LALA 94 1 X X 
  LCH II 17  X 
  LCH III 5  X 
  LMB 84 3  X 
  LMB 89 2  X 
  R-CHOP 1  X 
  SAKK NHL 1  X 
  SIOP HD IV 87 3  X 
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Table S2. P-values for interaction of glucocorticoid use in childhood cancer survivors with 
sociodemographic and clinical characteristics (retrieved from multivariable logistic 
regressionsa) 
ALL, acute lymphoblastic leukemia; CCS, childhood cancer survivors; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; 
a: adjusted for gender, age at diagnosis, and time since diagnosis; 
b: p-value for interaction was calculated with the likelihood ratio test    
 p-values for interactionsb 
 CCS  
(n=1936) 
ALL 
(n=546) 
NHL 
(n=114) 
HL 
(n=195) 
Sociodemographic     
Gender 0.869 0.283 0.381 0.084 
Age at survey 0.943 0.207 0.466 0.834 
Clinical      
Age at diagnosis, years 0.633 0.800 0.670 0.756 
Year of diagnosis 0.672 0.373 0.665 0.971 
Time since diagnosis, years 0.343 0.502 0.5627 0.580 
Chemotherapy (No, Yes) 0.818 n.a. 0.707 0.434 
Cranial radiation therapy (No, Yes) 0.261 n.a. n.a. 0.422 
History of relapse (No, Yes) 0.138 n.a. n.a. n.a. 
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Figure S1. Time trends in exposure to glucocorticoids (cumulative dose) during treatment in CCS, 
ALL, NHL, and HL survivors  
ALL, acute lymphoblastic leukemia; CCS, childhood cancer survivors; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; 
p-values for testing trend of cumulative glucocorticoid dose across year of diagnosis by childhood cancer type  
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Figure S2. Response rates and study populations in the Swiss Childhood Cancer Survivor 
Study 
ALL, acute lymphoblastic leukemia; AML; acute myeloid leukemia; CCS, childhood cancer survivors; CNS, central nervous 
system; HL, Hodgkin lymphoma; HSCT, hematopoietic stem cell transplantation; NHL, non-Hodgkin lymphoma; SCCSS, Swiss 
Childhood Cancer Survivor Study 
 
  
4116 survivors eligible for the SCCSS 
513 no valid address available 
10 had died 
 
3593 (100%) traced and sent questionnaires 
850 (24%) did not respond 
216 (6%) refused 
2527 (71%) returned questionnaire 
119 (3%) had missing data on self-reported 
height and weight at survey 
1936 (54%) available for analyses 
546 (15%) 
ALL survivors 
114 NHL (3%) 
survivors 
355 (10%) were >45 or <15 years old at survey 
1081 (30%) other CCS: 
• 52 Other leukemias, e.g. AML 
• 69 Other lymphomas, e.g. Burkitt 
• 282 CNS neoplasm 
• 76 Neuroblastoma 
• 49 Retinoblastoma 
• 114 Renal tumor 
• 13 Hepatic tumor 
• 88 Malignant bone tumor 
• 114 Soft tissue sarcoma 
• 94 Germ cell tumor 
• 52 Other tumor 
• 78 Langerhans cell histiocytosis 
 
 
117 (3%) had HSCT 
195 HL (5%) 
survivors 
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Figure S3. Prevalence of overweight in childhood cancer survivors, their siblings, and the 
general population 
ALL, acute lymphoblastic leukemia; CCS, childhood cancer survivors; CI, confidence interval; HL, Hodgkin lymphoma; NHL, non-
Hodgkin lymphoma; 
Comparison groups were standardized on gender, age at survey, migration background, and language region according to CCS; 
The dotted line reflects the overweight prevalence in the general population 
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Figure S4. Dose-response relationship between cumulative A. Prednisone, B. 
Dexamethasone, C. Glucocorticoids combined (prednisone and dexamethasone) and BMI Z-
score in childhood cancer survivors (N=1936), adjusted for cumulative dose of cranial radiation 
therapy 
BMI, body mass index; CI, confidence interval; No, number; 
p-values for testing trend of BMI Z-score across cumulative glucocorticoid dose   
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Figure S5. Dose-response relationship between cumulative A. Prednisone, B. Dexamethasone, C. 
Glucocorticoids combined (prednisone and dexamethasone) and BMI Z-score in ALL survivors (N=546), 
adjusted for cumulative dose of cranial radiation therapy  
ALL, acute lymphoblastic leukemia; BMI, body mass index; CI, confidence interval; No, number; 
p-values for testing trend of BMI Z-score across cumulative glucocorticoid dose  
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Chapter 8 
 
 
General discussion 
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This thesis addressed dietary adherence, its determinants, and the prevalence and risk factors 
for being overweight during and long after childhood cancer treatment. For this purpose, I used 
1) available data from the first questionnaire of the Swiss Childhood Cancer Survivor Study 
(SCCSS); 2) new data from a follow-up questionnaire including a food frequency questionnaire 
which I developed and mailed to adolescent and adult survivors; 3) new data from a multicentre 
validation study which I set up. This study compared dietary intake assessed via the food 
frequency questionnaire with urine spot samples from survivors and patients (analyses 
ongoing), and 4) available data from childhood cancer patients in a multicentre cohort study 
(Introduction, Figure 5).  
 
MAIN FINDINGS IN CONTEXT OF OTHER LITERATURE  
An overview of the studies in this thesis can be found in Table I. Our results do not indicate 
that childhood cancer survivors (CCS) adhere better to dietary recommendations than their 
peers. In addition, prevalence and risk factors for overweight in CCS are similar to peers. 
Within patients we saw that being diagnosed with acute lymphoblastic leukaemia (ALL) and 
lymphoma were both risk factors for weight gain.  
 
“Low adherence to dietary recommendations in adult childhood cancer survivors” 
(Chapter 2)  
According to our research, CCS poorly adhered to dietary recommendations, but equally poor 
as their siblings and the general Swiss population. Our findings on low adherence are in line 
with previously published data within the general Swiss population [1, 2] and CCS in other 
countries [3-9]. In line with our results, previous studies reported no relevant differences in 
level of dietary adherence between CCS and comparison groups [3, 8]. We found that 
predictors of adherence in CCS were similar in siblings and the general population. Adherence 
to dietary recommendations was not better among CCS with a higher cardiovascular disease 
(CVD) risk because of cardiotoxic treatment. As in accord to our study, a small US study in 91 
CCS found little to no difference between dietary intake and cancer diagnosis and therapy [8]. 
An exception was exposure to cranial radiation therapy (CRT), which was related to even 
poorer adherence.  
 
“Dietary intake of Swiss adult survivors of childhood cancer compared to the general 
population” (Chapter 3) and “Urine spot collection in childhood cancer patients and 
survivors: a pilot study” (Chapter 4)  
We assessed CCS’ dietary intake in more detail with a food frequency questionnaire (FFQ, 
Chapter 3) and compared the FFQ with nutrient measurements in urine spot samples 
(analyses ongoing, Chapter 4). Till now far, only two reports on detailed dietary intake  
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information have been published within a large CCS study population (≥500) [4, 10]. Both 
reports where from the St. Jude Lifetime Cohort Study, US.  
 
“Overweight in childhood cancer patients at diagnosis and throughout therapy: a 
multicentre cohort study” (Chapter 5)  
We found that the prevalence of overweight of Swiss childhood cancer patients (CCP) 
increased from 8% at diagnosis to 13% at the end of treatment. A smaller Dutch prospective 
study in 133 CCP with a medium age of 8 years found a lower prevalence (diagnosis: 5%; one 
year after diagnosis: 10%). This was likely due to the used cut-offs to define overweight (>2 
standard deviations), which were less conservative than in our study where we used cut-offs 
of the International Obesity Taskforce [11]. US studies found higher prevalences of overweight 
at diagnosis: 21-55% and at end of treatment: 40-69% [12, 13]. This is in accord with the higher 
prevalences also seen in the general US population [14]. ALL and lymphoma patients in our 
study showed a continuously increasing trend in BMI Z-scores over time during treatment in 
line with previous literature [12, 13, 15-18].  
 
“Overweight in childhood cancer survivors: the Swiss Childhood Cancer Survivor 
Study” (Chapter 6)  
Long after cancer diagnosis (median 15 years), we found that 26% of all CCS were overweight. 
This prevalence was comparable to that of their healthy peers (siblings: 22%; general 
population: 25%). However, CCS diagnostic groups differed: 31% of central nervous system 
(CNS) tumour survivors were overweight, whereas only 13% of neuroblastoma and 18% of 
soft tissue sarcoma survivors were overweight. CNS tumour survivors are exposed to several 
risk factors that might lead to hypothalamic obesity such as CRT, hypothalamic tumours, and 
surgical damage [19-21]. In line with previous studies, we confirmed that receiving ≥20 Gy 
CRT was associated with being overweight [22-24]. The US Childhood Cancer Survivor Study 
(CCSS) in 7195 CCS reported also that those who were treated for neuroblastoma and soft 
tissue sarcoma were less likely to be obese compared to the general population [24].  
 
“No evidence for overweight in long-term childhood cancer survivors after 
glucocorticoid treatment” (Chapter 7)  
We saw that CCS who received CRT and glucocorticoids were more overweight than CCS 
who were only treated with CRT, 49% versus 37%. However, there was no evidence for a 
dose-response relationship between the cumulative glucocorticoid dose and being overweight, 
except for a possible effect at the highest doses (prednisone ≥8000 mg/m2). In contrast, dose-
response relationships were observed at end of treatment and shortly after (<5 years) in 
studies among ALL survivors [25, 26], but the given cumulative glucocorticoid dosages were 
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higher than in our study population. Similar to our study, no long-term association between 
cumulative glucocorticoid dose and obesity was found in 784 US ALL survivors who were 
followed over 26 years [27]. But, the association between glucocorticoids and obesity could 
have been masked as ALL survivors with low glucocorticoid doses in this US study received 
high CRT doses.  
 
Table I. Overview of the studies and main findings presented in this thesis 
Ch. Design Population, n Aim Findings 
Dietary intake 
2  Cohort Survivors, 1864 
Comparison groups: 
-Siblings, 698 
-SHS, 8258 
Dietary adherence of 
food groups and 
determinants for 
adherence 
-% of CCS which met recommended dietary intakes: meat 
(43%), fruit (34%), fish (30%), dairy products (18%), 
vegetables (11%), combined fruit and vegetables (7%).  
-Dietary adherence was associated with: gender, parental 
education, migration background, language region in 
Switzerland, smoking, alcohol consumption, and sport 
participation.  
3  Cohort  Survivors, 878 
Comparison groups: 
-Bus Santé, 9216 
-CoLaus, 1311 
-menuCH, 1189 
Detailed dietary intake 
and quality (FFQ) and 
clinical determinants 
-Analyses are ongoing 
4  Validation Patients, 6 
Survivors, 119 
Correspondence 
between FFQ and urine 
spot samples 
-Response rate: patients (75%), outpatients (50%). 
-Patient recruitment is difficult. 
-Analyses are ongoing.  
Overweight 
5  Cohort Patients, 327 Weight development 
during treatment and 
risk factors for weight 
gain 
-During the first half of treatment, BMI Z-scores increased in 
acute lymphoblastic leukaemia (ALL) and lymphoma 
patients, whereas for patients with central nervous system 
tumours, sarcoma, or other types of cancer BMI Z-scores 
tended to drop initially. During the second half of treatment 
BMI Z-scores of all patients tended to increase. 
-Risk factors for weight gain: being a boy, diagnosed with 
ALL or lymphoma. 
6 Cohort  Survivors, 2365 
Comparison groups: 
-Siblings, 819 
-SHS, 9591 
Overweight prevalence 
and sociodemographic 
risk factors 
-Overweight prevalence: 26%  
-Risk factors for being overweight: male sex, both young 
and older age at study, lower education, migration 
background, no sports participation, and being treated with 
cranial radiotherapy (≥20 gray) 
7 Cohort  Survivors, 1936 
Comparison groups: 
-Siblings, 546 
-SHS, 9591 
Association between 
cancer treatment and 
overweight  
-No dose-response relationship between cumulative 
glucocorticoid doses and overweight  
-No evidence that cranial radiotherapy modified the effect of 
cumulative glucocorticoid dose treatment on overweight. 
BMI, body mass index; FFQ, food frequency questionnaire; SHS, Swiss Health Survey 
 
METHODOLOGICAL CONSIDERATIONS  
Most of the methodological considerations of the studies included in this thesis are discussed 
in the corresponding chapter. We focus here on the relevant epidemiological issues as a whole 
to interpret the results, e.g. internal and external validity of the observed observation and 
causation.  
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Internal validity  
Challenges in dietary intake assessment 
Within the SCCSS, dietary intake was assessed with self-reported general brief questions at 
the time of first survey. These questions on fruit, vegetables, meat, fish, milk(-products), and 
fast-food were derived from the Swiss Health Survey (SHS 2007). In this thesis, I attempt to 
improve the available dietary intake information among CCS in the SCCSS follow-up 
questionnaire. We made use of a validated FFQ which was send to all CCS who filled in the 
first questionnaire and who were 16 years or older at time of the follow-up survey, used urine 
spot samples as an objective biomarker, and included comparison groups in which diet was 
assessed with the same FFQ.  
 
The used FFQ in the SCCSS follow-up questionnaire was originally only developed and 
validated for the French speaking language region of Switzerland [28, 29]. As the SCCSS is a 
nationwide study we investigated if most frequent food products consumed in the German and 
Italian speaking language regions were also included and extended the FFQ with 15 additional 
food products.  
Between 1993-2012 a small decrease in total energy intake was seen in the “Bus 
Santé” Geneva study [30]. This may suggest that the dietary habits over time including a higher 
consumption of processed food changed minimal in the French speaking language region of 
Switzerland. Therefore, although the FFQ was already developed in 1991 [28], we believe that 
our conclusions would not have substantially differed if we would have had a more up-to-date 
dietary intake assessment tool.  
The assessed absolute dietary intake needs to be interpreted with caution. Reporting 
bias could have occurred; overweight CCS tend to underreport their total energy intake but 
whether this is done in a similar degree as in the general population is unknown [31]. To adjust 
for reporting bias we excluded CCS with a potential unreliable dietary intake, e.g. extreme 
energy intakes and unrealistic values for nutrient intakes. Furthermore, in conjunction with self-
reported dietary intake from the FFQ we used urine biomarkers.  
 
Challenges in body weight and height assessment  
In the studies of this thesis, we used BMI calculations as an indirect measure of overweight 
and obesity. In the performed studies, we had information on weight and height at time of 
survey from self-administered questionnaires for CCS and most comparison groups. Study 
participants were instructed to record height without shoes and weight without clothes. 
Differential misclassification could have occurred, as overweight and obese adult participants 
tend to underestimate their weight more than normal weight participants do [32, 33].  
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The indirect measurement of body fat with BMI, instead of direct measurements like 
underwater weighting (densitometry) and dual-energy x-ray absorptiometry has several 
shortcomings. First, BMI calculations do not take age, gender, and muscle mass percentage 
into account. Second, body fat increases and lean mass decreases with age and the 
relationship between BMI and body fat differs between men and women [34]. Thus, 
participants with a similar BMI could have different body fat percentages.  
Several errors in height and weight report could have occurred. Height and weight 
might be better monitored in CCS than in the general population. This could make CCS more 
aware of their true height and weight than the general population, which could have caused 
surveillance bias. Reporting bias could have occurred as the questionnaire first asks CCS 
about late effects and then about height and weight. For example, participants with chronic 
health conditions could have underreported their weight more as they became aware of their 
health status than participants without chronic health conditions. However, because height and 
weight were self-reported in most of our study populations we expected the degree of 
nondifferential error of BMI assessment to be similar across CCS and comparison groups. An 
exception are the comparison groups in chapter 3, e.g. participants of the studies Bus Santé, 
CoLaus (“Cohorte Lausannoise”), and menuCH as their height and weight were measured by 
study staff.  
 Finally, we divided BMI into two categories: overweight (overweight and obesity) 
versus non-overweight (underweight and normal) although obesity is a chronic disease 
associated with multiple co-morbidities, whereas overweight is only a stage of pre-obesity. 
We dichotomized BMI as separate categories were small and outcomes for the categories 
overweight and obesity were in the same direction and magnitude as for the category 
overweight or obesity combined. 
 
Confounding  
Potential bias by confounding is common in observational studies and can bias the association 
of interest. Studies in this thesis (Chapter 2, 3, and 5) and other studies show that CCS with a 
good adherence to dietary guidelines and healthy body weight seem to be a more health 
conscious group who adopted various healthy lifestyle habits [4, 10]. They are more likely to 
be non-smokers [3, 10, 35] and have a higher physical activity level [10, 36-38] than those with 
a poor dietary adherence and high body weight. These differences between demographic and 
lifestyle factors between survivors (overweight/obese CCS versus those with a healthy body 
weight and CCS with a good versus a poor dietary adherence) could have affected our results. 
For this reason, we evaluated several potential lifestyle and health status-confounding factors 
in our regression models. Nevertheless, residual confounding can never be completely ruled 
out.  
 169 
 
Like in the general population, CCS with a poor health status seem to have a lower 
social economic status (SES) [39]. Within epidemiological studies, participant’s education level 
is a common used marker for SES and a strong predictor for good health and a healthy lifestyle 
[40, 41]. Within the SCCSS, some CCS were too young to reach their final level of education 
at time of survey or completed their final educational achievement with some delay [42]. For 
this reason, we used both the education level of CCS and their parents as a marker for SES. 
Adjusting for individual income would have misclassified participants as some CCS were still 
studying or chose to stay home for their children. Information on household income was often 
missing. Furthermore, simultaneous adjustment for educational level as a SES marker and 
other lifestyle factors could potentially have led to overadjustment of lifestyle factors.  
 
External validity  
In this section, we discuss the heterogeneity of the study population and the 
representativeness of the study results.  
 
Heterogeneity of the study populations  
We combined survivors of all childhood cancer diagnoses in several chapters of this thesis 
although each type of cancer has its own treatment protocols. For example, treatment duration, 
type, and dosage may vary per type of cancer as well as side effects and treatment related 
late effects. Within the different paediatric oncology clinics, we also saw differences in the used 
cancer treatment protocols for the same cancer type. For example in the past, clinics in the 
German speaking region of Switzerland tended to use more often protocols of the 
“Berlin/Frankfurt/Muenster study group” compared to the other language regions, where US 
protocols were more common.  
The risk profiles of the study populations would have been more homogenous if we 
would have investigated CCS diagnosed with the same cancer type and treated with similar 
cancer protocols. However, as childhood cancer is rare and therefore numbers are low we 
combined all types of cancer to have sufficient power and performed subgroup analyses where 
possible.  
 
Representativeness of study populations  
The representativeness of the study populations is important for the translation of our findings 
to the whole population of CCS. Within the SCCSS, selection bias in CCS could have occurred 
due to nonresponse and nonparticipation. To reduce nonresponse, eligible survivors who did 
not filled in the first questionnaire were send a second copy of the questionnaire. Non-
responders to the second copy were contacted by phone. This resulted in a response rate of 
70%. Rueegg et al. estimated the effect of nonresponse bias on selected prevalence estimates 
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(somatic health, medical care, mental health, and health behaviours) in 930 early responders, 
671 late responders, and 727 nonresponders to the first SCCSS questionnaire by constructing 
the complete population using inverse probability of participation weights. They found that 
nonresponse might only play a minor role, suggesting that responders were generalizable to 
the whole Swiss CCS population [43]. However, they did found differences in socio-
demographic characteristics between responders and nonresponders. Responders were more 
likely to be women and non-immigrants but did not have a higher socioeconomic position 
based on neighbourhood level. From studies in the general population, we know that survey 
participants have more often a higher SES and education level, are less likely to be obese, 
and have in general a healthier lifestyle, e.g. are less likely to smoke, to drink frequently, to 
have a poor diet quality, and have less health conditions compared to nonparticipants [44-46]. 
Thus, the observed dietary intake could have been better and the obesity prevalence in CCS 
could have been lower than in reality.  
For the follow-up questionnaire we selected only those survivors that filled in the first 
questionnaire. Non-responders to the follow-up questionnaire were send a second and if 
needed a third copy of the questionnaire. We obtained a response rate of 58%.  
Survival bias could have also occurred within the SCCSS as CCS who survive longer 
tend to have an overall better health [47]. Furthermore, CCS who are underweight or obese at 
diagnosis and during survivorship tend to have a higher mortality and relapse rate [48-51]. 
Therefore, survivors with a healthier lifestyle and normal body weight could have been more 
likely to be eligible to participate, since the SCCSS included only survivors who survived at 
least five years after diagnosis.  
 
In this thesis, we made use of several comparison groups reflecting the general population. 
Response rates in these comparison groups were overall lower than in CCS; SHS 2007 (66%), 
siblings (57%), Bus Santé (55-75%), SHS 2012 (53%), CoLaus (41%), and Swiss National 
Nutrition Survey (38%). These lower response rates could have affected the 
representativeness of the study populations for the general population.  
To increase the validity of the comparison between CCS and the comparison groups, 
we standardised comparison groups for gender, age, migration background, and language 
region, according to the distribution in CCS. Within the used comparison groups, more women 
and older persons were included than within CCS. Also migrants and non-German speakers 
were less frequent among siblings, but more frequent in the general population than within 
CCS. The Bus Santé and CoLaus studies included only participants from the French language 
region in Switzerland.  
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Causation  
No statement on causation can be made based of the currently conducted observational 
studies. In chapter 2, 3, 6, and 7, we made use of cohort studies with cross-sectional data. 
Since we did not have prospective follow-up data we could not assess the timing of an 
unhealthy dietary intake and weight status before, during and after treatment in CCS. Reverse 
causation could have biased our results, e.g. a lack of sports participation could have been 
due to overweight.  
 
IMPLICATIONS FOR PUBLIC HEALTH AND CLINICAL PRACTICE 
The national organisation Swiss Cancer League (www.liguecancer.ch) emphasizes in cancer 
prevention campaigns to increase fruit and vegetable consumption and reduce alcohol, red 
and processed meat intake. This could partly explain the higher levels of adherence for fruit 
and meat intake in CCS (Chapter 2). However, it is unclear to which extent CCS are aware of 
these dietary recommendations and if diet is perceived as a risk factor for late effects. Current 
CCS guidelines do not specifically focus on diet [52] or have general dietary recommendations 
[53, 54]. However, given the strong evidence about diet and health in general and the 
increasing data for CCS, focus should be placed on the importance of good eating habits and 
physical activity during annual long-term follow-up visits. Follow-up visits are especially 
recommended for CCS with moderate to severe late health effects or high risk cancer 
treatment, a group which could benefit of dietary and lifestyle counselling [55]. However, 
nutritional counselling seems not to be the standard in Switzerland in follow-up care. We 
performed a short survey among the heads of the nine Swiss paediatric oncology clinics to 
assess whether they discussed diet issues during follow-up visits. Six replied that they discuss 
diet in case CCS suffer from nutritional related late effects, and three indicated to discuss it 
routinely during each follow-up visit (personal communication). The growing research on 
dietary intake in CCS could help clinicians in the future to provide consistent uniform and 
comprehensive nutritional counselling during and after treatment.  
 
This thesis showed risk factors for overweight development in childhood cancer patients and 
survivors (Chapter 5, 6, 7). Since overweight prevalence and risk factors for being overweight 
were similar in CCS as to the general population prevention methods can be the same as in 
the general population. An important exception are CNS tumour and leukaemia survivors 
treated with ≥20 Gy CRT and patients diagnosed with ALL and lymphoma, who have the 
highest risk of becoming overweight. The importance of obesity on long-term health needs to 
be raised especially in these patients and survivors. Since early overweight is a risk factor for 
overweight later in life, weight management interventions should be individually tailored during 
treatment. However, counselling during this period, when patients and families face the crisis 
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of a life-threatening illness and nutritional status is not a first priority, is challenging. In addition, 
children may receive high steroid doses, which increase appetite and fatty tissue, and they 
may experience fatigue or be immobilized for some time, which reduces their physical activity. 
During clinical follow-up, visits with multi-profession teams, including physicians, dieticians, 
nurses, and physiotherapists, might be a promising approach. Existing surveillance 
recommendations should be harmonised using an evidence-based approach to effectively 
implement standardised care in Switzerland and the rest of the world. International harmonised 
recommendation could benefit early detection, prevention, and intervention of overweight.  
 
FUTURE RESEARCH PERSPECTIVES  
Based on current evidence and the conclusions in this thesis, future research needs to be 
performed before evidence-based and standardised dietary and overweight/obesity 
surveillance guidelines for CCS can be composed. We recommend several future research 
opportunities in dietary assessment and weight management below.  
 
Future research opportunities in dietary assessment  
• We made use of a FFQ that was developed and validated only for the French-speaking Swiss 
adult population. I extended the FFQ with additional food products based on data of the Swiss 
National Nutrition Survey to include frequent food products consumed in the German and 
Italian-speaking part of Switzerland. Since the currently used FFQ is not validated for whole 
Switzerland, a new FFQ should be developed suitable for all language regions (Chapter 3).  
• Although FFQs have become the primary method for measuring dietary intake in 
epidemiologic studies [56], continues efforts are needed to develop a new dietary assessment 
tool. This new tool should be easier to complete, rely less on memory, have correct portion 
sizes, not be restricted to a given food list, and rely less on question interpretation. Assessment 
via a smart phone application with a photo function could be the base for a new tool.  
• In this thesis, we made the first steps to investigate the dietary intake of CCS long after 
treatment, when late effects could already have occurred and might influence dietary intake. 
Prospective and repeated dietary assessments from treatment onwards could investigate the 
potential association between dietary intake and late chronic health effects. As a next step, I 
recommend to investigate dietary interventions to prevent or reduce nutrition-related late 
effects during early survivorship.  
• Evidence based dietary guidelines specific for CCS are needed to avoid long-term morbidity 
in this vulnerable population. Future epidemiologic studies should be performed in different 
types of childhood cancer so that dietary recommendations, if relevant, could be adapted to 
diagnosis and treatment exposures. A detailed and standardized survey among all paediatric 
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oncologists in Switzerland would give more information about the current situation in nutritional 
counselling practice.  
• Currently, it is unclear to which extent CCS are aware of dietary recommendations and if diet 
is perceived as a risk factor for late effects. Therefore, I recommend a survey among CCS to 
investigate their attitude and knowledge of nutrition.  
 
Future research opportunities in weight management 
• Most research to date on overweight and obesity in CCP and CCS are based on BMI 
calculations from self-reported height and weight. I recommend direct body fat measurements 
as indirect measurements can introduce differential misclassification, which may result in a 
bias towards or away from the null. Furthermore, direct body fat measurements will give more 
insights in CCS body composition; lean mass versus fat mass. If direct body fat measurements 
are impossible to perform, I recommend BMI calculations with standardised measured height 
and weight by medical staff.  
• Future studies are needed to investigate risk factors for overweight and obesity development 
over time, to which extent the risk for overweight and obesity differs between cancer types, 
and if there are any lifestyle interventions that can alter this risk. Our results indicated that CRT 
is a risk factor for overweight in CCS (Chapter 6 and 7), but less is known about abdominal 
radiation, TBI, and other fields, their potential dosage cut-off values, and if fractionation 
matters. We found that glucocorticoid treatment is not a reason for concern for long term 
overweight in CCS but this needs to be confirmed in other studies with exact patient dose 
levels, bigger study population of CCS treated with dexamethasone, and direct measurements 
of body fat and lean body mass (Chapter 7).  
• We do not know if risk factors for overweight/obesity are country specific or if they are 
applicable to all CCS worldwide. Therefore, we will investigate if the effect of risk factors on 
overweight and obesity are the same in US and Swiss CCS within a collaboration with the US 
CCSS, Duke Cancer Institute Durham, Cancer Survivor Program - Children`s Health Care of 
Atlanta, and the Memorial Sloan Kettering Cancer Center New York (Appendices- Future 
projects).  
• International evidence-based clinical practice guidelines for surveillance of overweight and 
obesity in CCS are needed to combine all available information and look for areas of 
concordance and discordance across existing guidelines. The metabolic syndrome workgroup 
of the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG, 
www.ighg.org), in which I am a member, is working on the development of these surveillance 
guidelines (Appendices- Future projects).  
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Chapter 9 
 
 
Summary 
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SUMMARY 
 
Late effects like cardiovascular and endocrine disorders secondary to childhood cancer or its 
treatment are frequently reported in childhood cancer survivors (CCS) (Chapter 1). Health 
promoting lifestyles, including improved diet and a healthy body weight could modify the 
morbidity and mortality trajectory that CCS experience due to their earlier cancer treatment. 
Therefore, the aims of this thesis were to get a better understanding of the dietary intake of 
Swiss CCS and to gain insights in the potential risk factors for being overweight during and 
long after treatment (Chapter 1). 
In chapter 2 we compared adherence to national dietary recommendations between 
1864 CCS, 698 siblings, and 8258 participants in the Swiss Health Survey (SHS), a 
representative survey of the general population, identified determinants of adherence, and 
assessed the association of adherence with cardiovascular disease (CVD) risk profiles. We 
found that only 43% of the CCS met the recommended dietary intakes for meat, 34% for fruit, 
30% for fish, 18% for dairy products, 11% for vegetables, and 7% for combined fruit and 
vegetables. Results were similar for both control groups. In all groups, dietary adherence was 
associated with gender, parental education, migration background, language region in 
Switzerland, smoking, alcohol consumption, and sport participation. CCS with a higher CVD 
risk profile because of cardiotoxic treatment had no better adherence. Therefore, based on 
this research we conclude that CCS have similar food patterns as their siblings and the general 
population, and poorly adhere to current recommendations. Awareness of the importance of a 
healthy diet should be raised among CCS, to prevent chronic diseases like CVD. 
In chapter 3 we assessed dietary intake with a food frequency questionnaire (FFQ). 
We assessed dietary intake and quality of 878 CCS in comparison to three random samples 
of the general Swiss population represented by data from 9216 participants of Bus Santé, 1311 
participants of CoLaus, and 1189 participants of the Swiss National Nutrition Survey. We also 
identified whether clinical characteristics had an impact on CCS long-term dietary intake. 
A multicentre validation study has been set up in order to investigate the relation 
between the self-reported FFQ (Chapter 3) and the objective biochemical indicators obtained 
from urine spots. CCS who had filled in the FFQ during the follow-up study of the SCCSS were 
invited to collect a first morning urine spot at home and send it to CHUV. Hospitalised childhood 
cancer patients (CCP) were asked to collect an urine spot sample during their stay at CHUV 
or HUG. These samples were used to control the quality of the urine samples that were send 
by post mail by the CCS. The design, current status, and the study setup are discussed in 
chapter 4.  
In chapter 5, 6, and 7 we showed results of studies that investigated the socio-
demographic, lifestyle, and clinical risk factors to develop overweight during and long after 
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treatment. Being overweight or obese is a modifiable risk factor to develop chronic health 
conditions like diabetes, dyslipidaemia, hypertension, and cardiovascular disease. Since CCS 
are more susceptible to develop these chronic health conditions due to their cancer treatment, 
it is important to prevent an early onset of excessive weight gain and keep a healthy weight 
throughout life. 
In chapter 5 we assessed prevalence of overweight in CCP at diagnosis and at the 
end of treatment, determined risk factors, and identified weight change during treatment by 
type of cancer. We performed a multicentre cohort study in which we collected height and 
weight measurements of 327 CCP at diagnosis and repeatedly during treatment. We found 
that at diagnosis 8% of the CCP were overweight versus 13% at end of treatment. Risk factors 
for weight gain during treatment were being a boy and having been diagnosed with ALL or 
lymphoma. During the first half of treatment, BMI Z-scores increased in ALL and lymphoma 
patients, whereas for patients with CNS tumours, sarcoma, or other types of cancer BMI Z-
scores tended to drop initially. During the second half of treatment BMI Z-scores of all patients 
tended to increase. Based on these findings, we concluded that CCP diagnosed with ALL or 
lymphoma are at increased risk of weight gain during treatment, and might particularly benefit 
from early lifestyle interventions. 
In chapter 6 we assessed the prevalence of overweight in 2365 CCS, with a focus on 
leukaemia survivors, compared it with their peers (819 siblings, and 9591 SHS participants), 
and determined potential risk factors. We found that the prevalence of and risk factors for being 
overweight are similar in long-term CCS and their peers. Therefore, it is suggested that 
prevention methods can be the same as in the general population. An important exception are 
CCS treated with cranial radiotherapy (CRT) ≥20 gray who may need extra attention during 
follow-up care.  
In chapter 7 we investigated if overweight in long-term CCS was associated with the 
cumulative glucocorticoid dose received, if there was a dose-response relationship between 
cumulative glucocorticoid dose and BMI, and if the respective effects of prednisone and 
dexamethasone differed. We studied the entire group of 1936 CCS, and separately 546 ALL, 
114 NHL, and 195 HL survivors. Prevalence of overweight was 24% in CCS treated with 
glucocorticoids only, 37% in those with CRT, and 49% in those with both glucocorticoids and 
CRT. We found no evidence for a dose-response relationship between cumulative 
glucocorticoid doses and overweight and no evidence that CRT modified the effect of 
cumulative glucocorticoid dose treatment on overweight. This study suggested that 
glucocorticoids used for the treatment of childhood cancer are not associated with long-term 
risk of overweight. 
Concluding, our studies show that CCS equally poor adhere to dietary guidelines as 
the general population. In addition, overweight prevalence and risk factors for being overweight 
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are similar as to the general population. This suggests that prevention methods can be the 
same as in the general population. An important exception are survivors treated with cranial 
radiotherapy of 20 gray or more who may need extra attention during follow-up care. Besides, 
patients diagnosed with ALL or lymphoma might benefit from early lifestyle interventions.  
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FUTURE PROJECTS I 
  
Childhood Cancer Survivor Study 
Analysis Concept Proposal 
 
STUDY TITLE 
Risk factors for overweight and obesity in childhood acute lymphoblastic leukemia survivors 
in the US and Switzerland: A comparison of two cohort studies  
 
WORKING GROUP 
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Kevin.Oeffinger@duke.edu; phone 919-668-0222  
 
Lillian Meacham, MD, PhD  Pediatric Endocrinologist  
Medical Director of Cancer Survivor Program, Children`s Health 
Care of Atlanta, GA, USA  
lmeacha@emory.edu; phone 404 785 1717  
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Emily Tonorezos, MD  General Internist  
Adult Long-Term Follow-Up Program, Memorial Sloan Kettering 
Cancer Center, New York, NY, USA  
tonoreze@mskcc.org; phone 616-888-80802  
 
Yutaka Yasui, PhD   Statistician  
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Department, Memphis, TN, USA  
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St. Jude Children`s Hospital, Epidemiology & Cancer Control 
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Greg.Armstrong@stjude.org; phone 901-595-5892  
 
 
BACKGROUND & RATIONALE  
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer accounting for 
25% of all cancers in childhood and adolescence [1, 2]. Five-year survival rates exceed 80% 
leading to a growing population of long-term survivors of pediatric ALL [1-3]. Late effects 
after treatment for pediatric ALL are significant and contribute to increased morbidity and 
mortality later in life [4, 5]. Therefore, it is important to identify additional, preventable risk 
factors such as overweight and obesity to reduce the already elevated burden of chronic 
diseases. Overweight and obesity are reported frequently in pediatric ALL survivors (6-8). 
Multiple risk factors seem to contribute to the development of overweight and obesity in 
pediatric ALL survivors:  
• Age at survey influences overweight and obesity prevalence. In the Swiss Childhood 
Cancer Survivor Study (SCCSS), risk factors for overweight and obesity were both 
young (5-14 years) and older (25-29 years) age in childhood cancer survivors 
including ALL survivors [9]. Children and adolescent ALL survivors were also at 
higher risk for obesity in a meta-analysis including studies from several countries [8].  
• Conflicting results have been described for gender; female ALL survivors were more 
overweight or obese in the US Childhood Cancer Survivor Study (CCSS) [10-12], 
whereas male ALL survivors were more overweight in the SCCSS [9].  
• Other socio-demographic factors potentially also increase the risk for overweight 
and obesity, e.g. race/ethnicity, migration background, lower education status [13, 
14].  
• Lifestyle factors including physical inactivity and an unhealthy diet may increase the 
risk for overweight and obesity like in the general population [15]  
• Age at diagnosis; children diagnosed at a young age (<5 years) [7, 8].  
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• A clear association between cranial radiation therapy (CRT) and increased BMI has 
been found in the CCSS [10-12] and the SCCSS [13, 16]. In contrast, a systematic 
review by Zhang et al. described conflicting results for this association. In the meta-
analysis that they performed they found a high prevalence of obesity in ALL survivors 
regardless of CRT therapy [17].  
 
The prevalence of overweight and obesity varies across studies and countries. In a 
systematic review including US and European studies, the prevalence of overweight and 
obesity ranged from 34 to 46% for long-term (≥10 years off treatment) pediatric ALL survivors 
of whom the majority were adults [8]. A US study reported a prevalence of overweight and 
obesity of up to 60% in long-term adult pediatric ALL survivors [6]. In contrast, the prevalence 
of overweight and obesity was only 26% in Swiss adult survivors 16 years after treatment for 
pediatric leukemia, of whom 88% had ALL [13]. But the US and Swiss study populations 
differed in terms of socio-demographic (age at survey, time since diagnosis, race/ethnicity, 
migration background, living situation), socio-economic (health insurance, education level), 
lifestyle (smoking, physical activity, diet), and clinical factors (treatment protocol, frequency 
and dose of CRT, chemotherapy). This may have influenced the observed overweight and 
obesity prevalence. Therefore it is difficult to conclude the reasons of the observed 
differences.  
 
We propose a de novo analysis of the CCSS and SCCSS datasets that allows a direct 
comparison between results from the US and Swiss datasets, by: 
• Applying the same inclusion criteria for the US and Swiss study population, so that 
we have a broad overlap between the two populations regarding age at diagnosis, 
age at study, and treatment era.  
• Adjusting the dataset and the analysis for important confounding factors (gender, 
age at diagnosis, age at study)  
• Using the same analytical approach.  
 
This method will give better insights into the risk factors and might help to understand why 
prevalence of overweight and obesity differs between the two countries. 
 
AIMS & OBJECTIVES  
We aim  
1) To compare the overweight and obesity prevalence between pediatric ALL 
survivors and their siblings in the US and Switzerland.  
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Hypothesis: We hypothesize that the absolute prevalence of overweight and obesity 
in ALL survivors and their siblings is higher in the US than in Switzerland. But we 
hypothesize that the association between cancer survivorship and overweight and 
obesity is similar.  
 
2) To identify socio-demographic (gender, age at survey, race/ethnicity, migration 
background, living situation), socio-economic (health insurance, education level), 
lifestyle (smoking, physical activity, diet), and clinical (year of diagnosis, age at 
diagnosis, radiation, chemotherapy) risk factors for overweight and obesity and 
investigate whether the direction and strength of the effects are similar in the US and 
Switzerland.  
 
Hypothesis: We hypothesize that the effects of treatment are similar in both 
countries, but that effects of socio-demographic, socio-economic, and lifestyle factors 
differ. 
 
ANALYSES FRAMEWORK  
Outcome of interest  
Overweight and obesity (body mass index [BMI] as continuous variable)  
 
Study population  
Inclusion criteria 
1) All CCSS survivors diagnosed with ALL (diagnosed 1976-2010) and siblings, ≥18 
years of age at time of survey (baseline; follow-up 1, 2000; follow-up 2, 2003; follow-
up 3, 2005; follow-up 4, 2007; follow-up 5, 2014).  
2) All SCCSS survivors diagnosed with ALL (diagnosed 1976-2010) and siblings, ≥18 
years of age at time of survey (baseline 2007-2013, follow-up 2017).  
 
Potential explanatory risk factors (Figure 1)  
• Sociodemographic risk factors  
 Age at survey; young and older age [9, 17]  
 Gender; contradicting associations [6, 7, 9, 17] 
 Race/ethnicity; Hispanic ethnicity [14] 
 Migration background [13] 
 Living situation; living alone  
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• Socioeconomic risk factors  
 Health insurance: health care access  
 Socio-economic status/education level; low education level [9] 
• Lifestyle factors  
 Smoking  
 Physical activity/sports; physical inactivity [9] 
 Diet; unhealthy diet  
• Clinical factors  
 Year of diagnosis, 
 Age at diagnosis; younger age [7, 8, 18, 19] 
 Radiation  
- Cranial [6-9, 16, 20] 
- Total body irradiation: proxy for more severe disease, involvement of cranial field 
[21]  
 Chemotherapy, Glucocorticoids (prednisone, dexamethasone [yes/no]): no long-
term association [16], short-term [15, 22-25] 
 
 
Figure 1. “Lifetime causal diagram” of overweight and obesity at survey  
BMI, body mass index; dx, diagnosis 
*: not available information 
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Statistical plan  
Direct comparisons between the populations of interest (survivors versus siblings, US versus 
Swiss populations) are problematic because these populations may differ in many aspects 
which may confound associations assessed. For comparisons between survivors with 
siblings (aim 1), we will attempt to correct for this using weighted analyses. Siblings will be 
weighted such that they become representative of survivors regarding the distribution of key 
socio-demographic variables (gender, age at survey, race/ethnicity, and migration 
background). For this, we will first fit a logistic regression with survivorship status as the 
outcome and the key demographic variables as predictors. Analysis weights for siblings will 
then be calculated as the inverse probability of being a survivor estimated from this 
regression. We will not pool the data from the CCSS and SCCSS since the study populations 
differ in overweight and obesity prevalence, study design, and data collection. We will rather 
run the same analysis in both populations and qualitatively compare results.  
For better comparison between ALL survivors and siblings, we will weight siblings for gender 
and age at survey (inverse probability weighting). Standardization will be performed for the 
US and Swiss population separately. Furthermore, we will match Swiss with US ALL 
survivors based on gender, year of diagnosis, and age at survey on a 1:3 ratio or with 
frequency matching. 
We will describe characteristics of survivors (socio-demographic, socio-economic, lifestyle, 
and clinical) and siblings (socio-demographic, socio-economic, and lifestyle) using means 
(SD) and medians (IQR) in both cohorts.  
 
To evaluate the difference in overweight and obesity prevalence between ALL survivors and 
siblings (aim 1), we will perform univariable and multivariable logistic regressions. We will 
adjust for socio-demographic, socio-economic, and lifestyle factors and include survivorship 
as an exposure. Variables with p-values <0.01 in univariable models will be jointly included in 
a multivariable model. We will run models for both the US and the Swiss population. 
We will use multinomial logistic regressions [BMI categories] to determine risk factors 
associated with overweight and obesity at survey in pediatric ALL survivors (aim 2). 
Regressions will be run separately for US and Swiss pediatric ALL survivors. We will select 
potential risk factors a priori based on a literature review, e.g. gender, age at diagnosis, age 
at survey, physical activity, cumulative CRT, steroid usage. Variables with p-values <0.01 in 
univariable models will be jointly included in a multivariable model.  
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TABLES AND FIGURES 
  
Table I. Sociodemographic and lifestyle characteristics by country population 
  ALL survivors Siblings 
Characteristics  USA 
n=…. 
Switzerland 
n=671 
USA 
n=…. 
Switzerland 
n=678 
Gender, n (%)     
 Female  319 (48)  402 (59) 
 Male  352 (52)  276 (42) 
Age (years), n (%)     
 Mean (SD)  23.5 ± 7.8  29.4 ± 8.0 
 Median (IQR)  21.9 (17.5-28.2)  28.1 (23.0-34.8) 
 18-24  416 (62)  234 (35) 
 25-34  190 (28)  281 (41) 
 35-44  61   (9)  136 (20) 
 ≥45  4     (<1)  27   (4) 
Country of birth – Race/ethnicity, n (%)     
 Non-Hispanic White  660 (98)  676 (100) 
 Non-Hispanic Black  -   
 Hispanic  1      (<1)   
 Asian  5      (1)   
 Other/Unknown  5      (<1)  2      (<1) 
Living situation, n (%)     
 Alone  90   (13)*  97   (14) 
 Other  581 (87)  581 (86) 
Education level (highest degree), n (%)     
 Lower than university/ post graduate   572 (85)*  502 (74) 
 University/post graduate  99   (15)  176 (26) 
Current employment, n (%)     
 No  367 (55)*  236 (35) 
 Yes  304 (45)  442 (65) 
Insurance, n (%)     
 No  -  - 
 Yes  671 (100)  678 (100) 
Smoking status, n (%)     
 Never  449 (67)*  423 (62) 
 Former  76   (11)  124 (18) 
 Current  146 (22)  131 (19) 
Alcohol consumption, n (%)     
 Never/rarely  382 (57)*  358 (53) 
 Weekly, ≥1 std drink/week  270 (40)  290 (43) 
 Daily, 1 std drink/day  16   (2)  18   (3) 
 Frequently, >1 std drink/day  3     (<1)  12   (2) 
Physical activity, n (%)     
 Inactive  106 (16)*  108 (16) 
 Activea  437 (65)  570 (84) 
 Missing  128 (19)   
BMI, n (%)     
 Underweight  51    (8)*  12   (2) 
 Normal   443 (66)  477 (70) 
 Overweight  120 (18)  152 (22) 
 Obese  29   (4)  37   (5) 
 Missing  28   (4)   
IQR: interquartile range, SD: standard deviation  
a: ≥150 minutes of moderate intense or ≥75 minutes of vigorous intense or a combination of moderate and vigorous intense physical 
activity per week. 
* Will be updated for Switzerland after follow-up information is available – currently in data entry phase   
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Table II. Clinical characteristic of ALL survivors by country 
  ALL survivors 
Characteristics  US 
n= 
Switzerland 
n=671 
Age at diagnosis (years), n (%)   
 Mean (SD)  6.4 ± 4.2 
 Median (IQR)  5.1 (3.1-9.1) 
 <5  331 (49) 
 6-9  196 (29) 
 10-14  118 (18) 
 ≥15  26   (4) 
Year of diagnosis, n (%)   
 <1980  63   (9) 
 1980-1990  219 (33) 
 1991-2000  267 (40) 
 2001-2010  122 (18) 
Time since diagnosis, n (%)   
 Mean (SD)  17.1 ± 7.4 
 Median (IQR)  15.8 (11.0-22.3) 
 <10  125 (19) 
 11-14  176 (26) 
 15-19  149 (22) 
 ≥20  221 (33) 
Chemotherapy, n (%)   
 Any  499 (74) 
 Prednisone  495 (74) 
 Dexamethasone  173 (26) 
 Prednisone and dexamethasone  169 (25) 
 Missing  153 (23) 
Cranial radiation therapy (gray), n (%)   
 None  521 (78) 
 <18   67   (10) 
 ≥18  83   (12) 
Abdominal radiation therapy (gray), n (%)   
 None  670 (100) 
 <10  1      (<1) 
 ≥10 to <20  - 
 ≥20  - 
Total body radiation, n (%)   
 No  656 (98) 
 Yes  15   (2) 
Hematopoietic stem cell transplantation, n (%)   
 No  642 (96) 
 Yes  29   (4) 
Relapse, n (%)   
 No  590 (88) 
 Yes  81   (12) 
IQR: interquartile range, SD: standard deviation 
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Table III. Overweight and obesity in ALL survivors compared to siblings by country 
ALL: acute lymphoblastic leukemia 
a: Standardized on gender, age at survey… according to ALL survivors  
b: adjusted for…. 
 
 
 
 
Table IV. Predictors for overweight and obesity in ALL survivors by country (retrieved from 
multinomial logistic regressions) 
CI: confidence interval; OR: odds ratio; ALL: acute lymphoblastic leukemia 
a: Column percentages are given;  
b: Adjusted for: 1) socio-demographic/-economic variables: gender, age, education … and 2) lifestyle factors: smoking, physical 
activity, …;  
c: global p-value for an association between overweight/obesity and the variable as a whole (Wald test comparing models with 
and without the variable). 
 
 
 
 Non overweight/obese 
OR (95%CI) 
Overweight 
OR (95%CI) 
Obese 
OR (95%CI) 
 Univariable Multivariableb Univariable Multivariableb Univariable Multivariableb 
US 
   Siblingsa  
   ALL survivors 
 
1.00 (ref) 
 
 
1.00 (ref) 
 
 
1.00 (ref) 
  
 
1.00 (ref) 
 
 
1.00 (ref) 
 
 
1.00 (ref) 
 
Switzerland 
   Siblingsa  
   ALL survivors 
 
1.00 (ref) 
 
 
1.00 (ref) 
 
 
1.00 (ref) 
 
 
1.00 (ref) 
 
 
1.00 (ref) 
 
 
1.00 (ref) 
 
 Overweight Obese 
 US ALL survivors Swiss ALL survivors US ALL survivors Swiss ALL survivors 
 %a    OR (95%CI)b p-valuec %a OR (95%CI)b p-value c %a OR (95%CI)b p-value c %a OR (95%CI)b p-value c 
Gender              
Female  1.00 (ref)   1.00 (ref)   1.00 (ref)   1.00 (ref)  
Male             
Age, y             
  18-24  1.00 (ref)   1.00 (ref)   1.00 (ref)   1.00 (ref)  
  25-34             
  35-44             
  ≥45             
…             
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Figure 1 (EXAMPLE). Risk factor specific OR and 95%CI for overweight in Swiss and US 
pediatric ALL survivors (from multivariable logistic regression1)  
Squares, OR for overweight; whiskers, the respective 95% CI 
Abbreviations: CI, confidence interval; CRT, cranial radiation therapy; Gy, gray  
1 Adjusted for gender, age … 
 
 
 
 
  
 : Swiss ALL survivors 
 : US ALL survivors   
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FUTURE PROJECTS II 
 
International Late Effects of Childhood Cancer Guideline Harmonization Group 
(IGHG): Metabolic Syndrome 
 
The IGHG, is a worldwide effort initiated by several national guideline groups and the Cochrane 
Childhood Cancer Group in partnership with the ‘PanCare Childhood and Adolescent Cancer 
Survivor Care and Follow-up Studies’ (PanCareSurFup) Consortium to collaborate in guideline 
development (www.ighg.org). 
 
Representatives of the North American Children’s Oncology Group (COG), the Dutch 
Childhood Oncology Group (DCOG), the Swiss Childhood Cancer Survivor Study group 
(SCCSS), and members of other international paediatric oncology groups will work together to 
develop guidelines for metabolic syndrome surveillance. The members will look for areas of 
concordance and discordance across existing guidelines. They devised clinical questions to 
address areas of discordance for surveillance of metabolic syndrome covering obesity, 
hypertension, diabetes, and hyperlipidaemia and following key issues: who needs surveillance; 
at what age or time from treatment should screening be initiated; how often, and what 
surveillance modality should be used (obesity and impaired glucose metabolism/ diabetes 
mellitus). Please, see below the specific (sub)questions for the obesity work group where I 
take part in.  
 
Working group obesity 
 
Overweight/Obesity – Who needs surveillance?  
Definition: Overweight/Obesity: includes BMI ≥25 kg/m2, BMI > 95th percentile, increased waist 
circumference, increased waist-hip ratio, increased body fat mass  
 
Research questions: 
1. What is the risk of obesity in childhood, adolescent, and young adult (CAYA) cancer 
survivors compared to the general population of the same age? 
2. Treated with chemotherapy; do risks differ between different agents? What is the risk 
after higher doses? 
3. Treated with radiotherapy 
a. Cranial  
b. Abdominal 
c. Total body irradiation 
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d. Other fields 
e. Is dose relevant?  
f. Does fractionation matter? 
4. Treated with hormonal therapy 
5. Treated with steroids 
a. Is type of steroids, dose or potency relevant? 
6. Treated with stem cell transplantation 
7. Cranial surgery (hypothalamus) 
8. Does the risk of obesity in CAYA cancer survivors differ between sexes?  
9. Does the risk of obesity in CAYA cancer survivors differ by races/ethnicities?  
10. Does the risk of obesity in CAYA cancer survivors depend on the age at treatment?  
11. What is the evidence that endocrine abnormalities affect the risk of obesity in CAYA 
cancer survivors? 
a. Gonadal hormone status 
b. Thyroid hormone deficiency or excess 
c. Growth hormone or other pituitary hormone deficiencies or excess 
d. Does treatment of these endocrine abnormalities alter the risk? 
12. Is the risk of obesity in CAYA cancer survivors associated with lifestyle factors?  
a. Smoking, physical activity, diet? 
b. Are there any lifestyle interventions that alter this risk?  
13. Is there a role of pre-treatment factors (e.g. birthweight, body weight status at 
diagnosis)? 
14. Do cancer-unrelated factors modify the risk for obesity in cancer survivors (e.g. weight 
status of parents, ethnicity, socioeconomic status)?  
15. Does the risk for obesity in CAYA cancer survivors differ between different cancer 
types? 
a. Leukaemia’s, lymphomas 
b. Brain tumours 
c. Solid tumours, including musculoskeletal tumours 
 
Obesity – What surveillance modality should be used?  
16. What is the value of BMI versus waist circumference vs. measurement of body 
composition (e.g. waist to height ratio or percent body fat by skin folds or dual energy 
x-ray absorptiometry) to define obesity in CAYA survivors? 
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Obesity – At what age or time from exposure should surveillance be initiated? At what 
frequency should surveillance be performed? 
17. What is the latency time (time of onset) to develop obesity in CAYA cancer survivors? 
18. What is the likelihood of change (improvement or deterioration) of body weight/waist 
circumference in CAYA cancer survivors after cancer treatment (chemotherapy, 
hormonal therapy, radiotherapy and/or stem cell transplantation) 
a. What is the timing of such change?  
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Team members International Harmonization of Metabolic Syndrome Surveillance 
Guidelines for Childhood, Adolescent and Young Adult Cancer Survivors 
 
Chairs: 
Oeffinger, K. 
Gietema, J. 
Kremer, L. 
Skinner, R. 
Hudson, M. 
 
Co-Chairs: 
Nuver, J. 
Tonorezos, E. 
 
Advisor: 
Mulder, R. 
 
Working 
Group: 
Obesity Hypertension Diabetes Hyperlipidaemia 
 
Metabolic syndrome/ 
CVRF Cluster 
Leader: Kamdar, K. Armenian, S. Neville, K. Fossa, S. van den Heuvel-Eibrink, M. 
Members: Belle, F. 
Lupo, P. 
Prasad, P. 
Ness, K. 
Denzer, C. 
Schindera, C. 
Otth, M. 
Steinberger, J. 
Mulrooney, D. 
van Dalen, E. 
Haugnes, H.S 
Feldman, D. 
Friedman, D. 
Chemaitilly, W. 
Ehrhardt, M. 
Neggers, S. 
Wei, C. 
Fullbright, J. 
Haupt, R. 
Morsellino, V. 
Feli, F. 
 
Walwyn, T. 
Levitt Haworth, G. 
Rath, S. 
Nock, N. 
Giwercman, A. 
Passmore, J. 
Bardi, E. 
Number of 
abstracts 
for review 
1562 1160 638 483 371 
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Cochrane systematic literature search 
 
P (Population)  Childhood, adolescent and young adult cancer survivors  
I (Etiologic/risk factor) Chemotherapy (dose), radiotherapy (dose), hormonal therapy, 
HSCT, steroids, surgery, gender, race/ethnicity, age, family 
history, endocrine abnormalities, lifestyle factors, pre-treatment 
factors 
C (Comparison)  General population for Q1, N/A for other questions 
O (Outcome)  Obesity 
 
Search 1:  
Childhood 
cancer 
(leukemia OR hemothe* OR hemother* OR (childhood ALL) OR AML OR 
lymphoma OR hemothe* OR hemoth OR hemoth* OR T-cell OR B-cell OR 
non-hodgkin OR sarcoma OR sarcom* OR sarcoma, Ewing’s OR Ewing* OR 
osteosarcoma OR hemotherapy* OR wilms tumor OR wilms* OR 
nephroblastom* OR neuroblastoma OR neuroblastom* OR 
rhabdomyosarcoma OR rhabdomyosarcom* OR teratoma OR teratom* OR 
hepatoma OR hepatom* OR hepatoblastoma OR hepatoblastom* OR PNET 
OR medulloblastoma OR medulloblastom* OR PNET* OR neuroectodermal 
tumors, primitive OR retinoblastoma OR hemotherapy* OR meningioma OR 
hemothera* OR glioma OR gliom*) OR (pediatric oncology OR paediatric 
oncology) OR (childhood cancer OR childhood tumor OR childhood tumors)) 
OR (brain tumor* OR brain tumour* OR brain neoplasms OR central nervous 
system neoplasm OR central nervous system neoplasms OR central 
nervous system tumor* OR central nervous system tumour* OR brain 
cancer* OR brain neoplasm* OR intracranial neoplasm*) OR (leukemia, 
lymphocytic, acute) OR (leukemia, lymphocytic, acute*) OR breast cancer at 
a young age OR young breast cancer survivor OR testicular cancer OR 
germ cell cancer OR germ cell tumor OR seminoma OR seminoma* OR non-
seminoma OR non-seminom* 
Search 2:  
Chemotherapy 
Antineoplastic Protocols OR Antineoplastic Combined Chemotherapy 
Protocols OR Chemoradiotherapy OR Chemoradiotherapy, Adjuvant OR 
Chemotherapy, Adjuvant OR Consolidation Chemotherapy OR Induction 
chemotherapy OR Maintenance chemotherapy OR Chemotherapy, Cancer, 
Regional Perfusion OR Antineoplastic agents OR hemotherapy* OR high-
dose chemotherapy OR chemotherapy dose OR cumulative dose OR 
cytostatic agents 
Search 3:  
Radiotherapy 
Radiotherapy OR radiation OR radiation therapy OR irradiation OR irradiat* 
OR radiation injuries OR injuries, radiation OR injury, radiation OR radiation 
injury OR radiation syndrome OR radiation syndromes OR syndrome 
radiation OR radiation sickness OR radiation sicknesses OR sickness 
radiation OR radiation* OR irradiation OR radiations OR radiation dose OR 
radiation volume OR radiotherapy fractionation 
OR stereotactic RT OR stereotactic radiotherapy[tiab] OR gamma knife OR 
intensity modulated radiotherapy OR IMRT OR radiotherapy, intensity-
modulated[mh] OR (three dimenstional OR 3D OR 3d CRT) OR image 
guided radiotherapy OR IGRT OR radiotherapy, image-guided[mh] OR 
photon radiotherapy OR XRT OR “photons/therapeutic use”[Mesh] OR 
proton radiotherapy OR PRT OR proton therapy OR proton radiation OR 
proton beam OR carbon ion radiotherapy) 
AND 
a. cranial field 
b. abdominal field 
c. total body irradiation  
d. other fields 
Search 4: 
Hormonal 
therapy  
Hormonal therapy OR Endocrine therapy OR tamoxifen OR aromatase 
inhibitors OR androgen deprivation therapy OR antiandrogens OR hormone 
therapy OR estrogen/hormone receptor positive OR fulvestrant  
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Search 5: 
HSCT 
Hematopoietic stem cell transplantation OR HSCT OR stem cell 
transplantation OR conditioning therapy OR conditioning regimen OR 
reduced intensity conditioning OR allogeneic transplantation OR autologous 
transplantation OR reduced intensity transplantation OR graft versus host 
disease OR graft-versus-host OR GVHD 
Search 6: 
Steroids 
Glucocorticoids OR glucocorticoids therapy OR glucocorticoids 
administration OR steroids OR steroid hormones OR high dose steroids OR 
dexamethasone OR prednisone  
Search 7: 
Surgery 
Surgery OR site of syrgery OR surgery, site OR hypothalamic surgery OR 
pituitary surgery OR cranial surgery OR craniotomy OR surgery, 
hypothalamic–pituitary axis OR orchidectomy OR hemiorchidectomy OR 
hemicastration OR ovariectomy OR salpingo-oophorectomy OR surgery, 
thyroid, OR surgery, testis OR surgery, adrenal 
Search 8: 
Gender 
Sex OR gender OR female sex OR male sex OR female gender OR male 
gender 
Search 9: 
Race/ethnicity 
Race OR racial difference OR racial influence OR ethnicity OR racial/ethnic 
groups 
Search 10: 
Age 
Age at diagnosis OR age at treatment OR age at follow-up OR stage of 
puberty OR age at menarche 
Search 11: 
Endocrine 
abnormalities 
Endocrine abnormalities OR endocrine effects OR endocrine disorders OR 
endocrine dysfunction OR endocrine complications OR hormonal 
abnormalities OR hormonal disorders OR hormonal dysfunction OR 
endocrine system OR gonadal OR hypogonadism OR gonadotoxicity OR 
hypogonadal OR testosterone OR hormone supplements OR thyroid 
hormone deficiency OR thyroid hormone excess OR hyperthyroidism OR 
hypothyroidism OR thyroid supplements OR growth hormone OR pituitary 
hormone OR hypopituitarism OR pituitary disorders OR growth hormone 
deficiency OR hormone supplements OR endocrine deficiency OR endocrine 
excess OR pituitary-hypothalamus 
Search 12: 
Lifestyle 
factors 
Lifestyle OR lifestyle factors OR diet OR dietary habits OR healthy diet OR 
exercise OR sedentary OR physical activity OR physical fitness OR smoking 
OR cigarette use OR smoking cessation OR lifestyle intervention OR lifestyle 
program OR weight management OR health behavior OR weight loss 
Search 13: 
Pretreatment 
factors 
Birthweight OR weight at diagnosis OR comorbid conditions OR 
comorbidities OR chronic conditions OR parental weight OR maternal weight 
OR maternal BMI OR maternal body mass index 
Search 14: 
Obesity 
Obesity OR obese OR overweight OR Increased body mass index OR 
raised body mass index OR increased waist circumference OR increased 
waist-hip ratio OR increased body fat mass OR percent body fat OR waist to 
height ratio 
Search 1 AND (2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 
OR 12 OR 13) AND 14 
Filters: published since 1990; Humans; English language  
= … hits 
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Obesity – What surveillance modality should be used?  
 
Search 1:  
Childhood 
cancer 
(leukemia OR hemothe* OR hemother* OR (childhood ALL) OR AML OR 
lymphoma OR hemothe* OR hemoth OR hemoth* OR T-cell OR B-cell OR 
non-hodgkin OR sarcoma OR sarcom* OR sarcoma, Ewing’s OR Ewing* OR 
osteosarcoma OR hemotherapy* OR wilms tumor OR wilms* OR 
nephroblastom* OR neuroblastoma OR neuroblastom* OR 
rhabdomyosarcoma OR rhabdomyosarcom* OR teratoma OR teratom* OR 
hepatoma OR hepatom* OR hepatoblastoma OR hepatoblastom* OR PNET 
OR medulloblastoma OR medulloblastom* OR PNET* OR neuroectodermal 
tumors, primitive OR retinoblastoma OR hemotherapy* OR meningioma OR 
hemothera* OR glioma OR gliom*) OR (pediatric oncology OR paediatric 
oncology) OR (childhood cancer OR childhood tumor OR childhood tumors)) 
OR (brain tumor* OR brain tumour* OR brain neoplasms OR central nervous 
system neoplasm OR central nervous system neoplasms OR central nervous 
system tumor* OR central nervous system tumour* OR brain cancer* OR 
brain neoplasm* OR intracranial neoplasm*) OR (leukemia, lymphocytic, 
acute) OR (leukemia, lymphocytic, acute*) OR breast cancer at a young age 
OR young breast cancer survivor OR testicular cancer OR germ cell cancer 
OR germ cell tumor OR seminoma OR seminoma* OR non-seminoma OR 
non-seminom* 
Search 2: 
Obesity 
Obesity OR obese OR overweight OR Increased body mass index OR raised 
body mass index OR increased waist circumference OR increased waist-hip 
ratio OR increased body fat mass OR percent body fat OR waist to height 
ratio 
Search 3: 
Body mass 
index 
Body mass index 
Search 4: 
Waist 
circumference 
Waist circumference 
Search 5: 
Waist/height 
ratio 
Waist-hip ratio OR waist-height ratio 
Search 6: 
DXA 
DXA or dual energy x-ray absorptiometry OR bone densomitry OR DEXA 
Search 7:  
CT, BIA, or 
MRI for body 
fat 
BIA OR bioelectrical impedance analysis or body composition or body fat OR 
percent body fat OR visceral fat OR visceral adiposity  
Search 8:  
Air 
displacement 
Air displacement plethysmography OR bod pod OR whole-body air 
displacement OR ADP 
Search 1 AND (3 OR 4 OR 5 OR 6 OR 7 OR 8) AND 2 
Filters: published since 1990; Humans; English language  
= … hits 
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